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ABSTRACT 
DESIGN, SYNTHESIS AND BIOLOGICAL SCREENING OF NOVEL CUCS-
INSPIRED ESTRONE ANALOGUES TOWARDS TREATMENT OF 
HEPATOCELLULAR CARCINOMA 
MATER MAHNASHI 
2017 
      Cucurbitacins (CUCS) are natural products with highly oxygenated tetracyclic 
triterpenes produced mostly by Cucurbitaceae family plant. They are known for their 
therapeutic efficiency with different biological activities, such as anti-inflammatory, 
hepatoprotective and anti-cancer. Hepatocellular carcinoma (HCC) is the third leading 
cause of death worldwide. Previous reports have shown the ability of CUCS to inhibit the 
growth of hepatocellular carcinoma cell lines (HepG-2) significantly. Structural activity 
relationship studies suggested the potential of the 23, 24 enone side chain of CUCS to bind 
to the Epidermal Growth Factor Receptor (EGFR). Due to the limited quantities of CUCS 
upon isolation and the challenges of total synthesis of CUCS, therefore estrone skeleton 
were used as a starting scaffold to synthesize CUCS-inspire estrone analogues (CIEA) 
targeting HCC. Molecular docking study of cucurbitacin-inspired estrone analogs was 
conducted using 1M17 (EGFR receptor) co-crystallized with Erolitinib (known EGFR 
HCC anti-cancer chemotherapeutic drug) and several analogs were identified from the 
docking study and were processed for multiple steps organic synthesis. Novel CUCUS-
inspired estrone analogs with aliphatic enone side chain such as MMA102, MMA132 were 
synthesized by installing the CUCS side chain at C17 of estrone scaffold. In addition, 
various CUCUS-inspired estrone analogs with different aliphatic, aromatic and 
xviii 
 
  
heterocyclic pharmacophores at C-3, C-16 and C-25 were synthesized. The novel analogs 
showed a comparable affinity to EGFR receptor based on the docking study and improved 
binding through hydrophobic filling of the binding of EGFR pocket and hydrogen bonding 
interactions. Cell proliferation inhibition assay results demonstrated the ability of 
analogues MMA102 and MMA132 to inhibit HCC cell line (HepG2) proliferation with 
IC50  3µM and 2µM, respectively in comparison to Erlotinib IC50 (of 25 µM). Western blot 
experiments proved that compounds MMA132 has the ability to bind to the EGFR-TK and 
inhibit its phosphorylation by 90%. Flow-cytometry/cell cycle arrest study showed that our 
lead compound MMA132 induce a significant change in G1/S phases at different IC50 
concentrations (1µM, 2µM and 3µM). The novel synthesized cucurbitacin-inspired estrone 
analogs showed a significant 12 times more cytotoxicity than standard chemotherapy and 
bind through hydrogen bonding to the same amino acids that Erlotinib binds to in the 1M17 
EGFR pocket. Compound MMA311, which consist of 2-bromothiophene enone side chain 
along with methoxy at C-3 and double bond at C-16 and C-17, showed a significant and 
potent anti-proliferation activity with IC50 value of 0.7 µM. Due to the high hydrophobic 
character of the first set of compounds and the expected metabolism of estrone by O-
dealkylation of methoxy group at C-3, which may trigger estrone side effects, C-3 methoxy 
group were substituted with sulfamoyl moiety to improve the pharmacokinetic profile of 
the synthesized analogues. Several CIEA analogs that contain sulfamoyl group at C-3 and 
various aliphatic, aromatic and heterocyclic enone side chains at C-17 were synthesized 
and biologically tested as EGFR inhibitors. Compounds that contain heterocyclic enone 
side chains at C-17 along with sulfamoyl moiety or hydroxyl group at C-3 such as 
MMA297, MMA314, MMA313 and MMA312 showed an outstanding cytotoxicity with 
xix 
 
  
IC50 1 µM, 1.5 µM, 9 µM and 8 µM; respectively, in comparison to the Erlotinib IC50 of 
25 µM. The potential of our novel CIEA to overcome cancer resistance to current 
chemotherapy was explored and  identified their ability to decrease the drug resistance by 
inhibiting MRP1 utilizing high-content based assay in presence of calcein-AM as MRP1 
substrate. Compounds MMAmix, MMA242, MMA132, MMA335, MMA337 and 
MMA320 showed potential inhibitory activity on MRP1 with inhibitory activity of 70%, 
63%, 46.2%, 46%, 30% and 22%; respectively, in comparison to MK-571, which known 
MRP1 inhibitor. 
Our study demonstrated the design, synthesis of novel CIEA analogs of potent anti-
proliferation/anticancer activities toward hepatocellular carcinoma and potential 
application to overcome cancer resistance to current chemotherapeutic agents.
   1 
 
  
Chapter One 
General Introduction and Background 
1.1 Drug Discovery: 
Drug discovery is a convoluted procedure that consumes much time and money, 
taking an average time of 10-15 years and cost of around $ 1 billion to get a new drug in 
the market. This complex procedure needs a great number of steps, skills and technologies 
such as chemoinformatics, molecular modeling, chemical synthesis, toxicity screening and 
clinical studies [1]. Typically, the drug discovery pipeline starts from a disease description, 
followed by molecular targets identification and validation, thus utilizing high throughput 
screening (HTS) and/or Insilco–invitro screening to identify hit compounds. Finally, hit 
compounds will be optimized to find the lead compound followed by animal studies to 
identify the compounds pharmacokinetics, and finally the clinical trials to test the drug 
before it reaches the pharmaceutical market (Fig.1.1) [1, 2]. All of these steps will be 
completed sequentially so, if any one of these steps delayed, the whole process is slowed 
[2]. A strategy known as High Throughput Screening (HTS) has adopted by pharmaceutical 
industries to identify and develop a hit compounds which apply insilco molecular modeling 
and computer assisted drug design (CADD) using scoring function and docking (Fig.1.1). 
All of these processes used by pharmaceutical industries to speed the drug discovery 
process.  
HTS used by pharmaceutical companies to screen 1 to 5 million compounds in few 
weeks which is a very coasty process. For example, an HTS of 1 million compounds might 
cost an average of $ 500,000–1,000,000 [3]. However, the efficacy or toxicity problems 
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associated with many compounds are the reason behind the fail test at the last stages of 
clinical trials [4, 5]. 
 
Figure 1.1 Drug discovery processes (10-15 years/ 1 billion dollars). 
 
In addition, the physic-chemical characteristics such as, absorption, distribution, 
metabolism and elimination (ADME) could play an important role in the efficacy and 
safety of a new drug [6-8]. Therefore, to eliminate some of these issues, scientists create a 
virtual library of thousands of chemical compounds that can undergo virtual insilco 
screening to obtain hit compounds prior to the bench work, which includes synthesis and 
biological evaluation, to find potential drug candidates [8-10].  
 Virtual library generation in the drug discovery field is a time- and effort-saving 
step, where different factors can be chosen during the design process of the library. The 
process of designing the virtual library considers the possible synthetic approaches which 
can be utilized on a chemical structure, including the capability of installing diverse 
functional groups (pharmacophores) on the parent compound using viable chemical 
reactions [9]. One of the common approaches used in the design stage is the concepts of 
   3 
 
  
bioisostrism, which is a planning technique used in medicinal chemistry field to manage 
systematic molecular modifications aiming. The process of bioisostrism refers to 
substituting chemical functional groups with others similar in their physical or chemical 
properties, which generally result in similar or better biological activity. The bioisostrism 
molecular modification process uses a lead compound (LC) in which its chemical structure, 
mechanism of action, drug-protein interaction and important pharmacophores are known. 
Additionally, the concept of bioisostrism is utilized to either improve biological activity or 
to decrease the adverse side effects and toxicity of a compound [11].  
        At some point, the basic steps towards drug design should use either structure-
based or ligand-based drug design concepts to create a chemical database in order to define 
the desired scaffold or skeleton. The lead compounds (LC’s) will undergo additional 
optimization to find the hit compounds, followed by the development of a route to 
synthesize a high consensus score chemical scaffold with the designed functional groups, 
which is then used for high throughput screening and biological activity evaluation. 
            In conclusion, drug discovery is a long-term process used to find the lead 
compounds, which will go through different clinical tests and biological evaluation,s as 
shown in Figure 1.2.  
 
1.2  Natural Products and Drug Discovery: 
Natural products, biologicals, total synthetic or vaccines are the main sources of 
small organic molecule drugs [12]. Since ancient times, natural products have played an 
important role as a resource for medicine; for example, herbs can be chewed to relieve pain 
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or wrapped around wounds to heal them. Using natural products to treat diseases and 
injuries is now known as folk medicine [13, 14]. Lately, significant advances in biological 
screening techniques have allowed the study of the biological mechanisms and chemical 
profiles of living systems, which has encouraged researchers to investigate the 
pharmacological effects of natural compounds. Studies are done to clarify the natural 
products' synergistic impacts and their clinical effects on the individual body, which could 
help provide novel curative approaches to different diseases [15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Process of drug design. 
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Chain et al, 2006 clarified the criteria for evaluating natural products as three steps: 
1) the rate of display of novel compounds of wide structure diversity to be used as model 
and pharmacophore for systematic synthetic modification, total synthesis and semi-
synthetic; 2) different diseases healed or prevented by these compounds; and 3) their 
number of use for treatment of diseases can be valued by pharmacoeconomic analysis 
adjusting the number of prescriptions and the performance of the drugs. Currently, 56% of 
the prescribed drugs in the United States are related to natural products [16].  
 
A recent study ranked all drugs derived from natural products among the top 35 
worldwide best ethical drugs sellers [17]. Additoinally, Newman et al, 2012 proved the 
advantages and biological efficacy of the natural products approved by the Food and Drug 
Administration (FDA) between 1981 and 2010 (Chart 1.1) [18].  Natural products have 
been used as platform for drug discovery for many available drugs, such as anti-epileptics, 
anti-angina, anti-obesity, anticancer, anti-viral, anti-migraine and bronchodilators.  
 
Newman et al, 2012 additionally attracted attention to the significance of different 
types of synthetic approaches utilizing natural products, such as total synthesis of a natural 
product and semi-synthesis of compounds containing functional groups (parmacophore) 
imitating natural products. This clarifies the role of nature in inspiring future organic 
chemists to prepare novel organic compounds that can provide better or similar activity as 
the natural compound but with fewer side effects [18].  
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Chart 1.1 All New Chemical Entities between 1981 -2012 which approved by FDA. 
 
One of the better known examples of a natural product that has been used as a model 
for a total or semi-synthetic drug is Taxol. Another example used as model for a partially 
synthetic approach is cucurbitacins, a natural product which shows anti-cancer, 
hepatoprotictive and anti-inflammatory activities. 
 
1.3  Cucurbitacins: 
Cucurbitacins are natural compounds extracted mostly from the plant of 
cucurbitaceae family such as Ecballium Elaterium, Genystlus keithii, Cayaponia Tayuya, 
Citrillus Colocynthic, Trichosanthes Kirilowii and Ecballium Elaterium. In addition, they 
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can be found in other plant families, such as Scraphulaiaceae and Cruciferae [19]. The 
Cucurbitaceae family was first used in folk medicine because of its biological significance 
as an anti-inflammatory. According to various studies, the cucurbitacins plants were used 
for the first time in Asia, the Middle East and other parts of the world as herbal remedies. 
According to various studies, the cucurbitacins plants were used for the first time in Asia, 
the Middle East and other parts of the world as herbal remedies. The Cucurbita plants were 
used in ancient herbal medicine to treat chronic hepatitis, liver cirrhosis, jaundice, 
dyspepsia and cancer [19-23].  
 
The first isolation of cucurbitacins happened in 1831 usign Ecballium Elaterium, 
but this did not show up in the market as a biologically active product until the 1960s. 
There are twelve different types of cucurbitacins, as follows: A, B, C, D, and E, and so 
forth to T. Additionally, hundreds of cucurbitacin derivatives have been synthesized and 
identified [22]. 
 
Cucurbitacins can be isolated from different parts of the plant, including the seed, 
roots, rhizomes and aerial parts of Cantaloupe, Watermelon, Pumpkin, Honeydew Melon, 
Spaghetti Squash and Crenshaw Melon [23]. Various reports have proven the medicinal 
activity of the cucurbitacins and their clinical effects. Some of the cucrbitacins are still 
currently used as a treatment in some parts such as Asia, Africa and South America. Many 
biological impacts have been connected with cucurbitacins and their glycosylic derivatives 
[23-26]. Recently, cucurbitacins B,C, Q, and E showed antiproliferctive activity on 
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different cancer cell lines, such as HepG2, MDA-MB-468, MCF-7 and A549. Animal 
models and their apoptosis stimulating activity occurred through the inhibition of the Janus 
kinase (JAK), signaling marker and activator transcription3 (STAT3) signaling [19, 24-
26].  
 
Cucurbitacins R and 23, 24-dihydrocucurbitacin B have been isolated from the 
roots of Cayaponia Tayuya by Recio et al [27]. These two cucurbitacins showed several 
useful activities, such as anti-arthritic, anti-allergic and anti-inflammatory activity, both in 
vitro and in vivo. This was due to their capabilities to block the expression of tumor 
necrosis factor-Alpha (TFN-𝛼) in macrophages and in lymphocytes, as well as their 
involvement with the action of the nuclear factors [22, 27]. The activity of cucurbitacins as 
hepatoprotictive and anti-proliferative agents has been proved by Bartalis and Halaweish 
on two different cell lines, HepG2 (hepatocellular carcinoma cell line) and HSC-T6 
(Immortal hepatic stellate cell lines) [28].  
 
Kintak et al. 2010 showed that cucurbitacin B has an inhibitory activity on 
ERK/RAF/STAT3/MEK and RAS signaling pathway [29]. Subsequently, there is a huge 
need to synthesize cucurbitacins because of their outstanding biological results, and also 
their very low concentrations in natural sources. Several trials have been conducted trying 
to synthesize cucurbitacins, but all of them failed to provide a final compound [30-32]. The 
varieties of cucurbitacins functional groups or pharmacophores, as well as cucurbitacins' 
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main structural complexity, are the main reasons that totally synthesizing cucurbitacins has 
been difficult to achieve.  
 
1.3.1 Physical Characteristics of Cucurbitacins: 
Cucurbitacins are crystalline materials at room temperature which typically absorb 
ultraviolet light at the range between 228 and 234 nm. Petroleum ether, benzene, 
chloroform, ethel acetate, ethanol and methanol are the common solvents used to dissolve 
cucurbitacins, since they are insoluble in ether and poorly soluble in water [33]. All of these 
properties are reasonable because of the hydrophobic properties of the chemical structure 
of cucurbitacins [26]. Mdavi et al. proved that both cucurbitacin B and I are soluble and 
can be delivered in vitro and in vivo utilizing two different polymeric micelles, developed 
[poly (ethyleneoxide)-block-poly (Ecaprolactone) (PEO-b-PCL). By using a polyemiric 
micellar, the in vitro anti-cancer and STAT3 antagonist activity in the melanoma cell line 
(B16.F10) demonstrated a similar performance to the free drug using the same cell line. A 
mouse melanoma tumors study in vivo demonstrated similar anticancer activity against the 
B16.F10 cancer cell line using intratumoral administration. This yielded an insignificant 
drug level in the animal plasma while preserving high drug levels in the tumor. Some 
research has indicated potential ways to deliver cucurbitacins, such as polymeric micelles 
[34].  
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1.3.2 Chemistry of Cucurbitacins: 
Cucurbitacins are tetracyclic triterpenes characterized by highly oxygenated 
functional groups. They possess 30 carbon atoms on their general structure, known as 19-
(10     9-β)-abeo-5 α-lanostane (9-β-methyl-19-nor-lanosta-5-ene). Cucurbitacins have 
more than 100 different structures including glycosyl cucurbitacins and hexanol 
cucurbitacins (Fig.1.3) [19, 22, 23, 35].   
Cucurbitacins E and B are the most common in the cucubitacea plant family and 
their biosynthetic pathways have been documented in several studies. Since cucurbitacins 
are found in common plants, some of them are originated via enzymatic reactions during 
the plant's natural processes such as growth. For example, cucurbitacins A,D, C, F, G and 
H can be found via biotransformation of cucurbitanic B, whereas cucurbitacins I, K, J and 
L can be formed via biotransformation of cucrbitacin E [22]. However, due to the 
complexity of the stereochemistry of these natural analogues, organic synthesis has not yet 
been established.     
 
The cucurbitacins four-ring system resembles the structure of a steroid ring [36]. 
Two common features mark the difference between cucurbitacins and steroids structures, 
with cucurbitacins having a gem-dimethyl group at C-4 and a C-10 methyl in C-9. 
Cucurbitacins' main structures share common features, such as: 1) the double bond between 
C-6 and C-5; 2) a high level of oxidation due to the substitutions of many carbons (C-16, 
C-11, C-3, C-2) by oxygen atoms; 3) the presence of hydroxyl groups, α at C-16 and β at 
C-20 and C-25; and 4) α-β-unsaturated ketone in the side chain located at C-22, C-23 and 
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C-24. As shown in Figure 1.3, an aromatic ring is a common feature in some of the 
cucurbitacin derivatives, such as Fevicordin A [37, 38]. Additionally, cucurbitacins can be 
found as free glycone structures or glycosidic structures by a β-linkage to the hydroxyl 
moiety from monoside at C-2, C-3 and C-25 or from bidesmosides at C-26 or C-27 [39]. 
 
Different studies have demonstrated that the biological effects of cucurbitacins are due to 
the presence of a triterpenoid structure which resembles steroids. Additionally, multiple 
studies on different cell lines have investigated the structure activity relationship (SAR) of 
cucurbitacins. First, the presence of α-β-unsaturated ketone of the side chain at C-22 and 
C-24 is very significant for cucurbitacin’s biological activities; cucurbitacin B showed 
more activity than dihyedro-cucurbitacin B and cucurbitacin D showed more activity than 
that of dihydero-cucurbitacin D in U-937 cell lines which are histiocytic lymphoma cell 
lines in different intervals by about 1000 fold. Second, the toxicity of the glycosides of 
cucurbitacin E and I is less than that of aglecones, while the cucurbitacin biological activity 
increased by 1000 fold in the presence of 25-acetoxy moiety. For example, the IC50 of 
cucurbitacin B is less than that of cucurbitacin D in U-937 histiocytic lymphoma cell lines 
at different test intervals [39].  
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1.4  Cucurbitacins as Potential Drug Candidates Targeting Different Molecular 
Targets: 
1.4.1 Cucurbitacins Activity as Anti-inflammatory Compounds: 
Cucurbitacins have been proven to be anti-inflammatory compounds via targeting 
many biological targets to decrease the inflammation. The anti-inflammatory activity of 
cucurbitacins is due to the inhibition of cyclooxygenase (COX) enzymes, particularly 
cyclooxygenase 2 (COX-2). In comparing the non-steroidal anti-inflammatory drugs 
(NSAIDs) and cucurbitacins, the inhibitory rate for COX-2 by cucurbitacins is less than 
the NSAIDs; for example, at 100mM concentrated cucurbitacins B, D, E and I showed 
inhibitory rates of 32, 29, 35 and 27%, respectively, compared to the COX-2 of NSAIDs 
such as Refeoxib, Ibuprofen and Naproxen. This study also proved the selectivity of 
cucurbitacins towards COX-2, since they do not show any activity on the cyclooxygenase-
1 (COX-1) enzyme [27]. 
 
Additionally, other studies detected that 23, 24-dihydrocucurbitacin B particularly 
have a significant inhibitory activity against COX-2 without reducing its expression. Also, 
cucurbitacin R demonstrated noticeable inhibition in the proteins and mRNA for inducible 
NO synthase (iNOS) by preventing the activation of nuclear factor-KB (NF-KB) [27].   
    
Cucurbitacins isolated from the roots of C. tayuya such as cucurbitacin R and 23, 
24-dihydrocucurbitacin B displayed anti-arthritic, anti-allergic and anti-inflammatory 
activities in both in vivo and in vitro tests due to their efficacy to suppress tumor necrosis 
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factor (TNF-α) expression in macrophages and lymphocytes. The in vivo studies 
demonstrated the capability of both cucurbitacins to minimize the expression of nitric-
oxide cyclooxygenase-2 and synthease-2 (pro-inflammatory enzymes) [36].  
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F OH OH CH3 H OH - + 
H OH =O CH3 OH OH - - 
I OH =O CH3 H OH + + 
J OH =O CH3 OH OH + - 
 
Figure 1.3 General structures of cucurbitacin with various functional groups and steroid. 
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1.4.2 Cucurbitacins Effect on Filamentous-Actin: 
Some studies demonstrated the activity of cucurbitacins E, I, and B on the 
cytoskeleton, particularly on F-actin. Another study proved that some cucurbitacins 
derivatives including cucurbitacin E, stimulate actin cytoskeleton disturbance [40]. This 
disturbance connected with the effect of cucurbitacins on the actin-proliferative action in 
prostate cancer cell lins. One of the astonishing attributes of cucurbitacin E is that it has a 
selective inhibition on F-actin depolymerization, but not on monomeric globular G-actin, 
by forming a covalent bond with CYS 257 amino acid residue [41]. 
 
Recent studies on cucurbitacins D, E, and I were conducted utilizing breast cancer 
cell line (MCF-7) to detect their activities on actin-based structures and cell viability 
suggested that cytotoxic characteristics of cucurbitacins might be largely separated from 
their effects on cytoskeleton rearrangement [42]. In conclusion, cucurbitacins have 
demonstrated strong effects on the cell cytoskeleton by essentially simulating actin through 
the stimulation of depolymerization and aggregation.  
 
1.4.3 Mitogen Activated Protein Kinase (MAPK) Pathway Activation by 
Cucurbitacins: 
One of the key parts in the cellular process is the MAPK pathway, which has 
signaling transducing cascade including Ras/B-Raf/MEK/ERK (Fig.1.6). Very few 
research studies have addressed the potential biological activities of cucurbitacins targeting 
the MAPK pathway.  Chean et al. stated that cucurbitacin B inhibits the STAT3 and 
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RAS/B-Raf/MEK/ERK cell downstream signaling cascade using the K562 leukemia cell 
line [29]. Utilizing computational semi-flexible molecular docking, MTT cell viability 
assay and binding immune assay, Salama and Halaweish demonstrated the ability of 
several types of cucrbitacins to target MAPK signaling pathway using mutant B-Raf cell 
lines [43]. 
 
1.4.4 Cucurbitacins as Potential Modulator for Epidermal Growth Factor 
Receptors (EGFR): 
EGFR, in human cancer has been demonstrated to be involved in the mutation and 
deletion of the cell upstream and downstream targets, which makes EGFR a promising 
biological target for different types of human cancer [44]. Hollbro et al proved that ErbB 
receptors, a member of the GFR family, are very important targets for the treatment of 
different kinds of cancer [45]. Liovet et al. showed that activation of EGFR and its 
downstream cascade has increased the survival rate of patients in the late stages of 
hepatocellular carcinoma [46]. 
 
In conclusion, cucurbitacins have demonstrated wide and broad biological activities 
toward various molecular targets, including anti-inflammatory agents, hepatoprotective, 
anti-cancer agents and anti-virus agents. This makes cucurbitacins promising drug 
candidates for various diseases and health problems. Additionally, cucurbitacins have been 
proven to have effective inhibitory activity against various cancer cell lines, such as 
hepatocellular carcinoma cell line (HepG2), colon cancer cell line (HCT-116), lung cancer 
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cell lines (NCI-H460 and A-549), leukemia cell line (U-937), breast cancer cell line (MCF-
7) and melanoma cell line (B16/F10). 
 
Understanding the genetic changes in HCC and its molecular targets is essential for 
designing potential anti-cancer drugs. 
 
1.5   Hepatocellular Carcinoma (HCC): 
Hepatocellular carcinoma (HCC) is classified as one of the highest cause of 
mortality and the third causing of death worldwide [47]. Asia and Africa have the highest 
reports of HCC, with high incidence among men, while HCC is somewhat rare in the 
United States compare to the other countries. HCC is a continuous and slowly progressing 
disease that is generally associated with other factors, such as cirrhosis, hepatitis C virus 
(HCV), hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and 
alcoholic consumption) [48].  
 
1.5.1 Etiology of HCC: 
HCC influences all groups of people worldwide. However, regional differences and 
ethnicity are also a significant influence on the prevalence and etiology of HCC incidence 
[49, 50]. HCC is a continuous and slowly progressing disease that is generally associated 
with other factors such as cirrhosis, hepatitis C virus (HCV), hepatitis B virus (HBV) and 
toxin/ environmental disorders (obesity, diabetes and alcoholic consumption) [43, 49, 51]. 
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An additional factor that can lead to HCC is gender, with males having a higher prevalence 
for HCC than females [49]. 
 
 
1.5.1.1 Hepatitis B Virus (HBV): 
HBV is one of the Hepadnaviridae family, which consider as covered DNA virus. 
It is a very common viral disease in that 2 billion people are HBV carriers and about 
320,000 people die annually due to complications of HBV infection. Asia and Africa have 
the highest reports of HBV incidence worldwide[52]. This disease is very contagious, so it 
can infect other individuals in several ways— prenatally, percutaneouslly, and sexually 
[52, 53].  Reverse transcriptase (RT) enzyme is responsible for the virus genome replication 
[49, 53], but other proteins are also involved in the progression of HBV, such as capside 
proteins, common as hepatitis B core antigen (HBcAg), and other enveloped proteins 
connected with endoplasmic reticulum (ER) (HBV-1). Approximately one-third to one-
half of HBV-associated deaths are due to the progression of HCC [49, 53]. The influence 
of the HBV infection on the progression of HCC is connected with the high incidence of 
HCC in the infected individual, with a high level of HBV DNA in their biological serum 
[54].  
 
Various studies have proven the ability of HBV to transform into HCC. First, the 
genome integration of HBV is related to the host DNA microdeletion, which has the ability 
to target cancer-related proteins including platelet-derived growth factor receptor-B 
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(PDGFR-B), telomerase reverse transcriptase (TERT), and mitogen activated protein 
kinase-I (MAPK-I) [55, 56]. Second, an alteration in the expression of growth-control 
proteins such as Ras, Raf, MEK, ERK, JNK and tyrosine kinases takes place through 
activation of HBX transcription activity. Third, card inactivate and bind in invitro to the 
tumor oppressor P53, which accelerates the cellular proliferation and survival [49, 57, 58]. 
Genetic validation of HBx as a hepatocarcinoginic has been proven in transgenic mice, 
resulting in 90% transformation to HCC [59]. 
 
1.5.1.2  Hepatitis C Virus (HVC): 
HCV is a member of Flaviviridee family that is a single-stranded RNA non-
cytoplasmic type virus. It is a contagious virus that can infect other individuals by direct 
blood contact, perinatal from mother to fetus, and in rare cases, by sexual intercourse. 
China, Egypt and Pakistan have the highest number of HCV cases worldwide [49, 60, 61]. 
Approximately 170 million individuals are HCV infected worldwide [61]. Six HCV 
genotypes (1-6) have been isolated, with genotypes 1-3 being very common worldwide. 
Genotype 4 is common in Egypt and the Middle East, genotype 5 is prevalent in South 
Africa and genotype 6 is widespread in China [61, 62]. HCV has been shown to have 
biological uniqueness compared to HBV, which is an associated hepatocarcinogenesis. 
First, HCV has a better tendency (60-80%) to produce chronic infections compared to 
HBV, which has only a 10% tendency. That tendency is connected to HCV's ability to 
generate a fast rate of replication errors that can cause immune evasion [49, 63, 64]. 
Second, HCV has a 10-20 times higher tendency to initiate liver cirrhosis compared to 
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HBV, with 10% of the patients infected by HCV incubating liver cirrhosis after 10 years 
of contagion. The high connection of HCV with cirrhosis is a critical correlation in 
developing HCC. Finally, since HCV is an RNA virus, it cannot combine into a host 
genome [63]. 
1.5.1.3  Alcohol Consumption:  
Alcohol consumption is one of the significant causal factors for HCC. Chronic 
alcohol consumption causes pre-inflammatory cytokines by activating and disturbing the 
monocyte which leads to an abnormal evaluation circulating endotoxin concentration. This 
can cause the activation of Kupffer cells which emit various cytokines and chemokines, 
such as prostaglandin E2, TNFα, 1L6 and interleukin-1B (IL1B). These bring about 
hepatocyte damage [65]. In the case of chronic ethanol toxicity, the hepatocyte 
demonstrates a high sensitivity to the TNFα cytotoxicity effect, which is a clear sign of 
chronic hepatocyte disturbance, activation of stellate cell, liver cirrhosis, and eventually, 
HCC [66]. 
 
In addition, alcohol can destroy the liver via a process called oxidative stress. An 
increase in the isoprstane level is a sign of alcohol hepatitis, which indicates lipid 
peroxidation [67]. Three explanations can be given for the connection between oxidative 
stress and the liver damage that leads to HCC. First, oxidative stress elevates the 
progression of cirrhosis and fibrosis, which are considered the main causes of HCC [68]. 
Second, oxidative stress resulting from ethanol toxicity shows a relevant effect on the 
HCC-signaling cascade, such as a decrease in the tyrosine phosphorylation of the signaling 
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transducer and the activator of transcription I (STATI) [69]. Third, oxidative stress might 
increase the rate of telomere shortening which may interrupt the DNA replication process 
and cause HCC [70]. 
1.5.1.4  liver Cirrhosis: 
Liver cirrhosis consider as the main reason for HCC development, which mainly 
caused by the most two common livers viral infection, HBV and HCV [71, 72]. Table 1.1 
shows the annual percentage of individual who develop HCC from cirrhosis caused by 
liver viruses or liver complications [71].  
While these results show HCC development via liver cirrhosis caused by different 
liver diseases, the development of HCC may also include additional factors [73]. The 
development of cirrhosis usually comes when patients have chronic liver disease over a 
period of years, which can be distinguished by a decrease in hepatocyte proliferation as a 
sign of liver damage. This causes an increase in the fibrous tissue and a disturbance of liver 
cells that leads to the development of liver cancer [71, 74]. Various studies have been 
conducted to determine the exact mechanism associated with HCC development from liver 
cirrhosis, but only a few possible mechanisms have been proposed, including micro- and 
macro-environmental changes that induce cellular proliferation and telomese dysfunction 
[75]. 
 
 
 
   21 
 
  
Table 1.1 Annual percentage of HCC incidences caused by liver cirrhosis. 
 
Disease Annual percentage % 
HBV 1-15 
HCV 1-8 
Liver disease due to alcohol 
consumption 
1 
Liver disease due to non-alcoholic 
reasons 
2.6 
 
1.5.1.5 Aflatoxin B1 and Environmental Factors: 
Aflatoxin B1 (AFB1) is a mycotoxin found in Aspergillus fungus that infects 
different foods, such as peanuts and corn. AFB1 has been proven as carcinogenic based on 
several animal studies [75, 76]. When AFB1 is absorbed in the blood circulation, it is 
activated by metabolism to AFB1-exo-8, 9-epoxide. The active metabolite binds to DNA 
and damages it, so it can be distinguished by the activation of the P53 protein [77]. This 
DNA damage has been distinguished in 30%- 60% of HCC patients in AFB1 epidemic 
regions [78]. AFB1 as a risk factor for HCC development was supported by several studies 
done between 1992-2007. These studies were conducted on an aflatoxin metabolite 
developed from urine assays in order to find signs of aflatoxin-damaged DNA [75]. 
Environmental disorders such as obesity, diabetes mellitus and tobacco have also 
been studied and proven as risk factors for HCC development [75]. A study on 900,000 
people with obesity over a period of 16 years found that the incidence of hepatocarcinoma 
death was five times higher than that of non-obese people [79]. Diabetes mellitus, 
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specifically type-2, is another factor for HCC development via non-alcoholic fatty liver 
disease (NAFLD) and non-alcoholic steatohepaties (NASH). The connection between 
type-2 diabetes mellitus and HCC has been studied in several countries, with several 
studies showing a significant connection between HCC and type-2 diabetes [75]. Another 
significant factor involved in HCC development is cigarette smoking. Numerous studies 
on HCC patients demonstrated positive and negative associations between tobacco and 
HCC [80]. 
1.5.2 Diagnoses and Treatments of HCC: 
1.5.2.1  Diagnosis of HCC: 
HCC can be diagnosed by various tests, including imaging, histology and serological tests. 
Imaging tests, such as ultrasound (US), computerized tomography (CT) and magnetic 
resonance imaging (MRI) can be used to detect hepatic nodules. The molecular biomarker 
test for the diagnosis of HCC is now becoming popular. With this test, the three types of 
alfa-fetoprotein (AFP-1L1, AFP-L2 and AFP-L3) are the most popular molecular 
biomarkers for the diagnosis of HCC [47, 81, 82]. The biomedical problems associated 
with the AFP molecular biomarker are that it can be found in high levels in some non-
malignant cells such as with pregnancy and severe liver diseases. In addition, it can be 
found in various levels in different types of HCC [81, 83]. Figure 1.4 demonstrates the 
diagnostic strategy of the American Association for the Study of Liver Diseases (AASLD). 
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1.5.2.2 Treatments of HCC: 
Various treatment choices are available for HCC, with the type of treatment depending on 
factors such as the condition of liver function, the HCC level, the type of local medical 
resources available and the prevalence of other chronic diseases [47]. The treatment of 
HCC can be divided into two types— curative and palliative. The curative options for HCC 
treatment include ablation, surgical resection and liver transplantation; these usually 
provide a high percentage of treatment response which increases the survival rate. On the 
other hand, the palliative options of HCC treatment, such as chemotherapy and 
radiotherapy, do not tend to provide a high rate of response compared to the curative 
options, but they can improve the survival rate of HCC patients in general [84].  
 
 
 
 
 
 
 
 
Figure 1.4 Diagnosis strategy of the American Association for the study of liver diseases 
(AASLD) (reprinted from [81]). 
 
 
   24 
 
  
1.5.2.2.1 Surgical Resection: 
HCC patients with a non-cirrhotic liver, an early stage of HCC and good liver function are 
good candidates for the resection surgery. The process of liver resection consists of 
removing the specific part of the liver that has the tumor mass, along with a small range of 
liver tissues around the mass, leaving the healthy part of the liver to renew the whole organ. 
Among all the HCC treatments choices, surgical resection for the early stage of HCC is 
considered the best choice because it provides complete extirpation of the tumor mass and 
allows for liver function regeneration [81]. However, surgical resection has some 
limitations for curing HCC. First, some clinical tests should be made on the liver to ensure 
that the remaining part of the liver has the ability to renew the liver function. For example, 
HCC patients with liver cirrhosis are not suitable for surgical resection. Second, removing 
the liver tumor mass will not remove the tumor completely, which will increase the chances 
of generating a de novo primary tumor mass. The statistical studies indicate that 75-80% 
of HCC patients who have had the tumor mass removed will survive [85]. Third, the chance 
of treating HCC by surgical resection will be small if there are several tumor masses in the 
liver. In addition, HCC diagnosed at the late stages with the association of liver cirrhosis 
will make surgical resection an impractical option [86]. 
 
1.5.2.2.2 Liver Transplantation:  
Liver transplantation is considered one of the best curative treatment options for 
HCC patients, especially in the early stages, since it removes the whole liver including its 
tumor masses. It thus provides a solution for the underlying cirrhosis [87]. The main 
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problem with liver transplantation is the spread of the tumor to another organ. Mazzafero 
et al, 1996 developed the Milan Criteria, which are criteria used to distinguish HCC 
patients who are suitable for liver transplantation. These criteria include: a solitary tumor 
< 5cm in diameter, total of 3 lesions <3cm in diameter, and no spread of the tumor to the 
other organs or vessels. The Milan Criteria increased the survival rate to 80% and returning 
survival rate to 83% after liver transplantation [81, 87]. The limited number of liver donors 
is the major issue with this process [47]. 
 
1.5.2.2.3 Ablation Therapy: 
Ablation therapy provides local management of the HCC cancer cells with only a 
small influence on the neighboring cells and other hepatic tissues. Ablation therapy is a 
convenient technique for HCC patients who are still in the early stage and do not have a 
match for liver resection or liver transplantation. The three types of ablation therapy 
include radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) and 
microwave ablation (MWA). RFA uses an electrical current with a high frequency to 
deliver heat to the liver tissues and cause coagulative necrosis. PEI mainly causes liver cell 
dehydration, which is responsible for the death of the exposed liver tissues, also produces 
coagulative necrosis. Unlike RFA, MWA generates heat by applying an electromagnetic 
source to the liver tissues that can cause the tumor masses to die [47, 81].  
1.5.2.2.4 Chemotherapy: 
The name chemotherapy refers to a treatment using drugs or medicines. Treatment 
of HCC with chemotherapy agents has not been very promising to date, since they have 
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not increased the survival rate. The major reason for this is multidrug resistance associated 
with most of the drugs available [88]. Chemotherapy treatment is suitable for the patients 
who are in advanced stages of HCC and do not fulfill the criteria for surgical resection or 
liver transplantation [81].  Several goals are possible when using chemotherapy to treat 
HCC patients, including curing the cancer, slowing cancer growth, and treating cancer 
symptoms [89]. In general, four anti-cancer drugs types are available, including alkylating 
agents, antineoplastic agents, intercalating agents and molecular target anti-cancer agents. 
However, the Food and Drug Administration has approved only a few drugs for the 
treatment of HCC (Sorefenib and Erlotinib), which are considered molecular target anti-
cancer agents. [90]. 
 
1.5.2.2.5 Radiotherapy: 
Radiotherapy is another option for the treatment of HCC. This therapy can achieve 
necrosis by killing the tumor cells in a small liver tumor mass. However, radiotherapy has 
some risks for the patients, such as causing abdominal injuries or extensive hepatitis. For 
these reasons, the use of this technique for treating HCC is very limited [88]. 
 
1.5.2.3   Resistance of the Chemotherapeutic Agents: 
The main available treatments for cancer are chemotherapeutic agents which can 
either stop or slow the abnormal fast division of the cells. The major problem associated 
with the available chemotherapeutic agents is drug resistance, which occurs with 30%-80% 
of cancer patients. Cancer cells such as HCC cells produces drug resistance via three 
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mechanisms: multidrug resistance (MDR), P-glycoprotein drug resistance (P-gp) and 
multidrug resistance protein (MRP). All of them are activated and effective in the HCC 
treatment process [94, 95]. Therefore, there is an urgent need to find a new agent to 
overcome chemotherapeutic resistance. 
1.5.3 Molecular Targets for Treatment of HCC: 
HCC can be cured by either liver transplantation or surgical resection if discovered 
in its early stages. However, most of the HCC cases are discovered in the late stages, which 
decreases the general survival rate [91]. The HCC patients who are suitable for curative 
treatments represent approximately 15% of those diagnosed [92]. The essential reason for 
this disappointing survival rate is the lack of effective chemotherapeutic agents that can 
cure HCC in its late stages. A large number of studies have demonstrated that only 10%-
20% of HCC patients respond to the chemotherapy treatments, with toxicity and cellular 
resistance to available chemotherapeutic agents being the main obstacle to successful 
treatment [93]. In conclusion, searching for new active molecular target anti-cancer agents 
for HCC has become a popular area for research due to the urgent need to overcome the 
toxicity and cellular resistance problems. In addition, identifying molecular targets is 
essential for the discovery of a therapeutic treatment that overcomes the resistance and 
decreases the side effects.   
 
1.5.3.1 Epidermal Growth Factor:  
Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) is one of the 
tyrosine kinases that has been studied as a promising target for the treatment of different 
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carcinomas, including HCC [96]. EGFR, which is also known as ErbB1, is a member of a 
family of growth factor receptors that also includes ErbB2, ErbB3 and ErbB4 (Fig. 1.5). 
Paracrine or juxtacrine extracellular ligand binding, such as epidermal growth factor 
(EGF), and transforming growth factor (TGF)-α stimulate the EGFR which leads to hetro- 
or homo-dimerization and conformational change that activates the tyrosine kinase and 
allows autophosphorylation. When the phosphorylation occurs, a number of signaling 
pathways activate, leading to cancer cell invasions, proliferation, metastasis, inhibitory of 
apoptosis and angiogenesis (Fig. 1.5).   
 
Figure 1.5 Potential molecular targets for treatment of HCC. 
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Therefore, inhibition of the EGFR-TK signaling cascades provides a potential 
approach for the treatment of hepatocellular carcinoma (HCC). In the signaling cascade, 
either upstream or downstream targets of EGFR can be used for the treatment of any cancer 
in general and HCC specifically [97-100]. Different organic compounds, such erlotinib and 
lapatinib (Fig. 1.6), have shown potent inhibitory activity against EGFR by inhibiting its 
phosphorylation; these are known chemotherapeutic agents for the treatment of HCC (Fig 
1.6). Erlotinib (Tarceva) is a very active and selective inhibitor of the EGRF-TK protein. 
It has an advantage over most of the anti-cancer agents in that it can be taken orally, inhibits 
cellular proliferation and causes cell cycle arrest at the G1 phase. In addition, it has been 
approved as an active drug for pancreatic and lung cancer by the FDA but is still in Phase 
II clinical trials as an anti-cancer drug for HCC [101].      
  
1.5.3.2 Vascular Endothelial Growth Factor (VEGF): 
HCC is considered a hypervascular cancer, which has a large amount of tumor 
vascularity. VEGF is connected to the angiogenesis of various cancer types and is a 
significant part of HCC angiogenesis [102], enhancing the progression of HCC and its 
resistance [97]. HCC and all other tumor masses need blood vessels to survive and enlarge, 
so these blood vessels are considered abnormal since they are responsible for the high fluid 
pressure inside the tumor mass. Therefore, VEGF targeting agents may cause a decrease in 
the tumor vessels' supplies and their sinuosity, which leads to a decrease in the internal 
pressure of the tumor mass. All of these processes will lead to normal blood vessels [103].  
Gerber et al, 2005 proved the ability of anti-VEGF drugs, in combination with other anti-
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cancer agents, to cause a fast decrease in the internal vessel pressure of the tumor mass, 
which resulted into faster targeting of the agents to the tumor mass, a reduction in the tumor 
size and an increase in the survival rate [104]. Different agents have been designed to treat 
HCC by targeting VEGF or VEGFR. Some of them have been proven effective, such as 
Sorafenib (Fig. 1.6), and some are still in clinical trials to verify their pharmacokinetic 
profiles. Sorafenib is the first molecular target drug approved by the Food and Drug 
Administration (FDA) for the treatment of HCC. It is considered a multi-kinase agent that 
stops tumor cell proliferation by inhibiting different molecular targets, including VEGFR 
and PDGFR tyrosin kinases, which produces an anti-angiogenic effect. In addition, it 
targets the downstream cascades such as the Raf/MEK/ERK signaling pathway (Fig. 1.6) 
[91, 97, 105].  
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Figure 1.6 Structures of known Chemotherapeutics that target EGFR for treatment of 
HCC. 
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1.5.3.3  Mitogen Activated Protein Kinase (MAPK) Pathway: 
MAPK includes, in its downstream, four main kinases— Ras, Raf, MEK and ERK 
(Fig. 1.5)— which communicate with each other by phosphorylation. They are responsible 
for cell division, growth and regulation. These downstream proteins are connected to the 
upstream receptors such as PDEFR, EGFR, and VEGFR (Fig. 1.5) [105, 106]. So the 
MAPK pathway is an essential player in the growth and survival of HCC cells, which 
makes it a promising target for the treatment of HCC [107, 108]. ABT-100 is one of the 
anti-cancer agents in phase II clinical trials that inhibits the farnsylation process of the 
protein Ras by inhibiting the enzyme farnesyl transferase, which leads to a decrease in 
tumor cell growth [105, 109]. The family of the protein Raf includes three members: A-
Raf, B-Raf, C-Raf. Hyperactivation of C-Raf (wild type) in various cancer types, including 
HCC, was the only reported one, which makes it a valuable target for treating HCC [110]. 
Sorefineb is an approved HCC chemotherapeutic agent that inhibits B-Raf, C-Raf, FGFR, 
PDGFR and VEGFR [111]. The family of the protein MEK includes two subunits, MEK1 
and MEK2. Huynh et al reported that overexpression of MEK1 and MEK2 lead to an 
activation of ERK1 and ERK2; in the case of HCC, this occurs in different percentages. 
Additionally, it has been proven in in vitro studies that the addition of a MEK1 or MEK2 
inhibitor to HepG2 or Hep3B HCC cell lines will inhibit the autophosphorylation and cause 
cell apoptosis. MEK inhibitors, including include Selunetinib, RDEA119 and ASCO2010, 
are still in phase II clinical trials, [112].   
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1.5.3.4   PI3K/Akt/mTOR Pathway: 
PI3K/Akt/mTOR pathway is a downstream signaling cascade that connected to the 
upstream receptors of the cell (Fig. 1.5). Cellular activation of the protein PI3K will 
automatically activate the Akt protein kinase and result in number of phosphorylation, 
which leads to cellular proliferation and apoptosis. In the case of HCC, this pathway will 
be superexpressed, making it a good target for the treatment. mTOR is a protein that is 
responsible for the regulation of the cellular translation process. This process includes 
various numbers of initiation factors, such as 40s ribosomal, protein S6 kinase and 4E-
binding protein-1, which are involved in the mRNA translation process during cell 
proliferation and angiogenesis. All of these features make mTOR an interesting target for 
the treatment of HCC [113]. The immunosuppressive and antibiotic agent Rapamycin is 
known as an mTOR inhibitor and has demonstrated inhibition activity against HCC cell 
lines [105, 114].   
 
In general, to find new agents that have the ability to selectively target the biological 
molecular targets, understanding the nature and behaviors of these molecular targets with 
the designed compounds is essential. One of the known techniques to assist with the design 
and to predict the simulation of the designed compounds inside the molecular targets is 
molecular modeling.    
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Figure 1.7 Approved and clinical trials agents for treatment of HCC. (Copied from 
[106]). 
 
1.6 Molecular Modeling: 
1.6.1 Introduction: 
Research and development to discover a new drug in the pharmaceutical industries 
requires much time and a high cost, so new approaches are always needed to reduce the 
time and cost. Molecular modeling is one means to provide a fast prediction of the proposed 
compounds' behavior in the molecular biological target with a low cost [115]. Molecular 
modeling is used to calculate the action and characteristics of each atom and molecule of 
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the structure with a logical conclusion of the synthetic strategies and verification of the 
mechanistic approaches by predicting the patterns of transition states (TS). In addition, the 
molecular docking technique can be utilized to calculate the binding affinity between the 
compounds and the molecular biological targets, such as proteins, receptors and enzymes, 
in order to determine the potential drug candidates and hit compounds [115, 116]. 
Molecular modeling has a number of programs and applications that can predict the 
physical and chemical properties of a compound, such as absorption, distribution, 
metabolism and excretion (ADME) [117].  
 
The drug discovery process has improved since the use of computational 
approaches began in the 1980s [116, 118]. Several computational methods have been 
involved in the process of drug discovery, such as structure-based drug design (SBDD) and 
ligand-based drug design (LBDD) [118]. SBDD utilizes the 3D structure and biological 
data of the protein of interest to determine the best compounds (usually small organic 
molecules) that bind to the selected protein. The compounds that show a high binding 
affinity to the targeted protein are called a "hit" which will be screened in a fast biological 
screening system, called high throughput screening (HTS), to find the lead compound (LC). 
On the other hand, LBDD uses known active compounds (known drugs) and then identifies 
their pharmacophores as the origin for the lead compound determination [119]. LBDD is 
considered a significant approach in the drug discovery process; however, it needs a large 
group of known ligands for which biological tests are handy. Thus, SBDD considered 
easier to utilize for the process of drug discovery [118].  
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Molecular docking is a process where small organic compounds are docked against 
a specific molecular active site of a protein (target). This is considered a very helpful 
process in the computational methodology of drug discovery. The main goal of the 
molecular docking process is to find the appropriate conformational structure that binds to 
the active site of the protein and score a high binding affinity. Therefore, the docking 
process is a powerful technique because it can provide a pattern of set compounds with 
specific pharmacophores based on their interaction with the targeted protein. This may lead 
to the discovery of promising novel candidates. The process of docking begins with the 
building of a database of molecules and a structure of targeted proteins in order to detect 
the compound with a high binding affinity to the protein. The main obstacle involved in 
this process is comparing the resulting binding affinity of the proposed molecules toward 
a specific protein with the binding affinity of known standards; this is called relative 
binding affinity. In general, molecular docking may take a long time to determine the hit 
molecules which can be optimized to a lead compound (LC). However, docking is a safe 
financial technique that protects the research in case of a failure to discover the lead 
compound; the research can then return to the database to find another hit molecule [120].  
 
1.6.2 Molecular Docking Approaches: 
Two main approaches have been developed to conduct molecular docking: 1) the 
simulation approach, which is based on a computer simulation to calculate the energy 
differences during the compound-protein docking process; 2) the shape complementarity 
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approach, which uses a specific application to estimate the compound-protein surface 
complementarity [121, 122]. 
 
1.6.3 Molecular Docking Types: 
Molecular docking consists of three different types based on the docked molecules 
and the protein of interest. First, flexible molecular docking includes different conformers 
of the ligands, as well as the targeted proteins, to find the best ligand-protein conformers 
complex. This type relies on the induced-fit model [121, 123, 124].  The second type is 
semi-flexible molecular docking, in which different conformers of the compounds will be 
generated and docked on a rigid protein to find the best ligand conformer to create a stable 
complex with the protein. This type of molecular docking is the most popular type among 
all molecular docking types [121]. Third, in rigid molecular docking, both the compounds 
and the targeted proteins are rigid, so the concept of key and lock will be applied [121].  
 
1.6.4 Limitation of Molecular Docking: 
Some noticeable points in the molecular docking process, from both site ligand and 
protein, may cause limitations for the molecular docking process. These include 
conformational changes in both the ligands and targeted proteins that occur during the 
binding, the accuracy of the X-ray crystallography of the protein structure crystalized with 
the known ligand, entropic and enthalpic influence, the reality that the whole biological 
system can be represented by a single protein and the effect of metals and water molecules 
in the interaction between the ligand and protein [115, 119]. Multi-step approaches have 
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been used in the docking process to overcome all of these limitations. The steps begin with 
putting a small organic molecule (ligand) into the active site of a protein that mimics a 
favorable interaction with the protein. Then by evaluating the interaction between the 
ligand and the protein, their source of binding affinity can be determined; this is called 
scoring.    
 
1.6.5 Overview of Docking Scoring:  
The interaction between the protein and the ligand is the main output of the process and 
takes into consideration multiple molecular factors, such as H-bonds, hydrophobic 
interactions, overlay with the co-crystalized ligand, and types of amino acids involved in 
the interaction. During the docking, the protein can be represented at three different levels: 
atomic, surface and grid [125, 126]. In regard to the ranking steps of molecular docking, 
the atomic representation and potential energy function are relatively easy to determine due 
to the intricacy of computer calculations at the atomic interaction level. Protein-protein 
molecule docking can utilize surface-dependent molecular docking for their receptor 
representation. Various docking programs using potential energy grid functions are 
available to perform the energy calculation. Van der waals and electrostatic potential can 
be saved as grid points using grid-based docking [127, 128]. Ligand and protein flexibilities 
can be measured by utilizing algorithm search procedures. Three methods have been 
developed for measuring the ligand flexibility simulation— systemic and random methods. 
Molecular dynamics simulation is the cornerstone for simulation ligand flexibility search 
methods [129]. However, simulation search methods have a disadvantage, in that they 
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cannot pass high energy barriers during the measurement of flexibility in a short time. The 
ligand flexibility systemic search mainly discovers all possible classes of reedom in a 
ligand. However, an alternative method for a systemic ligand flexibility search starts by 
generating a library of compounds and creating different conformers for each one of the 
compounds. By utilizing this approach, the library of different ligand conformers will be 
docked against the biological target at one time, which reduces the time and efforts of this 
step. Lastly, the random ligand flexibility search method allows the ligand to change to 
different conformers and mimic the degrees of ligand freedom. Genetic algorithm and 
Mento Carlo are the most popular random ligand flexibility search methods [129].  
 
The ligand flexibility search method is considered more advanced than the protein 
flexibility search method [125]. In general, search methods measure the flexibility in a 
particular part of the protein, usually the side chain, which is accomplished by various 
methods such as rotomer libraries, molecular dynamic, protein ensemble grids and Monte 
Carlo [126, 130, 131]. 
 
1.6.6 Types of Docking Scoring Functions: 
The main goal of docking scoring is to calculate the energy difference (∆G) of the 
binding of a ligand-protein complex. Generally, various attempts have been made to 
accomplish the ∆G calculation in a short time, since it is considered a time- and money-
consuming process. The three types of docking scoring functions are called empirical-
based, force-field based and knowledge-based [125]. Empirical-based scoring functions 
   39 
 
  
rely on the binding energy of the ligand-protein complex that can be measured by the 
addition of single unrelated terms; the coefficients of the terms are measured from a 
regression examination utilizing experimental measurements of binding energy and known 
data from an X-ray crystallography (3D structure). In the force-field scoring function, the 
sum of the internal-ligand energy and protein-ligand energy is the main consideration. The 
majority of force-field scoring functions do not count the various conformer structures of 
one protein, which make the internal protein energy measurement useless for most 
purposes [125, 128]. The force-field scoring functions are dependent on various groups of 
force-field parameters, including AMBER, Tripos force field, OPLS-AA and MMFF94. 
Electrostatic and Van der Waals energy interactions are the parameters that describe the 
protein-ligand interactions. The electrostatic expression is described by Coulomb equations 
that explain the force interaction between two differently charged particles, while the Van 
der Waals interaction expression is explained by Lennrd-Jones potential functions, where 
scoring functions are responsible for different results [125, 128]. Knowledge-based 
docking scoring functions were invented to ignore binding energy and instead lean on 
experimental X-ray crystallography (3D structure) [125]. The complex interaction of a 
ligand-protein is designed utilizing an uncomplicated atomic interaction system.  
The computational effort is the distinguishing characteristic of these scoring 
functions, which facilitate the process of scoring huge libraries in a short time. However, 
their use relies on known information from small numbers of ligand-protein complex 
structures. The numerous interactions that rule ligand-protein interaction formation cannot 
be managed by a single scoring function. Therefore, consensus scoring functions are very 
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common, since they acquire information from various scores, which minimizes the errors 
of a single score and enhances the chance of finding the hits [125, 132]. However, if the 
terms in the various scoring functions are safely matched, it may destroy the balance and 
increase the errors.  
 
In conclusion, molecular modeling is a helpful technique to find potential 
candidates to be synthesized and structurally optimized. These candidates can then be 
followed by biological evaluation to provide the clinical form of the synthesized 
compounds.  
 
1.7 Biological Evaluation of Synthesized Compounds: 
All new compounds should be biologically screened on various biological assays. 
Biological evaluation can be conducted in animals, isolated organs, lower organisms, or 
ex-vivo and in-vivo screening assays. Some of these assays, such as whole animal 
evaluations, are very expensive to use, especially in the early stages of biological screening, 
compared to less expensive biological assays such as cultured cell lines known as in-vitro 
assays [133].  
 
The most commonly used in-vitro biological assay is cytotoxicity. This assay 
measures the lowest concentration of a particular compound that can inhibit the growth of 
50% of a particular cell line (IC50). The cell growth inhibition can be tested by one of the 
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following tests: cellular biomass assay, membrane integrity assays, day binding assays and 
metabolic impairment assays. 
 
To measure the dissolution of enzyme activity or the concentration metabolites, a 
metabolic impairment assay can be used by adding a toxin. The MTT assay mainly checks 
the capability of live cells to convert by reduction the yellow 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltrazollium bromide salts, known as MTT salt, to its purple formazan state 
utilizing a mitochondrial oxidoreductase enzyme [134].   
 
The ligand-binding biological assay is a very common assay in the drug discovery 
process. This assay can be conducted utilizing Enzyme Linked Immunoassays (ELISA) 
which simply confirm the binding between the protein and the ligand [135, 136]. In order 
to pinpoint a particular protein in the cell, the target specific assay in a cell-based ELISA 
kit can be utilized to identify this particular protein. This is considered a very powerful 
assay compared to other assays, such as the western blot.     
 
In conclusion, biological evaluation is one of the cornerstones of the drug discovery 
process because it confirms the hypothesis using molecular modeling studies. In addition, 
it helps to identify the significant pharmacophores for further chemical optimization in the 
synthetic scheme. All of these connected steps are very helpful in order to develop active 
promising candidates for future drugs.   
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1.8 Project Objectives: 
This project concentrated on using cucurbitacins as a natural product that has 
inhibitory activity toward the epidermal growth factor receptor (EGFR) to develop drug 
candidates for the treatment of hepatocellular carcinoma (HCC). Few studies have defined 
the activity of cucurbitacins toward EGFR in HCC cell lines, such as the HepG2 cell line. 
In addition, no cucurbitacin-like compounds have been synthesized and biologically 
evaluated targeting HCC. The main objectives of this project are: 
A- Design of novel CUCS-inspired estrone analogues targeting epidermal growth factors 
receptor (EGFR) using molecular modeling studies. 
B- Synthesis of novel CUCS-inspired estrone analogues targeting epidermal growth factors 
receptor (EGFR). 
C- Biological screening of the synthesized novel CUCS-inspired estrone analogues targeting 
epidermal growth factors receptor (EGFR).  
D- Inhibitory activity screening of CUCUS-inspired estrone on MRP1 in order to overcome 
the cancer resistance for current chemotherapeutic drugs.    
E- Structure activity relationships (SAR) studies on the synthesized novel CUCS-inspired 
estrone analogues.  
Docking studies were performed on cucurbitacins structure to identify the 
significant pharmacophores in order to design novel CUCS-inspired estrone analogues 
targeting epidermal growth factors receptor (EGFR). The synthetic route was designed and 
outlined by using hybrid structural design methods in which the cucurbitacin side chain 
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was installed in the steroidal skeleton structure, then structural modifications were 
conducted on the C-17 and C-17, C-3 and B/C juncture of the steroidal skeleton structure. 
In addition, a series of various aldehydes were installed on the side chain as part of the 
chemical design using Aldol condensation reactions. The biological screening tests were 
used to analyze the synthesized compounds to be evaluated for further optimizations 
targeting EGFR. 
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Chapter Two 
Design of CUCUS-Inspired Estrone Analogs (CIEA) Targeting Epidermal Growth 
Factor Receptor (EGFR) 
2.1 Introduction: 
Natural products are known as one of the major source for drug design and 
treatment of cancer. Cucurbitacins is a group of steroidal-triterpene tetracyclic natural 
products, which reported for their anti-cancer activities [1, 2]. Although cucurbitacins have 
reported for their potent activities, synthesis of these compounds is challenging due to the 
complexity of the carbon skeleton and functionalities of these compounds. Current studies 
in Halaweish’s group to study cucurbitacins targeting epidermal growth factor receptor 
(EGFR) in unclear and limited [3].  
 
Molecular modeling and docking methods were utilized to find potential affinity 
between cucurbitacins and EGFR along with downstream proteins cascade including Ras, 
Raf, MEK and ERK (Fig. 1.5). In addition, additional studies including cytotoxicity, 
western blot and ELISA were used to confirm the molecular docking studies results. 
Cucurbitacins proved to have activities against different cancer cell lines; however, their 
activities don’t show specificity or selectivity toward their biological targets [4]. 
Gastrointestinal toxicity is one of the side effects involved with cucurbitacins subjections 
due to their cellular activations [5]. Potent cytotoxicity of cucurbitacins in in-vivo model 
toward renal carcinoma demonstrated narrow safety and have been withdrawn from 
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preclinical studies due to their fatal activity [6]. The broad biological activities of 
cucurbitacins, non-selectivity and toxicities are due to their complex chemical structures. 
Model the bioisosters of these compounds to mimic the structure functionalities on 
steroidal skeleton. Cucurbitacins inspired estrone compounds was accomplished in 
Halaweish’s group targeting melanoma [15]. The success in Halaweish’s group of utilizing 
the molecular docking inspired us to model novel analogues to target hepatocellular 
carcinoma (HCC).   
Due to the similarity in chemical structure, particularly the cyclopentane and the 
four-ring system, redesigning and mimicking cucurbitacins utilizing steroids may improve 
their biological activities and selectivities. Cucurbitacins side chain, which contain α-β-
unsaturated ketone, is significant pharmacophore for their biological activities. Also, the 
presence of C-16 hydroxyl group increased the chance of forming H-bond with C-24 
ketone which may enhance the electrophilisity of the α-β-unsaturated ketone [7,8].    
Studying and testing cucurbitacins as promising EGFR inhibitors is not favorable 
sometimes due to availability limitation, has encouraged us to identify the most significant 
pharmacophores of cucurbitacins in order to synthetically modify their main skeleton to 
increase the selectivity toward EGFR and minimized their undesirable side effects [14]. 
Few researches and studies on the structure modifications of cucurbitacins have been 
conducted including quantitative structure activity relationship (QSAR) studies of semi 
synthetic of cucurbitacins by Bartalis and Halaweish [8], partial synthesis of cucurbitacin 
B and D by Jung [9], hexanorcucurbitacin compounds by Ryu [10] and synthesis of 
dihydrocucurbitacin B by Lang [11]. However, some of these synthetic studies are 
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impracticable for certain wanted cucurbitacins pharmacophores to be modified for certain 
biological activities.  
In order to understand and test the potential interactions between the designed 
ligands and their biological targets, molecular modeling considered a precious technique 
for this study. Precise ligand conformation is highly recommended during drug design to 
perform an accurate structure-based drug design and virtual screening in order to have full 
understand of ligand-target complex interactions through reading the energy parameter [12, 
13].  
The biological activity of any molecule should rely on one conformation that 
possesses the lowest energy conformation which can be distinguished among all other low-
energy conformers by using Cambridge crystallographic database (Fig. 2.1). All of these 
signs promoted us to build an assumption that utilizing steroidal skeleton to install 
cucurbitacins pharmacophores to inhibit EGFR could be a potential assumption as shown 
in figure 2.2.   
 
Figure 2.1  X-ray crystallography of cucurbitacin D showing the potential functional 
groups for the binding with biological targets. 
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Cucurbitacin R1 R2 R3 R4 R5 ∆1,2 ∆23,24 
A OH =O MeOH H AC - + 
B OH =O CH3 H AC - + 
C H OH MeOH H AC - + 
D OH =O CH3 H OH - + 
E OH =O CH3 H AC + + 
F OH OH CH3 H OH - + 
H OH =O CH3 OH OH - - 
I OH =O CH3 H OH + + 
J OH =O CH3 OH OH + - 
Figure2.2 General structures of Cucurbitacins and steroid. 
 
Assigning the significant pharmacophores of the steroids is complicated mission. 
The B and C rings of the steroids have trans configuration but it is cis configuration at  
cucrbitacins B and C rings which should be taken in the consideration during the designing 
process [14, 15].  
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Bartalis et. al 2011 showed that possessing α-β-unsaturated ketone moiety of the 
cucurbitacins is essential for the biological activity [8]. In addition, Matsuda et al. 2010 
demonstrated the significant of α-β-unsaturated ketone moiety of the cucurbitacins 
scaffolds at C-22 and C-24 for their biological activities when he found that some 
cucurbitacins-like structures that has no α-β-unsaturated ketone such as hexanor 
compounds lost their biological activities [7, 15]. Furthermore, Rodrigues et al, 2016 
showed that one sixth of all known natural compounds contain α-β-unsaturated carbonyls 
[16].  Which prove the biological significant of α-β-unsaturated ketone at the cucurbitacins 
side chain.  
Estrogens including estriol, estradiol and estrone are group of popular steroids that 
naturally present in women and men and they involved in different biological processes 
[17]. In addition, estrogens are involved in the human body with hormonal activities and 
development of estrogen-dependent breast cancer [17, 18]. The ability of estrogens and 
their derivatives to influence various biological activities and their few adverse effects 
make them very interested analogues to be modified for other biological interests. For these 
reasons, estrone was chosen as starting material for installing the cucurbitacins α-β-
unsaturated ketone side chain with different functional groups to see their effects on the 
binding affinity toward the biological targets particularly EGFR. 
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Figure 2.3 Significant positions for biological activities in estrone main structure. 
 
Modifications of  steroids skeleton have got the interest of organic chemist due to 
number of reasons 1) steroidal skeleton provides important and significant chemical 
challenges; 2) modification in their main structure may provide an interested biological 
changes as these compounds may act as pharmacophore carrier; 3) their total synthesis is 
very interested for chemist which may need to find new synthetic approaches for further 
structural modifications [19]. Serious of estrone modified compounds have been developed 
based on the fact that small structure modifications on estrone skeleton scaffold may lead 
to large variations in the biological activities [20]. Estrone structural modifications can be 
categorized into two types 1) structural modifications by adding new chemical moieties to 
the estrone scaffold; 2) structural modifications on the steroids complicated ring system by 
either addition of heteroatoms to one of the steroids carbons, or by chemical modifications 
in one of the ring system (Figure 2.3) [20, 21]. The most popular type is the first one since 
it provides an overall synthetic tasks that is needed to combine various heteroatoms with 
the steroids skeleton structure.  
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Various pharmacophores of natural compounds such as cambretastatin A4, gallic 
acid and chelcones were installed into the estrone skeleton structure, which is known to 
possess estrogenic activity and anti-cancer activities targeting different biological targets 
[22, 23]. However, this hybrid structure modification is not always providing the desired 
biological activity. Another examples are derivatives of 2-methoxyestradiol such as alkoxy 
and benzyloxy methylestradiol which proved as anti-breast cancer agents through 
stabilizing the microtubule without having estrogenic activity as side effect [24]. Because 
of the low bioavailability of methoxyestradiol, number of modified estradiol in different 
positions such as C-17, C-16, C-3, and C-2 have been conducted to improve their 
bioavailability as well as their biological activities [24-27].  
Small modifications at C-2 of estrone main structure by installing sulfamate moiety 
change the biological properties of the estrone dramatically by blocking the estrogenic 
activity and performing anti-peroflorative activity in breast cancer cells [28]. Bodnar et al, 
2016 proved that triazol substitution at C-3 position of estrone enhanced the biological 
activity as anti-cancer with IC50=0.3-0.9µM [27]. Ahmed et al. 2014 demonstrated that 
substitution on C-17 of the estrone skeleton structure showed a potent inhibitory activity 
of MAPK pathway toward treatment of melanoma [15]. Therefore, by utilizing molecular 
modeling, series of modified estrone at C-25, C-17, C-16, C-11 and C-3 positions were 
designed and developed to target Epidermal Growth Factor Receptor (EGFR) toward 
treatment of Hepatocellular Carcinoma (HCC).  
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                               Estron                                                                     Cucurbitacin D 
 
MMA-132 
 
Figure 2.4 3-D structure demonstrated the conformations of Estrone, Cucurbitacin D and 
MMA-132 analog. 
 
2.1.1 Molecular Modeling and Rational of Inhibitor Design: 
2.1.1.1 Protein Kinase: 
Protein kinases are the most common family among human enzymes representing 
1.7% of the total proteins, which involve in the regulation of several of biological functions 
in the cell via autophosphorylation including angiogenesis, cell growth and differentiation, 
which make them an interested target for treatment of cancer [30].  
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Protein kinase transfer the ATP phosphate group to the amino acids residues of the 
protein such as theronin, tyrosin and serin. It consists of two main domains, cyctain-rich 
(CR) domain and ligand domain (LD). In order to design a protein kinase inhibitor, deep 
understanding of signaling pathway mechanism of interactions should be known, which 
categorized the protein kinases inhibitors into three categories. 1) Inhibitors that directly 
bind to the ATP binding pocket of the protein kinase, which usually consist of H-bond 
donors and acceptors to form at least single H-bond such as erlotinib, fasudil and gefitinib  
[32]. 2) Inhibitors that bind with inactive protein kinase ATP binding pocket which consist 
of extra hydrophobic site which increase the selectivity to this site compare the first type 
such as sorefinib, nilotinib and lapatinib. 3) Allosteric protein kinase inhibitors and they 
don’t compete with ATP to bind to its binding site.  
Briefly, most of the protein kinase inhibitors that approved as anti-cancer are ATP 
competitive inhibitors and form at least one H-bond with protein amino acid residues [29-
33].  
2.1.1.2 PI3K/Akt/mTOR and RAS/Raf/MEK/ERK Proteins Cascades: 
PI3K/Akt/mTOR is significant downstream proteins cascade which can be 
activated by various cellular activators that lead to number of cellular processes including 
cell-growth, cell-survival, translation, angiogenesis and transcription. Different types of 
cancer lead to disturbance in PI3K/Akt/mTOR pathway which make them promising 
targets for designing promising inhibitors as ant-cancer agents.  
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Known Raf inhibitor proved to be one of the ATP competitive inhibitors 
performing various kind of interactions with hydrophobic binding site such as PLX-4720 
which has been advanced by Plexxikon to possess high selectivity to B-Raf and high oral 
bioavailability. Other B-Raf inhibitors includes PLX-4032 (Vemurfenib) and Sorefinib. 
Various MEK inhibitors have been discovered such as Selumetinib, U0126, PD184352 and 
PD0325901. MEK inhibitors bind allosterically to the non-ATP binding site of MEK 
protein which increase their specificity and selectivity. MEK1/2 crystal structures 
demonstrated that they have outstanding hydrophobic binding pocket beside the ATP-
binding pocket [34, 35]. Some other compounds such as resorcyclic inhibitors which 
demonstrated MEK inhibitory activity and other kinases as well. The presence of enone-
based pharmacophore in these inhibitors as Micheal acceptor is the base of their broad 
biological activities [36]. Our hypothesis of development of esterone to possess anti-cancer 
activities is by installing the cucurbitacins enone side chain which consist of α-β-
unsaturated ketone at C-22 and C-24 of the estrone main scaffold.  
 
2.1.1.3 Compounds with α-β-unsaturated Carbonyl (Micheal Acceptor):  
Michael acceptor or α-β-unsaturated carbonyl pharmacophores considered as one 
of the most reactive functional groups in natural compounds. Recent review in nature 
chemistry showed that 1/6 of the all known natural compounds contain α-β-unsaturated 
carbonyl groups. It is a question mark about weather adding Michael acceptor 
pharmacophores to design a potential candidates targeting specific biological target is 
valuable or not since these groups are very reactive electrophiles and have broad biological 
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activities because they can react with various number of nucleophiles in the body such as 
DNA, RNA and proteins which lead to unwanted side effects. However, Michael acceptor 
functional groups demonstrated various beneficial activities such as anti-oxidants by 
trapping thiol and radical scavenger [16, 37].  
Therefore, a virtual library of estrone modified structures at different positions 
including C-3, C-11, C-16, C-17, C-24 and C-25 were generated containing cucurbitacins 
enone side chain , known EGFR inhibitors and cucurbitacins to be investigated as anti-
hepatocellular carcinoma agents utilizing OpenEye® Scientific software including Omega, 
FRED and VIDA. The designing strategies were divided into two different series using 
molecular modeling. First series is to assemble cucurbitacins enone side chain at C-17 of 
estrone with different aliphatic and aromatic moieties at C-25, double bond at C-16 and C-
17 and methoxy moiety at C-3. The last functional groups is to block the estrogenic activity 
of the estrone. Second series is to install cucurbitacins enone side chain at C-17 of estrone 
with different aliphatic and aromatic moieties at C-25 and sulfamyl or hydroxyl groups at 
C-3.  
2.2 Methods of Molecular Modeling: 
All computer works were conducted on Gateway Computer with Windows XP. OpenEye® 
software, semi flexible molecular docking program, were utilized to conduct the docking 
process. It consist of different applications such as OMEGA, FRED and VIDA and each 
one of them is directly related to the other functionally as they will be described in detail 
in next paragraphs.    
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Figure 2.5 Proposed modified estrone structures. 
2.2.1 2-D and 3-D Structures Molecular Modeling:  
A virtual library of 200 CUCUS-inspired estrone analogues, which contain 
cuucurbitacins enone side chain assembled in C-17 of estrone skeleton, other related 
derivatives, known EGFR inhibitors and different cucurbitacins as standards were 
generated utilizing Chem office 2012, and using MMFF94 calculation for energy 
minimization in order to acquire similar structural confirmation mimic to natural 3-D 
structure for each compound. 
 
2.2.2 Utilizing OMEGA to Generate Conformers: 
The energy minimized compounds were converted into *.pdb forms and then all of 
the *.pdb files collected as one *.pdb file to be utilized as an input parameter for Omega 
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calculations. Omega created different conformers of each single compound in the virtual 
library using MMFF94 calculation parameters so as to perform ligand-protein flexible 
docking. Some of Omega settings were modified from the default settings such as highest 
number of output conformers 400 (GP-NUM-OUT-CONFS), rejecting conformers that has 
energy differences compare to standards minimum ˃  0.5 Kal/mol (GP-ENERGY-WINDO) 
and choosing the conformers with lowest energy from the final calculations (GP-SELECT-
RANDOM false). Furthermore, increase the number of free rotatable bonds in each ligand 
to be 30 (GP-MAX-ROTORS) so as to create different conformers for all molecules in our 
library [38].  
 
2.2.3 Preparation of the Receptor Utilizing FRED: 
PDB format of the receptors were downloaded from the protein data bank (PDB) 
database (EGFR PDB ID # 1M17, RAS PDB ID # 4DTS, RAF PDB ID # 3OMV, MEK 
PDB # 4AN2, ERK PDB ID # 2OJJ) (Fig.2.6). These proteins were prepared utilizing 
FRED (Receptor preperation program of OpenEye® software). For the preparation of the 
proteins, graphical interface was used as part of FRED make receptor application. There 
are three main components of FRED make receptor application including mode selection, 
mode control and 3D viewing window [39]. 
The process of receptor preparation started by opening the receptor of interest into 
the FRED make receptor application which convert the .pdb file into 3-D view of the 
receptor chains including its binding ligands and co-factors. Then the next step is pointing 
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to the binding pocket and the co-crystalized ligand binds to it. Then mode selection window 
of the application will allow the generation of the grid box which should be in specific size 
not exceeding 60,000 Ao. However, if a large grid box is required to accommodate (larger 
than 60.000 Ao) then the box can be divided to two sites, otherwise the docking process 
will not be conducted smoothly. Final step is the mode selection window which is the one 
responsible for specifying the pocket shape so the docking program can recognize the inner 
and outer contour [39]. After conducting all of the previous steps, the protein should be 
prepared for executive molecular docking.   
Newman et al, 2012 additionally attract attention to the significant of possessing 
different types synthetic approaches utilizing the natural products such as, total synthesis 
of natural product and semi-synthesis of compounds contain functional groups 
(parmacophore) mimic from natural products, which clarify the role of the nature to inspire 
future organic chemist to prepare novel organic compounds, that can give better or the 
same activity as the natural compound with less side effects [18].  
Consensus score of the docking study can be calculated by various scoring 
functions at the final stage such as shapegauss, chemgauss3, oechemscore, screenscore and 
PLP. All the functional commands for OpenEye® FRED can be found in this link 
www.eyesopen.com/products. 3D structure of the docked ligands with protein can be 
visualized utilizing OpenEye®  VIDA application where 3D picture of the ligand-protein 
complex can be taken [40]. 
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Figure 2.6 3-D structure of all proteins and their standards inhibitors (downloaded from 
PDB). 
 
PDB ID: 1M17 
Epidermal Growth Factor 
Receptor tyrosine kinase 
domain with 4-
anilinoquinazoline inhibitor 
erlotinib.  
PDB ID: 4DST                                                                
Small-molecule ligands bind to a 
distinct pocket in Ras and inhibit 
SOS-mediated nucleotide exchange 
activity. 
 
PDB ID: 3OMV 
Crystal structure of c-Raf 
(Raf-1). 
 
PDB ID: 4AN2 
Crystal structures of human MEK1 with 
carboxamide-based allosteric inhibitor 
XL518 (GDC-0973), or related analogs. 
PDB ID: 2OJJ 
Crystal structure of ERK2 in complex with (S)-N-(1-(3-
chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-
chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide. 
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2.3 Results and Discussions: 
The prepared virtual library, which include estrone modified structures, 
cucurbitacins and known receptors inhibitors, were docked on five different proteins 
starting from the upstream cellular receptor EGFR and going down to the cellular 
downstream proteins pathway including Ras, Raf, MEK and ERK. Novel visual 
compounds of the CUCUS-inspired estrone analogues were designed in systemic way by 
assembling the cucurbitacins pharmacophores I n the estrone scaffold. Specifically, five 
main positions of the estrone skeleton were modified. First, installing cucurbitacins enon 
side chain at C-17 with different functional groups at C-25. Second, substituting C-3 
hydroxyl group with methoxy or sulfamoyl moieties. Third, modification at ∆9,11 position 
of the estrone core structure. Finally, installing various functional groups at C-25 of the 
enone side chain (Fig. 2.5).  
An average of 40-55 modified estrone showed lower consensus scores (better 
binding affinity) toward the targeted receptors than the known inhibitors such as erlotinib, 
cobimetinib and sorefinib.  
All of the designed virtual compounds were divided into two main groups: 1) 
modified estrone compounds with cucurbitacins enone side chain at C-17 of the estrone 
scaffold, double bond at C-16 and C-17 position, methoxy group at C-3 and different 
aliphatic and aromatic functional groups at C-25 (Fig.2.7); 2) modified estrone analogues 
with cucurbitacins side chain at C-17 of the estrone skeleton structure, sulfamoyl or 
hydroxyl groups at C-3 and various aliphatic and aromatic functional groups at C-25 
(Fig.2.8 and Fig.2.9).   
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The rational of building these different groups of estrone derivatives is to compare 
between different enon side chain by adding various functional groups at C-25 and their 
effect on the biological activities (to be discussed in Ch.3 and Ch.4).  
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Figure 2.7 First set of synthesized MMA analogues that contain methoxy at C-3, double 
bond at C-16 and C-17 and various aliphatic and aromatic functional groups at C-25. 
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Figure 2.8 Second set of synthesized MMA analogues that contain sulfamoyl at C-3 and 
various aliphatic and aromatic functional groups at C-25. 
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Figure 2.9 Third set of synthesized MMA analogues that contain hydroxyl at C-3 and 
various aliphatic and aromatic functional groups at C-25. 
2.3.1 Results of the Molecular Modeling of CIEA on EGFR: 
The results of molecular docking on the crystal structure of EGFR showed an 
outstanding binding affinity with the CUCUS-inspired estrone analogues containing 
various functional groups compare to the known EGFR inhibitor, Erlotinib. Modified 
estrone at C-17 with isopropanol enon side chain, methoxy group at C-3 and double bond 
at C-16 and C-17 position such as MMA102, MMA128, MMA129 and MMA132 
demonstrated various binding mods with EGFR binding pocket. MMA102 and MMA132 
are diastereomers to each other and showed varieties in the binding mode with the receptor. 
MMA132, which possess the stereochemistry of cucurbitacin D side chain, showed an 
outstanding binding mode with EGFR by forming H-bond with MET:769:A, which is same 
amino acids residues that erlotinib binds to in EGFR to induce anti-cancer activity by H-
bonding with the same amino acid MET:769-A; also MMA132 perform hydrophobic 
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interactions with the amino acids residues inside the binding pocket. While MMA102 
which has the opposite stereochemistry of cucurbitacin D demonstrated less binding 
affinity toward the EGFR binding site only with a hydrophobic interaction mode with the 
EGFR binding pocket. This result proved the significant of assembling the enone side chain 
with the stereochemistry of cucurbitacin D (Fig.2.10).  
 
 
 
 
A 
B 
Figure 2.10 Visual 
representation of A) MMA-
102 (orange) B) MMA-132 
(blue) in the EGFR ATP-
binding site along with 
Erlotinib (purple). 
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In addition, the presence of C-16 and C-17 double bond plays a significant role for 
the binding affinity which corresponds to our group publication before [14]. On the other 
hand, CUCUS-inspired estrone analogues with aromatic enone side chain such as 
MMA265, MMA270, MMA271, MMA287, MMA288, MMA289, MMA290, 
MMA292, MMA305 and MMA311 showed good binding affinity with H-bonds and 
hydrophobic interactions with the crystal structure of EGFR. Compounds with strong 
electron withdrawing groups at C-25 of the enone side chain such as MMA290, MMA292 
and MMA311 showed both H-bonds and hydrophobic mode of interactions (Fig.2.11); 
while compounds with electron donating groups at C-25 of the enone side chain such as 
MMA-265 showed only hydrophobic-hydrophobic interaction with amino acid residues of 
the EGFR (Fig2.12).     
 
Figure 2.11 Visual representation of MMA-292 (Red) in the crystal structure of EGFR. 
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Figure 2.12 Visual representation of MMA-265 (Green) in the crystal structure of EGFR. 
 
Second group of modified estrone that contain enone side chain at C-17, sufamoyl 
or hydroxyl groups at C-3 and different aliphatic and aromatic functional groups at C-25, 
such as MMA-240, MMA-241, MMA-294, MMA-295, MMA-297, MMA-300, MMA-
301, MMA-306, MMA-307, MMA-308, MMA-309, MMA-310, MMA-312, MMA-313 
and MMA-314, docking calculations showed strong binding affinities with the EGFR 
binding site with H-bonds and hydrophobic interactions with the amino acid residues at the 
binding site. Compounds with different enone side chains at C-17, sulfamoyl moiety at C-
3 and different functional groups at C-25 demonstrated outstanding binding affinity with 
the EGFR binding pocket by forming both H-bonds and hydrophobic interactions, while 
analogues with same functionalities at C-17 but with hydroxyl group at C-3 showed less 
binding affinity and lost their ability of forming H-bonds and only demonstrated 
hydrophobic interactions. These results revealed the significant of the presence of 
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sulfamoyl moiety at C-3 for the binding affinity toward the binding pocket of the 3D 
structure of EGFR (Fig.2.13). 
 
In conclusion, CUCUS-inspired estrone analogues with cucurbitacin D enone side 
chain at C-17, double bond at C-16 and C-17 and methoxy group at C-3 such as MMA-
132 are showing the highest binding affinity toward the crystal structure of the EGFR 
binding pocket with H-bonds and hydrophobic interactions. On the other side, estrone 
derivatives with cucurbitacins enone side chain at C-17 and sulfamoyl group at C-3 
demonstrating significant binding mode comparet to the known EGFR inhibitor 
(Erlotinib).  
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2.3.2 Results of Molecular Docking of CIEA on Ras:  
 CUCUS-inspired estrone analogues with various functional groups demonstrated 
special binding affinity with the 3D structure binding pocket of Ras protein. In particular, 
estrone cmodified compounds with cucurbitacins enone side chain at C-17, double bond at 
C-16 and C-17, methoxy group at C-3 and various aliphatic and aromativ functional groups 
A 
B 
Figure 2.13 Visual 
representation of A) 
MMA-240 (Red) B) 
MMA-301 (purple) 
in the EGFR ATP-
binding site. 
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at C-25 such as MMA102, MMA128, MMA129, MMA132, MMA265, MMA270, 
MMA271, MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and 
MMA311 showed strong binding affinities toward the targeted pocket in Ras protein. The 
presence of Cucurbitacin D enone side chain stereochemistry or the opposite 
stereochemistry in some derivatives such as MMA102 and MMA132 did not play role in 
affecting the binding affinity since both compounds demonstrated very good binding mode 
with Ras along with H-bons and hydrophobic interactions as shown in figure 2.14.  
 
 
 
A 
B 
Figure 2.14 Visual representation 
of A) MMA-102 (blue) B) MMA-
132 (purple) in the Ras binding 
site. 
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Estrone derivatives with aromatic functional groups at C-25 of enone side chain, 
methoxy at C-3 and double bond at C-16 and C-17 positions such as MMA265, MMA270, 
MMA271, MMA271, MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 
and MMA311 showed slight decrease in the binding affinity toward the Ras crystal 
structure in comparison to the aliphatic enone side chain such as MMA-102, MMA-128, 
MMA129 and MMA132 which has higher binding affinity (Fig.2.15). 
  
 
 
On the other hand, CUCUS-inspired estrone analogues with cucurbitacins enone 
side chain at C-17 of the estrone skeleton structure, sulfamoyl or hydroxyl groups at C-3 
A 
B 
Figure 2.15 Visual 
representation of A) MMA-
132 (purple) B) MMA-311 
(purple) in the Ras binding 
site. 
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and various aliphatic and aromatic moieties at C-25 such as MMA240, MMA241, 
MMA294, MMA295, MMA297, MMA300, MMA301, MMA306, MMA307, 
MMA308, MMA309, MMA310, MMA312, MMA313 and MMA314 demonstrated 
lower binding affinity toward the 3D structure of Ras compare to that of first group 
discussed before. Even though most of these analogues don’t show high binding affinity 
but they show both H-bonds and hydrophobic interactions with the binding pocket of Ras 
(Fig.2.16), which may demonstrate significant biological activities as Ras inhibitors.  
 
Figure 2.16 Visual representation of MMA-240 (Blue) at the binding pocket of Ras. 
 
2.3.3 Results of Molecular Modeling of CIEA on Raf: 
Molecular docking calculations of CUCUS-inspired estrone analogues with Raf 
protein showed varieties of binding modes. Cucurbitacins enone side chain at C-17 of 
estrone  analogues scaffold, methoxy at C-3, double bond at C-16 and C-17 and various 
aliphatic and aromatic moieties at C-25 showed different binding modes such as MMA132, 
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which possess the stereochemistry of cucurbitacin D side chain, has hydrophobic 
interaction with Raf binding pocket, while MMA102, which has the opposite 
stereochemistry of cucurbitacin D, which show H-bonding with the same targeted protein 
(Fig.2.17).  
 
 
 
 
In addition, compounds with aromatic functional groups at C-25 of the enone side 
chain such as MMA265, MMA270, MMA271, MMA271, MMA287, MMA288, 
MMA289, MMA290, MMA292, MMA305 and MMA311 demonstrated various binding 
A 
B 
Figure 2.17 Visual 
representation of A) MMA-102 
(purple) B) MMA-132 (yellow) 
in the Raf binding pocket. 
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affinities toward the targeted protein, Raf. For example, MMA292, which contain P-
trifluromethyl benzene at C-25 of the enone side chain, showed significant binding affinity 
toward the crystal structure of Raf compare to MMA-311, which has bromothiophene at 
C-25 of the enone side chain (Fig.2.18).  
 
 
 
For the second group of CUCUS-inspired estrone analogues that contain 
cucurbitacins enone side chain at C-17 of the estrone skeleton structure, sulfamoyl or 
hydroxyl groups at C-3 and different aliphatic or aromatic groups at C-25 of the enone side 
A 
B 
Figure 2.18 Visual 
representation of A) MMA-292 
(blue) B) MMA-311 (green) in 
the Raf binding pocket. 
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chain such as MMA240, MMA241, MMA294, MMA295, MMA297, MMA300, 
MMA301, MMA306, MMA307, MMA308, MMA309, MMA310, MMA312, MMA313 
and MMA314, the molecular docking study revealed that they demonstrated different 
levels of binding mods toward the targeted Raf protein. For example, compounds that 
possess strong electronwithdrawing aromatic functional groups at C-25 of the estrone 
enone side chain such as P-trifluromethyl benzene in MMA300, showed lower level 
binding affinity compare to the other compounds that have electron donating groups at the 
same position such as MMA267 which has P-methoxy benzene at C-25 (Fig.2.19). 
 
 
 
 
 
 
 
 
A 
B 
Figure 2.19 Visual 
representation of A) MMA-267 
(yellow) B) MMA-300 (orange) 
in the Raf binding pocket.  
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2.3.4 Results of Molecular Docking of CIEA on MEK: 
The first set of CUCUS-inspired estrone analogues that consist cucurbitacins enone 
side chain at C-17 of the estrone scaffold, methoxy at C-3, double bond at C-16 and C-17 
and different functional groups at C-25 including MMA102, MMA128, MMA129, 
MMA132, MMA265, MMA270, MMA271, MMA287, MMA288, MMA289, 
MMA290, MMA292, MMA305 and MMA311 showed strong binding affinities toward 
MEK protein. Stereochemistry of the enone side chain play an important role in the binding 
affinity; for example, analogue MMA132, which contains the stereochemistry of 
cucurbitacin D side chain, showed less binding affinity toward MEK with hydrophobic 
interaction compare to analogue MMA102, which has the reversed stereochemistry of 
cucurbitacin D side chain, that demonstrated an outstanding binding affinity with H-bonds 
and hydrophobic interactions with MEK amino acid residues at the binding pocket 
(Fig.2.20).  
On the other hand, the estrone analogues with C-17 enone side chain, sulfamoyl or 
hydroxyl groups at C-3 and number of aliphatic and aromatic functional groups at C-25 
showed structural specificity correlation with binding affinity; for example, derivatives 
with aliphatic enone side chain showed higher binding affinities with H-bonds and 
hydrophobic interactions such as MMA240 in comparison to the other derivatives that 
have aromatic enone side chain such as MMA314 (Fig.2.21).  
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A 
B 
Figure 2.20 Visual 
representation of A) MMA-
102 (blue) B) MMA-132 
(red) in the MEK binding 
pocket. 
   91 
 
  
  
 
 
In addition, the presence of sulfamoyl moiety at C-3 of the esterone scaffold along 
with the enone side chain at C-17 of MMA300 showed a significant increase for the 
binding affinity by forming H-bonds and hydrophobic interactions with the crystal 
structure of MEK binding pocket compare to the derivatives that have hydroxyl group at 
C-3 along with the enone side chain such as MMA308 (Fig.2.22). 
A 
B 
Figure 2.21 Visual 
representation of A) MMA-
240 (green) B) MMA-314 
(purple) in the MEK binding 
pocket. 
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2.3.5 Results of Molecular Docking with ERK:  
The molecular docking study of CUCUS-inspired estrone analogues that contain 
cucurbitacins enone side chain at C-17 of the estrone scaffold, methoxy at C-3, different 
aliphatic and aromatic moieties at C-25 and double bond at C-16 and C-17 such as 
MMA102, MMA128, MMA129, MMA132, MMA265, MMA270, MMA271, 
MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and MMA311 
A 
B 
Figure 2.22 Visual 
representation of A) MMA-
300 (brown) B) MMA-308 
(red) in the MEK binding 
pocket. 
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showed strong binding affinities  toward ERK 3D structure which is consistent to their 
structure; for example, compound MMA132, which possess the stereochemistry of 
cucurbitacin D side chain, showed very high binding affinity toward the ERK binding site 
compare to analogue MMA102, which has the opposite stereochemistry of the side chain 
which proved the important of the stereochemistry choice for the structure design 
(Fig.2.23).  
 
 
  
A 
B 
Figure 2.23 Visual 
representation of A) MMA-
102 (green) B) MMA-132 
(purple) in the ERK binding 
pocket. 
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 Very distinguishable results of the molecular docking calculations that all of the 
derivatives with aromatic enone side chain substituents at C-25 form H-bonds with the 
same amino acid (MET:106:A) at the ERK binding site; while all aliphatic enone side 
chain derivatives at C-25 don’t bind to that particular amino acid (MET:106:A), which 
may play role for their biological activities (Fig.2.24).  
 
Figure 2.24 Visual representation of Various Modified estrone with aromatic functional 
groups at C-25. 
 
CUCUS-inspired estrone analogues along with cucurbitacins enone side chain at 
C-17 of the estrone scaffold, different aliphatic and aromatic substituents at C-25 and 
sulfamoyl or hydroxyl groups at C-3 such as MMA240, MMA241, MMA294, MMA295, 
MMA297, MMA300, MMA301, MMA306, MMA307, MMA308, MMA309, 
MMA310, MMA312, MMA313 and MMA314 proved by molecular docking studies to 
have some distinguishable results. For example, compound MMA240, which contain in its 
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structure cucurbitacin D enone side chain at C-17 of the estrone scaffold along with 
sulfamoyl group at C-3 showed high binding affinity toward the ERK binding pocket 
compare to MMA301, which has hydroxyl group at C-3 instead of sulfamoyl, by forming 
H-bonds with MET:106:A and ARG:65:A along with hydrophobic interaction with other 
amino acid residues inside the binding pocket (Fig.2.25), which prove the importance of 
sulfamoyl for the binding mods.  
     
 
 
 
A 
B 
Figure 2.25 Visual 
representation of A) MMA-
240 (red) B) MMA-301 
(yellow) in the ERK binding 
pocket. 
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2.4 Conclusion:  
Molecular modeling for the drug design process is very powerful technique for drug 
discovery since it can calculate how the small organic compounds will behave in the 
biological system before spending millions of dollars without knowing their behaviors. In 
our molecular docking study, we considered the pharmacophores of cucurbitacins 
structures to be assembled on the estrone main skeleton targeting several EGFR proteins 
biological targets aiming to discover drug candidates for the treatment of HCC.  
 
The molecular docking study demonstrated the significance of CUCUS-inspired 
esterone analogues with cucurbitacins enone side chain at C-17 of the estrone main 
structure to bind to the EGFR. So, analogues with cucurbitacin D enone side chain at C-17 
(with the right stereochemistry) such as MMA132 showed significant binding affinity 
toward EGFR binding pocket compare to the opposite stereochemistry as in MMA102. In 
addition, CUCUS-inspired esterone analogues with cucurbitacins enone side chain at C-17 
and sulfamoyl moiety at C-3 of the estrone such as MMA240 proved by molecular docking 
to demonstrate significant binding modes with the 3D crystal structure of EGFR.  
 
All of the EGFR downstream pathway proteins such as Ras, Raf, MEK and ERK 
were presented in this molecular docking study, which showed the importance of the 
presence of cucurbitacins enone side chain at C-17 for the binding affinity with the targeted 
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proteins. Also, it revealed the significant of other functional groups such as double bond at 
C-16 and C-17, sulfamoyl group at C-3 and hydroxyl group at C-3.  
Therefore, the results of molecular docking calculations proved the possibility of 
designing drug candidates for the inhibition of EGFR and all downstream proteins (Ras, 
Raf, MEK and ERK) by assembling specific functional groups such as cucurbitacins enone 
side chain at C-17, methoxy, sulfamoyl, hydroxyl at C-3 and various aliphatic and aromatic 
functional groups at C-25.    
These results guided our tension to build our synthetic schemes for assembling the 
cucrbitacins enone side chain at C-17 of the estrone main skeleton, installing different 
functional groups at C-3 and assembling various aliphatic and aromatic groups at C-25.    
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Chapter Three 
 
Design, Synthesis, and Biological Screening of Novel CUCS-Inspired Estrone 
Analogues (CIEA) towards Treatment of Hepatocellular Carcinoma 
  
3.1 Introduction: 
        Natural products, biological compounds, total synthesis or vaccines are the 
main sources of small organic molecules used as drugs [1]. Since the ancient times, natural 
products play an important role as resource of medicines. For example, some herbes used 
to be chew to decrease the pain and some of them used to be wrapped around wounds to 
heal it. Using natural products to treat diseases and injuries known as folk medicine [2]. 
Lately, the large improve in developing materials to study the biological mechanism of all 
new chemical entities, encouraged researchers to investigate more in the pharmacological 
effects of natural compounds in order to clarify their synergistic impact and their clinical 
effects on the individual body. Natural compounds could be provide novel curative 
approaches toward a variety of diseases [3]. 
 
       Cucurbitacins (CUCS) (Fig. 3.1) are natural products extracted from plant of 
Cucurbitacea family such as Gonystylus keithii, Cayaponia tayu, and Citrillus colcynte. 
Cucurbitacins plant family first used in folk medicine due its biological significant as anti-
inflammatory agents. There are different types of cucurbitacins range as following A, B, 
C, D, and E, to T. Additionally, hundreds of cucurbitacins derivatives have been 
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synthesized and identified some of them listed in Fig. 3.1 [4]. They have been used for 
treatment of different diseases such as chronic hepatitis, liver cirrhosis, jaundice, 
dyspepsia, inflamation and cancer [5]. Recent studies have shown a significant activities 
of CUCS as potential candidates for treatment of hepatocellular carcinoma (HCC) [6]. 
Current knowledge of molecular targets and singling pathways of different types of cancers 
provide a clear understanding of tumor cell regulation, which in turn paved the way to 
design promising potential drug candidates. 
 
       Hepatocellular carcinoma (HCC) classified as one of the highest cause of 
mortality and the third causing of death worldwide [7]. Asia and Africa have the highest 
report of HCC with high incidence between men. HCC was somewhat rare in the United 
States compare to the other countries; however, in the last recent decades it became one of 
the main cause of death in the United States. HCC is a continuous and slowly progressing 
disease that is generally associated with other factors such as cirrhosis, hepatitis C virus 
(HCV), hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and 
alcoholic consumption) [8]. There are different therapeutical options for HCC such as local 
ablation therapy, surgical resection and liver transplantation. However, these options are 
not applicable for late diagnostic patients. Chemotherapeutic drugs such as Erlotinib, 
Soreftinib are common treatments for HCC. However, drugs resistance and undesirable 
side effects are the most common problems associated with these drugs [9]. Therefore, 
there is an urgent need to find a new drug candidate to overcome these problems. 
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        Two main complex mechanisms for HCC molecular pathogenesis; 1) 
mutation, which happen in some tumor suppress genes or oncogenes; 2) some diseases or 
metabolic disorder such as hepatitis infection, metabolic effects (such as obesity, insulin 
resistance, type-2 diabetes), toxin (such as alcohol) that cause tissue damage which lead to 
cirrhosis [10, 11]. Both of these mechanism have been connected with irregularity in 
different cell signaling pathways that continue the process of carcinogenic results. From a 
therapeutic view, all of these signaling pathways are very significant in order to treat HCC. 
Thus, growth factors-mediated, angiogenic signaling, epidermal growth factor (EGFR), 
vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF), insulin-
like growth factor (IGF), platelet-derived growth factor (PDGF), and the mitogen activated 
protein kinase (MAPK) pathways are the most distinguished targets for treating HCC due 
to their noticeable overexpression during the disease [10]. 
 
       Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) (Fig. 1.5) is 
one of the tyrosine kinase that have been studied as a promising target for the treatment of 
different carcinoma including HCC [12]. EGFR, which also known as ErbB1, is a member 
of family of growth factor receptors including ErbB2, ErbB3 and ErbB4. Paracrine or 
juxtacrine extracellular ligand binding such as epidermal growth factor (EGF) and 
transforming growth factor (TGF)-α stimulate the EGFR, which lead to hetro- or homo 
dimerization and conformational charge that activate the tyrosine kinase and allow 
autophosphorylation [13-15]. When the phosphorylation occurs, number of signaling 
pathways activated leading to cancer cell invasions, proliferation, metastasis, inhibitory of 
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apoptosis and angiogenesis [14-16]. Therefore, inhibition of EGFR-TK signaling cascades 
provides an approach for the treatment of hepatocellular carcinoma (HCC).  
   
 
Cucurbitacin R1 R2 R3 R4 R5 ∆1,2 ∆23,24 
A OH =O MeOH H AC - + 
B OH =O CH3 H AC - + 
C H OH MeOH H AC - + 
D OH =O CH3 H OH - + 
E OH =O CH3 H AC + + 
F OH OH CH3 H OH - + 
H OH =O CH3 OH OH - - 
I OH =O CH3 H OH + + 
J OH =O CH3 OH OH + - 
 
Figure 3.1 Structures of different types of Cucurbitacins and Starting Material Estrone. 
 
       CUCS demonstrated a wide range of biological activities due to their 
cytotoxicity on cancer cells and their potency on different biological pathways [17]. These 
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biological activities nominate CUCS as a potential drug that targeting multiple types of 
cancer. In order to avoid the undesirable adverse effects of the natural products and increase 
their selectivity, structural modifications to their structure may improve their efficiency 
[18]. Therefore, the identification of the most significant pharmacophore of the natural 
products is essential in order to conduct structural modifications. 
 
        Based on twenty-four different CUCS, Van Dang et. al. build some structural 
relationships of CUCS structures and determined the most significant pharmacophores 
[19]. They found that the presence of α-β-unsaturated ketone of the side chain, the free 
16α-OH, and the different functionalities on C-3 of the ring A are critical for the biological 
activity [19, 20]. Therefore, maintaining the CUCS’s side chain during the modifications 
is essential for the biological activity. In addition, installing different functional groups in 
various positions of the tetracyclic core structure of Estrone will enhance the biological 
activity of the synthesized compounds. 
 
       CUCS has tetracyclic moiety, they are very similar to that of steroids (Fig. 3.1). 
However, they are different from each other in the fact that C-10 methyl is located at C-9, 
possess a gem-dimethyl group at C-4 and the configuration of ring B and ring C [21]. Due 
to the similarity between the core structures of CUCS and steroids, the concept of hybrid 
drug design were used to install the essential pharmacophore of the CUCS into the steroid 
structure as promising alternative for the complicated functionalized structure of the CUCS 
[22, 23]. Specifically, using the estrone skeleton as a starting material to install different 
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functional moieties including the CUCS side chain and other functionalities has been done 
by Ahmed et. al [22]. Furthermore, adding various moieties to the estrone skeleton 
structure at C-3, such as methoxy and hydroxyl groups, beside the CUCS side chain at C-
17 in the presence of double bond at C16-C17 (Fig. 3.2) proved to enhance the biological 
activity of these series of compounds. The presence of the double bond at C16-C17 
changed the conformation of estrone CUCS-like compounds which improve its binding 
affinity towards the EGFR-TK [24]. Supporting to this hypothesis comes from the 
capability of estrone derivatives involved in other biological process a voiding its side 
effects as estrogen treatment [25-27].  
 
         To find hit compounds and to develop candidates targeting the EGFR-TK 
pathways, the concept of bioisosterism was utilized to systematically design and  install 
CUCS functionality on the steroidal core structure and to build a virtual library of 900 
compounds, then molecular docking was conducted for these virtual analogues against 
EGFR-TK [5]. The four structural positions of estrone skeleton investigated were; 1) 
combination of multiple substituted enone side chain at C-17; 2) Modification of C-16, C-
17; 3) Functionalization on C-3 of the phenol ring and 4) Installation of aliphatic, aromatic 
and heterocyclic functional groups at C-25 of the enone side chain (Fig. 3.2). OpenEye® 
Scientific software were used for the molecular modeling studies including fast exhaustive 
docking (FRED), Omega, and VIDA.  
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Figure 3.2 Proposed modified estrone structure. 
3.2 Results and Discussions: 
3.2.1 Results of Molecular Docking of CIEA on EGFR: 
      Molecular docking data for the estrone CUCS-inspired analogues containing olefin at 
C-16, C-17, cucurbitacins enone side chain with α,β-unsaturated ketones functional group 
and methoxy group at C-3 showed an outstanding binding affinity towards the crystal 
structure of EGFR, when compared with the standard EGFR inhibitors such as Erlotinib, 
which has H-bond with MET:796:A and this H-bond is responsible for its biological 
activity along with hydrophobic interaction as anti-cancer agent (Fig. 3.3). CUCS side 
chain at C-17 of the estrone scaffold, substitutions at C-3 and double bond at C-16 and C-
17 of the CUCS-inspired analogues such as MMA102 and MMA132 demonstrated a very 
promising binding affinity by making a hydrophobic interaction as in MMA102, which 
has the opposite stereochemistry of cucurbitacin D side chain (Fig. 3.3) with amino acids 
residues of the crystal structure of  EGFR binding pocket; while analogue MMA132, 
which possess the exact stereochemistry of the side chain of cucurbitacin D, demonstrated 
an outstanding binding affinity through hydrophobic interaction with amino acids residues 
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of the EGFR along H-bond with MET:796:A, which is the same amino acid that Erlotinib 
make H-bond with and responsible for its anti-cancer activity (Fig. 3.3). These results 
showed the significant of possessing the cucurbitacin D stereochemistry for the enone side 
chain at C-17 of the estrone scoffold, which make analogue MMA132 a very promising 
candidate to be synthesized and biologically tested to confirm its biological activity as an 
anti-cancer candidate.  
 
On the other hand, CUCUS-inspired estrone analogues with aromatic and 
heterocyclic enone side chain that possess the stereochemistry of cucurbitacin D side chain 
such as MMA265, MMA270, MMA287, MMA288, MMA289, MMA290, MMA292, 
MMA305 and MMA311 (Fig. 3.2) showed promising binding affinity with H-bonds and 
hydrophobic interactions with the binding site of the crystal structure of EGFR. 
Compounds with strong electron withdrawing groups at C-25 of the enone side chain such 
as MMA290, MMA292 and MMA311 showed both H-bonds and hydrophobic modes of 
interactions (Fig. 3.4); while molecules with electron donating groups at C-25 of the enone 
side chain such as MMA265 showed only hydrophobic-hydrophobic interaction with 
amino acid residues of the EGFR crystal structure (Fig. 3.5). CIEA possess cucurbitacin  
aromatic enon side chain with the opposite stereochemistry of cucurbitacin D such as 
MMA316, MMA317, MMA318, MMA319, MMA320, MMA321, MMA330 and 
MMA334 (Fig. 3.2) demonstrated  similar binding affinities to the estrone derivatives that 
have similar aromatic functional groups at the enone side chain but with stereochemistry 
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of the cucurbitacin D. All of the top consensus score compounds will be chemically 
synthesized in order to be evaluated biologically as anti-cancer candidates.  
 
 
 
 
 
A 
B 
Figure 3.3 Visual representation of A) MMA-102 (orange) B) MMA-132 
(blue) in the EGFR ATP-binding site along with Erlotinib (purple). 
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Figure 3.4 Visual representation of MMA-292 (Red) in the crystal structure of EGFR. 
 
Figure 3.5 Visual representation of MMA-265 (Green) in the crystal structure of EGFR. 
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3.2.2 Synthesis of MMA Analogues: 
       To explore these novel CUCS-inspired estrone analogues (CIEA), installation 
of cucurbitacins α,β-unsaturated ketone side chain with the double bond in C-16, C-17 
position into the estrone skeleton structure were synthesized at C-17 (Fig. 3.1). Number of 
synthetic approaches were investigated in order to accomplish this task. First approach was 
started with installing p-toluenesulfonyl hydrazide in C-17 of the estrone structure followed 
by Shipiro reaction (scheme 3.1) and adding two equivalents of strong base such as n-
butyllithium to form nucleophilic center followed by the addition of various electrophiles 
such as paraformaldhehyde, dimethyl formamide, N-methoxy-N-methylacetamide and 2,3-
butanedione [28, 29]  as shown in scheme 3.2. This approach was used to save steps from 
the original route, which will be discussed in the next paragraph, but unfortunately, several 
electrophiles gave a very small yield which make this approach not convenient to start with 
and built the whole scheme in (scheme 3.1).  
 
 
Scheme 3.1 The approach of Shapiro reaction. 
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Scheme 3. 2 Shapiro reaction followed by nucleophilic reactions with various 
electrophiles. 
 
Then synthesis of MMA analogues started again with protection of ketone at C-17 
of commercially available estrone (Fig. 3.1) with ketal group in order to methylate 
hydroxyl group at C-3 using methyl iodide in presence of potassium hydroxide to provide 
compound  2 [30, 31], followed by deprotection of the ketal group under acidic condition 
to produce methoxy estrone 3 [31]. This followed by addition of TMSCN in presence of 
ZnI2 was added to 3 to form cyanohydrin intermediate 4, followed by elimination reaction 
using POCl3 and DBU as a base to obtain double bond in C-16, C-17 position 5 [32].  
Nucleophilic substitutions reaction of nitrile group using methyl lithium was used to 
provide methyl ketone 6 [33]. Adding catalytic zinc iodide followed by TMSCN to ketone 
6 to form (1:1) diasteriomers mixture of cyanohydrin 7 [22]. It was very challenging to 
separate the diasteriomers mixture of 7 using silica gel chromatography which have the 
same RF on the TLC plate. Then by treatment of diasteriomers mixture of cyanohydrin 7 
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with methyl lithium resulted in formation of required diasteriomers mixture (1:1) of 
hydroxyl methyl ketone 8 (MMA225) and 8`  [22]. Column chromatography was  used to 
separate the diasteriomers mixture 8 and 8` to obtain pure seperated 8 and 8` (Scheme 3.3). 
The configuration of 8 (MMA225) were confirmed using X-ray crystallography (Fig. 3.5). 
At this stage of the synthesis, Aldol condensation reaction used to install aliphatic and 
aromatic aldehydes into hydroxyl ketone 8 and 8`, with in situ elimination in order to 
provide the required enone. In attempting to install CUCS-side chain, a three synthetic 
reactions steps were used to prepare aldehyde 14 which started by the protection hydroxyl 
group of methyl 2-hydroxyisobutyrate 11 using tert-butyldimtylsillyl chloride (TBSCl). 
The synthesized ester 12 was treated by reducing agent diisobutylaluminum hydride 
(DIBAL-H) to form alcohol 13. Control oxidizing agent tetrapropyl ammonium 
perrutherate (TPAP) and N-methylmorphline N-oxide (NMO) were utilized to prepare the 
desired aldehyde 14 [5] (Scheme 3.4) . Aldol optimized reaction condition of aldehyde 14 
and hydroxyl ketone 8 and 8` separately in presence of lithium diisopropylamine (LDA) at 
-78oC to room temperature to give enone 9 and 9`. Final compounds MMA102 and 
MMA132 were obtained by the addition of tetrabutyl ammonium fluoride (TBAF) in THF 
(schemes 3.5 and 3.6) [5].  
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Figure 3.6 X-ray crystal of compound 8 which confirm the right stereochemistry to 
install Cucurbitacin D enone side chain.  
 
 Further derivativesation into hydroxyl ketone 8  started with the assembly of ∆9,11 
olefin at the B/C ring ligament to gain the pseudo-cis configuration by adding 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) in methanol resulted in  ∆9,11 hydroxyl ketone 15 
and 15`. The produced intermediate ∆9,11 hydroxyl ketone 15 and 15` processed through 
the same Aldol condensation reaction with aldehyde 14 to produce in ∆9,11 enone 16 
followed by the deprotection of TBSCl using TBAF to obtain ∆9,11 enone MMA128 
(scheme 3.7) [5]. 
 
Different aromatic and heterocyclic aldehydes have been reacted with hydroxyl 
ketone 8 and 8 to produce different aromatic enone side chains that have two different 
stereochemistry of each analogue such as para-methoxybenzene (MMA265 and 
MMA333), para-flurobenzene (MMA279 and MMA334), para-chlorobenzene (MMA287 
and MMA316), para-bromobenzene (MMA288 and MMA319), para-
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dimethylaminobenzene (MMA289 and MMA317), 5-bromofuran (MMA290 and 
MMA318), para-trifluromethylbenzene (MMA292 and MMA320), para-nitrobenzene 
(MMA305 and MMA321) and 5-bromothiophene (MMA311 and MMA330) (scheme 
3.8). All aromatic α,β-unsaturated enone side chain increased the hydrophobicity of the 
CUCS-inspired analogues so, it can be compared biologically with more polar first  
synthesized set of compounds MMA102, MMA128, and MMA132.  
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Scheme 3.3 Synthesis of Disteriomers 8 and 8`. 
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Scheme 3.4 Synthesis of Aldehyde 14. 
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Scheme 3.6 Synthesis of MMA132. 
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R= P-PhMeO, P-PhF, P-PhCl, P-PhBr, P-N (CH3)2Ph, P-PhCF3, P-PhNO2, 5-Bromo-2-
thiophene, 5-Bromo-2-furan. 
Scheme 3.8 Synthesis of various aromatic enone side chains. 
 
3.2.3 Biological Evaluations of the CIEA for the Treatment of HCC :  
In vitro biological evaluation of CIEA was conducted to study their ability to target 
and inhibit EGFR-TK as anti-cancer candidates. First, MTT cell viability assay was used 
to measure the cytotoxicity and anti-proliferative activity of the synthesized compounds. 
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Analogues that contain aromatic enone side chains such as MMA265, MMA270, 
MMA287, MMA288, MMA292, MMA305, MMA316, MMA319, MMA320, 
MMA321, MMA333 and MMA334 showed strong cytotoxicity with IC50 values 16 𝜇𝑀, 
7 𝜇𝑀, 25 𝜇𝑀, 32𝜇𝑀, 2 𝜇𝑀, 29𝜇𝑀, 𝑁𝐴, NA, 3 𝜇𝑀, 20𝜇𝑀, 2 𝜇𝑀 and 8 𝜇𝑀 ; respectively 
toward hepatocellular carcinoma cell line (HepG2) in comparison to the known EGFR 
inhibitor, Erlotinib, which has IC50 value of 25 𝜇𝑀  (Table 3.1). While CIEA that contain 
heterocyclic enone side chains such as MMA290, MMA311, MMA318 and MMA330 
showed variety of cytotoxicity on HepG2 cell line based on their stereoisomer; for 
example, compound MMA290 and MMA311, which possess cucurbitacin D side chain 
stereoisomer, showed potent cytotoxicity with IC50 values 6 𝜇𝑀 and 0.7 𝜇𝑀, respectively. 
On the hand, the same compounds but with the opposite stereoisomer such as MMA318 
and MMA330 showed significant change in their cytotoxicity since analogue MMA318 
lost its cytotoxicity completely and compound MMA330 showed IC50 of 11𝜇𝑀 compare 
to 0.7 𝜇𝑀 in MMA311. These results demonstrated the importance of possessing the exact 
stereochemistry of cucurbitacin D enone side chain for antiproliferation activity of these 
isomers. Meanwhile, compounds MMA102, and MMA1320, which contain isopropanol 
enone side chains of cucurbitacin D, demonstrated outstanding cytotoxicity with IC50 
values 3𝜇𝑀, and 2𝜇𝑀, respectively (Table 3.1). All of the previous IC50 results were 
compared to Erlotinib (current chemotherapeutic drug for treatment of HCC), which has 
an IC50 value of 25 𝜇𝑀 (Table 3.1). Second, for more and deep understanding of the anti-
proliferation mechanism of the potent analogues, MMA102 and MMA132, western blot 
analysis was conducted (Fig. 3.8). The western blot data indicate the potential of compound 
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MMA132 to bind to the upstream signaling pathway through the inhibition of EGFR-TK 
and inhibit its phosphorylation at 2 𝜇𝑀 after 48 hours incubation compare to the loading 
control (Actin) and Erlotinib as positive control as shown in Figure 3.8. Third, cell cycle 
arrest experiment using flowcytometry was conducted on MMA132 at various 
concentration (1/2 IC50, IC50, 2 IC50), which showed its ability to induce G1/S phases cell 
cycle arrest as shown in Figure 3.9. The promising data of compound MMA132 
demonstrated the importance of the presence of the CUCS-side chain at C-17, double 
bound in C-16, C-17 and C-3 methoxy group. Docking results showed that compound 
MMA132 has H-bond with MET:796:A (Fig. 3.3), the same as the standard Erlotinib. 
This observation in addition to biological results demonstrated the importance of 
possessing the CUCS-side chain configuration to gain a promising binding affinity inside 
the pocket and inhibit the targeted receptor, EGFR. On the other hands, compounds that 
contain aromatic and heterocyclic enone side chains showed a wide range of cytotoxicity 
toward HepG2 cell line. The wide range of cytotoxicity can be attributed to several factors 
including stereochemistry of the enone side chain, types of the pharmacophores at enone 
side chain and the electron withdrawing or donating functional groups of the enone side 
chain that effect the electrophilicity of Michael acceptor at enone side chain. 
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Table 3.1 MTT cell viability results in HepG2 cell line. 
Compound IC50 (𝝁𝑴) Compound IC50 (𝝁𝑴) 
Erlotinib 25 𝜇𝑀 MMA305 29 𝜇𝑀 
MMA102 3 𝜇𝑀 MMA311 0.7 𝜇𝑀 
MMA132 2 𝜇𝑀 MMA316 NA 
MMA225 25 𝜇𝑀 MMA318 NA 
MMA265 16 𝜇𝑀 MMA319 NA 
MMA270 7 𝜇𝑀 MMA320 3 𝜇𝑀 
MMA287 25 𝜇𝑀 MMA321 20 𝜇𝑀 
MMA288 32 𝜇𝑀 MMA330 11 𝜇𝑀 
MMA290 6 𝜇𝑀 MMA333 2 𝜇𝑀 
MMA292 2 𝜇𝑀 MMA334 8 𝜇𝑀 
 
 
Figure 3.7 Chart represent the ability of CIEA to inhibit the growth of HepG2 cell line. 
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(Hepatocellular Carcinoma cell line).   
 
Figure 3.8 Analogue MMA132 manage to inhibit p-EGFR after 48h incubation at IC50 3 
μM. 
 
Figure 3.9. Cell cycle arrest analysis for analogue MMA132 showed induction activity 
for G1/S phases. 
 
3.3 Conclusion:  
         In conclusion, CUCS-inspired analogues were designed using molecular 
modeling to mimic cucurbitacins structure more specifically its side chain, which is the 
most important pharmacophore for its biological activities and installed it into the estrone 
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skeleton structure at C-17 in the presence of double bond at C-16, C-17 position and 
methoxy group at C-3 which significantly improved their activity and the selectivity. 
Assortment of enone side chain were installed at the estrone skeleton structure such as 
isopropanol, para-flourobenzene, para-chlorobenzene, para-bromobenzene, para-
methoxybenzene, para-trifluromethyl benzene, para-nitrobenzene, 5-bromofuran and 5-
bromothiophene along with methoxy at C-3 and alkene at C16, C17. The cytotoxicity 
results showed that MMA102 and MM132 are the most potent analogues among the 
compunds that contain aliphatic enone side chains with IC50 3 𝜇𝑀 and 2 𝜇𝑀 respectively. 
On the other hand compound MMA311 which contain thiophene enone side chain at C-25 
along with methoxy group at C-3 showed an outstanding IC50 value of 0.7𝜇𝑀. Further 
biological experiments including western blot showed that compounds MMA102 and 
MMA132 have the ability to bind to the EGFR-TK and inhibit its phosphorylation by 90%. 
Additionally, cell cycle arrest has been conducted on the same analogues and demonstrated 
that they have the ability to arrest the cell cycle at G1/S phases.    
 
3.4 Experimental section: 
3.4.1 General: 
All chemicals and solvents (ACS grades) were provided from Fisher Scientific or 
Sigma Aldrich and used without any additional purification. All glassware were cleaned, 
washed and dried in oven for overnight before conducting chemical reactions requires 
anhydrous environment and nitrogen gas applied at the reaction time. Pre-coated silica gel 
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PE plates were used to analyze the reaction condition and UV-light were also used at 254 
or 365 to visualize the chemical reactions spots. All synthetic intermediate and final 
compounds were purified using column chromatography with 230ˣ400 mesh silica gel.  1H 
and 13C NMR spectra were using Bruker AVANCE-400 MHZ and 600 MHZ NMR 
spectrometer, in CDCl3 and D-acetone. NMR chemical shifts were presented in 𝛿(PPM) 
using residual solvent peaks as standards (CDCl3, 7.26 (H), 77.16 (C)). High resolution 
mass (HRMS) was gained using thermofinnigan MAT 95XL mass spectrometer at Buffalo 
mass spectroscopy facility. X-ray crystallography were conducted in University of South 
Dakota on compound 8 using Bruker APEXᴵᴵ diffractometer.  
 
3.4.2 Protected Estrone:  
HO
H
Ethlyne glycol/ PTSA
O
H
H
HO
H
H
O
O
Toluene
H
Estrone 1
97%
 
To a stirred solution of estrone (5g, 18.49mmole) in 308 ml of toluene, ethylene 
glycol (4.52ml, 81.35mmole) was poured in one portion. Then para-toluene sulfonic acid 
(0.21g, 1.10 mM) was added. The reaction mixture was allowed tom be stirred and reflux 
for 8 hours utilizing Dean-Stark apparatus to prevent water from going back to the reaction 
mixture. Then the reaction was cooled to the room temperature followed by the addition of 
NaHCO3. Ethyl acetate (3 ˣ  50) was used to extract the aqueous level, then the organic layer 
dried over sodium sulfate anhydrous and evaporated by vacuo to provide white solid of the 
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protected estrone 1 (5.65g, 97%). The crude material was used in the next step without 
purification. 1H NMR proved >95% purity. 
 
 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH(1)), 6.72 (dd, J = 8.6, 
2.8 Hz, 1H, -CH (2)), 6.62 (d, J = 2.7 Hz, 1H, -CH (4)), 3.93 (m, 4H, 2X -CH2 (20, 21)), 
2.88 (m, 2H), 2.29 (m, 2H, CH2 (11)), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m, 6H), 0.92 (s, 
3H).  
13C NMR (100 MHz, CDCl3) δ 157.5 (C-3), 138.1 (C-5), 132.9 (C-10), 126.3 (C- 
1), 118.9 (C-17), 113.8 (C-4), 111.5 (C-2), 65.4 (C-20), 64.7 (C-21), 49.46 (C-13), 46.16 
(C-14), 43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11), 26.67 (C-7), 
26.05 (C-12), 22.48 (C-15), 14.4(C-18). 
 
3.4.3 Methoxy Protected Estrone 2: 
HO
H
H
O
O
O
H
H
H
O
O
DMSO
H
KOH/MeI
1
2
93%
 
Protected estrone 1 (5.65g, 17.97 mmole) was dissolved in DMSO (90 ml), 
followed by the addition of crushed granulate potassium hydroxide (4.032g, 71.88 mmole), 
then methyl iodide (2.24g, 35.94 mmole) was added to the reaction mixture. The reaction 
was stirred at room teprature for 2 hours and quenched by the addition of water (400 ml) 
to be stirred for 15 minutes. Methylene dichloride (3 ˣ100 ml) was used to extract the 
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aqueous layer. The organic layer was dried over sodium sulfate anhydrous and 
concentrated in Vacuo to obtained the methoxy protected estrone 2 (5.5g, 93%) as a white 
powder. The crude material was used in the next step without purification. 
 
 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH(1)), 6.72 (dd, J = 8.6, 
2.8 Hz, 1H, -CH(2)), 6.62 (d, J = 2.7 Hz, 1H, -CH(4)), 3.93 (m, 4H, 2 X -CH2 (20, 21)), 
3.77 (s, 3H, -OCH3 (3)), 2.88 (m, 2H), 2.29 (m, 2H), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m, 
6H), 0.92 (s, 3H). 
 
13C NMR (100 MHz, CDCl3) δ 157.5 (C-3), 138.0 (C-5), 132.5 (C-10), 126.3 (C-
1), 118.9 (C-17), 113.9 (C-4), 111.6 (C-2), 65.4 (C-20), 64.7(C-21), 55.8 (-OCH3), 49.46 
(C-13), 46.16 (C-14), 43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11), 
26.67 (C-7), 26.05 (C-12) , 22.48 (C-15), 14.43 (C-18). 
 
3.4.4 Methoxy Estrone 3: 
O
H
H
H
O
O
2
10%HCl/ 
Aceton
95%
O
H
O
H
H
3  
To stirred solution of methoxy protected estrone 2 (5.5g, 16.745mmole) in acetone 
(140ml), 10% HCl (140ml) was added. The reaction mixture allowed to stirred at room 
temperature for overnight. The reaction was quenched by dropwise addition of NaHCO3 to 
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balance the acidity of the mixture. Ethyl acetate (3 ˣ 50) was used to extract the aqueous 
level, and then the organic layer dried over sodium sulfate anhydrous and evaporated by 
vacuo. The crude product was purified using silica gel column chromatography (20% ethyl 
acetate in hexane) to provide methoxy estrone 3 (4.52g, 95%) as white solid.  
 
1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH (1)), 6.72 (dd, J = 8.6, 
2.8 Hz, 1H, -CH (2)), 6.62 (d, J = 2.7 Hz, 1H, -CH (4)), 3.77 (s, 3H, -OCH3 (3)), 2.88 (m, 
2H), 2.29 (m, 2H), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m, 6H), 0.92 (s, 3H). 
 
 13C NMR (100 MHz, CDCl3) δ 220.8 (C-17), 157.5 (C-3), 138.0 (C-5), 132.5 (C-
10), 126.3 (C-1), 113.9 (C-4), 111.6 (C-2), 55.8 (-OCH3), 49.46 (C-13), 46.16 (C-14), 
43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11), 26.67 (C-7), 26.05 (C-
12), 22.48 (C-15), 14.43 (C-18).   
 
4.4.5   Cyanohydrin: 
TMSCN/ZnI2
DCM
91%O
H
O
H
H
3
O
H
H
H
NO
Si
4  
To a stirred solution of 3 (6g, 21.09mmole) in a dry dichloromethane (DCM) (42.2 
ml), zinc iodide (0.6g, 1.87mmole) were added followed by the addition of trimethylsillyl 
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cyanide (TMSCN) (11.8ml, 94.94mmole). The reaction were allowed to be stirred for 3h 
at the room temperature then concentrated in vacuo. A mixture of water/ethyl acetate (1:1) 
ration were added to the concentrated slurry, then the aqueous layer was extracted using 
ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4) and concentrated 
under vacuo. The crude product was purified using silica gel column chromatography (20% 
ethyl acetate in hexane) to give (7.2g, 89%) of compound 4 as a white solid.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.04 (dd, J = 8.6, 1.0 Hz, 1H), 6.56 (dd, J = 
8.6, 2.8 Hz, 1H), 6.47 (d, J = 2.8 Hz, 1H), 3.61 (s, 3H), 2.70 (m, 2H), 2.36 – 2.18 (m, 2H), 
2.10 (td, J = 10.9, 10.4, 4.2 Hz, 1H), 1.91 – 1.58 (m, 5H), 1.48 (m, 1H), 1.39 – 1.27 (m, 
3H), 1.27 – 1.13 (m, 1H), 0.72 (d, J = 8.8 Hz, 1H), 0.68 (s, 2H), 0.11 (s, 9H). 
 
 13C NMR (101 MHz, Chloroform-d) δ 156.26, 136.44, 130.77, 125.08, 121.07, 
112.52, 110.26, 80.39, 53.86, 47.04,  46.95, 42.04, 38.04, 36.75, 32.00, 28.44, 25.90, 25.00, 
21.76, 10.97. 
 
 
 
 
 
 
   130 
 
  
3.4.6 Alkene 5: 
 
POCl3/ DBU
Pyridine
69%
O
H
H
H
NO
Si
4
O
H
H
H
N
5
 
To a stirred solution of 4 (5g, 13.047mmole) in dry pyridine (125ml), phosphorus 
oxychloride (POCl3) (8.65ml, 92.83mmole) and 1, 8-Diazabicyclo[20]undec-7-ene (DBU) (8.8ml, 
58.7115mmole). The mixture were heated to the reflux temperature and stirred for 28h, then cooled 
to the room temperature. The black mixture was spilled into cooled mixture of (1:1) 5% 
hydrochloric acid (75ml) and ethyl acetate (75ml). The aqueous phase was extracted with ethyl 
acetate (3ˣ50ml), dried with sodium sulfate anhydrous (Na2SO4), and concentrated under vacuo. 
The crude material was purified using silica gel chromatography (10% ethyl acetate in hexane) to 
yield (2.4g, 64.05%) as a white solid.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.24 (dd, 1H), 6.78 – 6.59 (m, 3H), 3.74 (s, 
3H), 2.97 (m, 2H), 2.40 (m, 2H), 2.31 – 2.11 (m, 2H), 2.04 (m, 1H), 1.89 (m, 1H), 1.72 – 
1.50 (m, 3H), 1.51 – 1.35 (m, 1H), 1.34 – 1.23 (m, 1H), 0.92 (s, 3H).  
 
13C NMR (101 MHz, Chloroform-d) δ 157.68, 147.36, 137.59, 132.07, 127.56, 
126.07, 115.90, 113.96, 111.56, 55.24, 55.22, 48.51, 44.15, 37.24, 34.13, 32.73, 29.59, 
27.74, 26.28, 16.47. 
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3.4.7 Methyl ketone 6: 
MeLi/MTBE
TFA
83%
O
H
H
H
N
5
O
H
H
H
O
6  
In a 2-nacked flask, methyl lithium (MeLi) (12.8ml, 20.4654mmole) were added in a 
dropwise matter to a stirred solution of alkene 5 (3g, 10.2327mmole) in methyl tert-butyl ether 
(MTBE) (55ml) at 0oC. the reaction stirred at 0oC for 1h, then the reaction cooled down to -78 oC 
to quench it with trifluroacetic acid (2.554ml, 33.38mmole) in one portion followed by the addition 
of 10%H3PO4 (26ml). The mixture was allowed to stir for 30 min. the mixture was poured into 
50ml ethyl acetate and 25ml 10% H3PO4. The aqueous layer was washed with ethyl acetate 
(3ˣ50ml). The organic extract was washed with 250ml water, 15ml 1M Na2CO3, then 250ml water, 
and 100ml water. The organic extract was dried over sodium sulfate anhydrous (Na2SO4), filtrated, 
concentrated under vacuo. The resulted product purified by silica gel column chromatography (10% 
ethyl acetate in hexane) to give (2.97g, 93.6%) of methyl ketone 6 as a white solid.  
 
1H NMR (400 MHz, Chloroform-d) δ 7.24 (m, 1H), 6.77 – 6.66 (m, 3H), 3.76 (s, 3H), 2.98 
(m, 2H), 2.56 (m, 2H), 2.44 – 2.30 (m, 2H), 2.27 (s, 3H), 2.19 – 2.04 (m, 1H), 1.96 – 1.85 (m, 1H), 
1.72 – 1.60 (m, 3H), 1.56 (m, 1H), 1.45 (m, 1H), 1.26 (m, 1H), 0.91 (s, 3H).  
 
13C NMR (101 MHz, Chloroform-d) δ 196.78, 157.48, 155.52, 144.38, 137.73, 132.75, 
126.13, 113.87, 111.41, 55.61, 55.20, 46.52, 44.26, 37.04, 34.84, 32.03, 29.67, 27.81, 27.19, 26.50, 
15.97. 
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3.4.8 Cyanohydrin 7:  
TMSCN/ZnI2
DCM
76%O
H
H
H
O
6
O
H
H
H
O NSi
7  
To a stirred solution of methyl ketone 6 (3g, 9.67mmole) in a dry dichloromethane 
(DCM) (20ml), zinc iodide (0.1g, 0.3mmole) were added followed by the addition of 
trimethylsillyl cyanide (TMSCN) (1.6ml, 12.6mmole). The reaction were allowed to be 
stirred for 3h at the room temperature then concentrated in vacuo. A mixture of water/ethyl 
acetate (1:1) ration were added to the concentrated slurry, then the aqueous layer was 
extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4) and 
concentrated under vacuo. The crude product was purified using silica gel column 
chromatography (10% ethyl acetate in hexane) to give a mixture (1:1) diasteriomers of 
Cyanohydrin 7 (3.1g, 78.3%).  
 
1H NMR (400 MHz, Chloroform-d) δ 7.33 (m, 1H), 6.86 – 6.68 (m, 2H), 6.04 (m, 
1H), 3.92 (s, 3H), 3.00 (m, 2H), 2.52 – 2.26 (m, 2H), 2.18 – 1.88 (m, 7H), 1.88 – 1.62 (m, 
2H), 1.60 – 1.39 (m, 2H), 1.33 – 1.08 (m, 3H), 1.08 – 0.93 (m, 1H), 0.42 (s, J = 2.9 Hz, 
9H).  
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13C NMR (101 MHz, Chloroform-d) δ 156.07, 152.88, 136.22, 131.08, 126.35, 
124.52, 120.07, 112.40, 109.95, 68.03, 67.21, 56.16, 53.58, 46.13, 45.60, 42.50, 35.70, 
34.16, 33.55, 33.28, 30.23, 29.35, 29.02, 28.21, 26.16, 24.98, 23.90, 21.29, 15.90, 12.80. 
 
3.4.9 Hydroxyl methyl ketone 8 and 8`:  
MeLi/ Et2O/ 0C
o
Glacial acetic acid
79%O
H
H
H
O NSi
7
O
H
H
H
O
HO
8 and 8  
To a stirred solution of diasteriomers 7 (2.5g, 6.108mmole) in a dry ether (18ml), 
methyl lithium (MeLi) (11.5ml, 18.324mmole) was added in dropwise at 00C. The reaction 
mixture was allowed to stir for 2h at 00C, then the reaction quenched by adding glacial 
acetic acid (2.3ml) in one portion at 00C and allowed to stir for 30 min. at 00C. Sodium 
bicarbonate solution was added to neutralize the acidic mixture. Dichloromethane (DCM) 
was used to extract the aqueous layer (3ˣ50ml), dried under sodium sulfate anhydrous 
(Na2SO4), then concentrated under vacuo. The resulted diasteriomers were purified by 
silica gel column chromatography (100% hexane, 5% ethyl acetate in hexane and 10% 
ethyl acetate in hexane) to give the two separated diasteriomers hydroxyl methyl ketone 8 
and 8`.  
Compound 8 1H NMR (400 MHz, Chloroform-d) δ 7.15 (m, 1H), 6.70 (m, 1H), 
6.62 (m, 1H), 5.90 (m, 1H), 4.25 (s, 1H), 3.76 (s, 3H), 2.87 (m, 2H), 2.31 – 2.14 (m, 3H), 
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2.10 – 1.99 (m, 2H), 1.91 (m,  2H), 1.66 – 1.53 (m, 3H), 1.53 (s, 3H), 1.48 – 1.33 (m, 1H), 
1.31 – 1.12 (m, 2H), 1.01 (s, 3H), 0.98 – 0.79 (m, 1H).  
13C NMR (101 MHz, Chloroform-d) δ 211.7, 157.45, 155.56, 137.86, 132.73, 128.85, 
126.04, 113.86, 111.39, 79.55, 57.49, 55.20, 47.79, 44.07, 37.09, 34.48, 31.05, 29.70, 27.64, 26.27, 
25.31, 23.33, 17.24.  
 
Compound 8` 1H NMR (400 MHz, Chloroform-d) δ 7.28 (m, 1H), 6.69 (m, 1H), 
6.62 (m, 1H), 5.89 (m, 1H), 4.08 (s, 1H), 3.76 (s, 3H), 2.96 – 2.85 (m, 2H), 2.85 – 2.78 (m, 
2H), 2.37 – 2.15 (m, 3H), 2.08 – 1.76 (m, 3H), 1.76 – 1.47 (m, 3H), 1.47 – 1.34 (m, 2H), 
1.30 – 1.08 (m, 3H), 1.06 – 0.85 (m, 3H), 0.85 – 0.80 (m, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 210.93, 157.40, 155.48, 137.78, 132.75, 128.71, 126.01, 113.81, 111.32, 
80.04, 56.61, 55.16, 48.09, 43.82, 37.16, 36.13, 31.01, 29.62, 27.59, 26.49, 24.88, 23.69, 
16.93. 
 
3.4.10 ∆9,11 hydroxyl methyl ketone 15 and 15`:  
O
H
H
H
O
HO
O
H
H
O
HO
DCM
DDQ/MeOH
72%
8 and 8 15 and 15  
To a stirred solution of hydroxyl methyl ketone 8 and 8` (1g, 2.823mmole) in a dry 
dichloromethane (DCM) (14.1ml), a solution of 2,3-Dichloro-5,6-dicyano-1,4-
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benzoquinone (DDQ) (0.83ml, 3.6699mmole) dissolved in methanol (31ml) was added at 
00C under nitrogen. The reaction was raised to the room temperature and allowed to be 
stirred for 1h. The resulted crude material was concentrated under vacuo, then silica gel 
column chromatography were used to purify the crude material (10% ethyl acetate in 
hexane) to provide ∆9,11 hydroxyl methyl ketone 15 and 15`(0.82g, 82.4%) as a white 
material.  
Compound 15 1H NMR (400 MHz, Chloroform-d)  δ 7.49 (m, 1H), 6.69 – 6.49 
(m, 2H), 6.25 (m, 1H), 5.73 (m, 1H), 4.42 (s, 1H), 3.70 (s, 3H), 2.80 – 2.68 (m, 2H), 2.23 
– 2.17 (m, 3H), 2.14 (m, 1H), 2.12 – 1.99 (m, 1H), 1.99 – 1.85 (m, 1H), 1.55 (m, 3H), 1.43 
(m, 1H), 1.35 – 1.24 (m, 1H), 1.18 (m, 2H), 1.03 (s, 3H), 0.79 (m, 1H).  
13C NMR (101 MHz, Chloroform-d) δ 211.13, 158.33, 153.91, 138.72,135.69, 
128.77, 127.45,125.16, 117.25, 113.30, 112.61, 79.73, 55.22, 54.01, 46.13, 37.14, 36.62, 
31.89, 29.96, 28.40, 25.59, 23.19, 17.15. 
 
3.4.11 Ester 12:  
O
O
OH
11
O
O
O
TBS
12
TBSCl/
Imidazol
DMF
 
To a stirred solution of commercially available methyl2-hydroxy isobutyrate 11 
(5g, 42.3mmole) in dimethyl formmide (DMF) (12.5ml), tert-butylsilyl chloride (TBSCl) 
(7.65g, 50.75mmole) were added followed by the addition of imidazole (7.45g, 
110mmole). The reaction was stirred for 24h, then solution of sodium bicarbonate (25ml) 
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was added. The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over 
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. The crude 
product was purified using silica gel column chromatography (10% ethyl acetate in hexane) 
to give ester 12 (7.2g, 73.2%) as a yellow oil. 
 1H NMR (400 MHz, CDCl3): d=3.60(s, 3H), 1.34 (s, 6H), 0.80 (s, 9 H), 0.08 ppm 
(s, 6H);  
13C NMR (100 MHz, CDCl3): d=175.8, 74.5, 51.4, 28.4, 25.5, 17.9, 3.2 ppm. 
 
3.4.12 Alcohol 13:  
O
O
O
TBS
HO
O
12
TBS
13
DiBAL-H
Hexane/ -78oC
 
To a stirred solution of ester 12 (7.2g, 30.98mmole) in hexane (98ml), 
Diisobutylaluminium hydride (DiBAL-H) (56.8ml, 68.16mmole) was added at -78oC in a 
dropwise matter. The reaction stirred for 30 min. at 00C, then for 20 min. at the room 
temperature. The reaction then cooled back to -78oC, followed by the addition of solution 
of potassium tartrate (45ml). The reaction was allowed to stir for overnight. The aqueous 
phase was extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
used to purify the crude material (20% ethyl acetate in hexane) to give alcohol 13 (5.75g, 
90.8%) as colorless liquid.  
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1H NMR (400 MHz, CDCl3): d=3.19 (s, 2H), 2.31 (s, 1 H), 1.11 (s, 6 H), 0.76 (s, 
9 H), 0.08 ppm (s, 6H);  
13C NMR (100 MHz, CDCl3): d=76.3, 74.4, 28.5, 28.0, 20.3, 0.3 ppm.   
 
3.4.13 Aldehyde 14: 
HO
O
TBS
H
O
TBS
O
13 14
TPAP/NMO
DCM/ 5oMS
 
To a stirred solution of alcohol 13 (2g, 9.7858mmole) in a dry dichloromethane 
(DCM) (98ml), active molecular sieves (4oA, 2.3g) was added, then the reaction mixture 
was allowed to stir for 5 min. followed by the addition on N-Methylmorpholine N-oxide 
(NMO) (2.3g, 19.57mmole), then Tetrapropylammonium perruthenate (TPAP) (0.34g, 
0.98mmole) was added at  00C. The reaction stirred at 00C for 2h, then at room temperature 
for 24h. Pad of silica gel were used to filtrate the reaction mixture using diethyl ether as 
eluting solvent. The filtrated material concentrated under vacuo to provide aldehyde 14 
(1.45g, 73.3%) as colorless oil.   
1H NMR (400 MHz, CDCl3): d=9.44 (s, 1H), 1.17 (s, 6 H), 0.79 (s, 9H), 0.08 ppm 
(s, 6H). 
13C NMR (100 MHz, CDCl3): d=206.4, 80.3, 28.0, 27.2, 20.4, 0.3 ppm. 
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3.4.14 Protected enone 9 and 9`: 
H
O
O
H
H
H
O
HO
8 and 8
LDA/ -78oC
THF
/THF,-78oC
OTBS
9 and 953%
O
H
H
H
O
HO
O TBS
 
To a stirred solution of hydroxyl ketone 8 and 8 (0.5g, 1.4115mmole) in a dry 
tetrahydrofuran (THF)  (3ml), lithiumdiisopropyl amine (LDA) (2.5ml, 5.08mmole) was added in 
a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 h, then the solution of 
aldehyde 14 (0.6g, 2.823mmole) in THF (18.8ml) was added to the reaction mixture at -78oC. The 
reaction was allowed to stir and warm to the room temperature for 24h. The quench of the reaction 
was completed by the addition of ammonium chloride (NH4Cl) (25ml). The aqueous layer was 
extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and 
concentrated under vacuo. Silica gel column chromatography was used to purify the crude material 
(10% ethyl acetate in hexane) to provide protected enone 9 and 9` (0.44g, 57.9%).  
Compound 9 1H NMR (400 MHz, Chloroform-d) δ 7.13 – 6.92 (m, 2H), 6.70 – 6.54 (m, 
2H), 6.52 (s, 1H), 5.82 (m, 1H), 4.32 (s, 1H), 3.65 (d, J = 4.2 Hz, 3H), 2.76 (m, 2H), 2.20 – 2.05 
(m, 1H), 1.97 (m, 1H), 1.86 – 1.76 (m, 1H), 1.81 – 1.68 (m, 1H), 1.54 – 1.39 (m, 2H), 1.37 (d, J = 
9.8 Hz, 3H), 1.33 – 1.19 (m, 6H), 1.23 – 1.03 (m, 4H), 0.93 (s, 2H), 0.91 – 0.81 (m, 1H), 0.86 – 
0.73 (m, 12H), 0.78 – 0.70 (m, 1H), 0.11 (s, 3H).  
 
13C NMR (101 MHz, Chloroform-d) δ 203.82, 159.48, 158.50, 157.15, 139.80, 134.70, 
131.27, 128.01, 120.90, 115.87, 113.42, 80.52, 76.84, 59.54, 57.12, 49.55, 46.26, 39.10, 36.14, 
33.07, 31.88, 31.72, 29.70, 28.37, 28.26, 27.88, 27.79, 27.75, 27.24, 20.22, 20.05, 19.98, -1.47.  
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Compound 9  1H NMR (400 MHz, Chloroform-d) δ 7.19-7.07 (m, 2H), 6.94-6.92 (m, 
2H), 6.65 (s, 1H), 5.90 – 5.77 (m, 1H), 4.26 (s, 1H), 3.67 (d, J = 4.2 Hz, 3H), 2.87 – 2.71 (m, 2H), 
2.22 (m, 1H), 2.19 (m, 1H), 2.15 (m, 1H), 1.62 (m, 1H), 1.55 – 1.42 (m, 2H), 1.41 (d, J = 9.8 Hz, 
3H), 1.31 – 1.21 (m, 6H), 1.21 – 1.12 (m, 4H), 0.93 (m, 2H), 0.91 – 0.81 (m, 1H), 0.88 – 0.75 (m, 
12H), 0.80 – 0.74 (m, 1H), 0.12 (s, 3H). 
 
 13C NMR (101 MHz, Chloroform-d) δ 203.55, 159.45, 157.93, 157.44, 139.86, 134.92, 
131.22, 128.12, 121.43, 115.91, 113.41, 81.27, 75.61, 58.83, 57.20, 50.10, 45.99, 39.28, 38.38, 
33.08, 31.92, 31.76, 29.74, 28.61, 28.41, 28.07, 27.90, 27.82, 27.12, 20.28, 20.12, 19.24, -1.43. 
 
3.4.15 MMA102 and MMA 132: 
O
H
H
H
O
OTBS
O
H
H
H
O
OH
TBAF
THF
9 and 9
MMA102 and MMA132
HO HO
 
To a stirred solution of protected enone 9 and 9` (0.4g, 0.742mmole) in 
tetrahydrofuran (THF) (11.5ml), tetrabutyl ammonium fluoride  (TBAF) (2.3ml, 
2.3mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added 
to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
used to purify the crude material (10% ethyl acetate in hexane) to provide MMA102 and 
MMA132 (0.28g, 88.88%).  
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Compound MMA102 1H NMR (400 MHz, Chloroform-d) δ 7.14 – 6.98 (m, 2H), 
6.65 – 6.45 (m, 2H), 5.83 (m, 2H), 4.02 (s, 1H), 3.67 (s, 3H), 2.77 (m, 2H), 2.26 – 2.06 (m, 
2H), 1.97 – 1.70 (m, 3H), 1.61 (m, 1H), 1.45 (s, 3H), 1.42 (m, 6H), 1.24 – 1.07 (m, 4H), 
0.85 – 0.74 (m, 2H), 0.65 (s, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 201.30, 157.39, 155.23, 154.75, 137.86, 
132.85, 129.19, 126.07, 119.36, 113.83, 111.36, 79.17, 71.18, 56.77, 55.21, 48.08, 43.87, 
37.21, 36.20, 31.08, 29.67, 29.45, 29.31, 27.61, 26.51, 24.90, 17.36. HR-FT-MS calcd for 
C27H36O4Na1 447.2506 found 447.24952. 
Compound MMA132 1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.01 (m, 2H), 
6.65 – 6.50 (m, 2H), 5.84 (m, 2H), 4.02 (s, 1H), 3.67 (s, 3H), 2.77 (m, 2H), 2.22 – 1.88 (m, 
2H), 1.78 (m, 3H), 1.64 (m, 1H),  1.57 (s, 3H), 1.36 (m, 6H), 1.28- 1.15 (m, 4H), 1.08 (m, 
2H), 0.98 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 201.55, 157.38, 155.40, 154.86, 137.88, 
132.75, 129.45, 126.01, 118.76, 113.81, 111.39, 78.61, 71.18, 57.40, 55.19, 47.71, 44.07, 
37.06, 34.29, 31.10, 29.70, 29.47, 29.42, 27.59, 26.23, 25.18, 17.27. HR-FT-MS calcd for 
C27H36O4Na1 447.2506 found 447.24952. 
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3.4.16 ∆9,11  protected enone 16:  
O
H
H
O
HO
15
O
H
H
O
HO
H
O
LDA/ -78oC
THF
/THF,-78oC
OTBS
O
TBS
1651%  
To a sirred solution of ∆9,11  hydroxyl ketone 15 (1g, 2.84mmole) in a dry 
tetrahydrofuran (THF)  (5.7ml), lithiumdiisopropyl amine (LDA) (5.112mlml, 
10.224mmole) was added in a dropwise at -78oC the reaction mixture was allowed to stir 
at -78oC  for 1 h, then the solution of aldehyde 14 (1.15, 5.68mmole) in THF (37.8ml) was 
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the 
room temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide ∆9,11  protected enone 16.  
 
1H NMR (600 MHz, Chloroform-d) δ 7.43 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 15.2 
Hz, 1H), 6.72 – 6.63 (m, 1H), 6.66 – 6.61 (m, 1H), 6.54 (dd, J = 14.5, 3.2 Hz, 1H), 5.94 
(dt, J = 5.2, 2.3 Hz, 1H), 5.85 (dd, J = 3.3, 1.6 Hz, 1H), 4.37 (s, 1H), 3.71 (s, 3H), 2.91 – 
2.71 (m, 2H), 2.26 (ddt, J = 13.9, 7.1, 3.6 Hz, 1H), 2.23 – 2.15 (m, 1H), 2.09 – 1.92 (m, 
2H), 1.91 (dt, J = 17.4, 3.2 Hz, 1H), 1.58 – 1.48 (m, 1H), 1.46 – 1.33 (m, 2H), 1.34 – 1.20 
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(m, 4H), 1.23 – 1.12 (m, 3H), 1.15 – 1.04 (m, 2H), 0.95 (s, 3H), 0.93 – 0.77 (m, 9H), 0.80 
– 0.71 (m, 6H).   
13C NMR (151 MHz, Chloroform-d) δ 203.89, 160.41, 158.95, 155.34 (d, J = 26.4 
Hz), 139.50, 137.55, 131.35, 129.65, 127.20, 120.62, 119.70, 115.42, 114.71, 80.74, 75.69, 
57.33, 56.15, 47.97, 38.91, 38.66, 33.96, 32.03, 31.96, 31.90, 30.48, 27.98 – 27.82 (m), 
27.56, 20.25 (d, J = 5.7 Hz), 19.23, -0.04 (t, J = 7.5 Hz). 
 
3.4.17 MMA 128 (∆9,11  OH enone):  
O
H
H
O
HO
O
TBS
16
TBAF
THF
O
H
H
O
HO
OH
MMA128
85%
 
 To a stirred solution of  ∆9,11  protected enone 16 and 16 (0.25g,  0.466mmole) in 
tetrahydrofuran (THF) (7.2ml), tetrabutyl ammonium fluoride  (TBAF) (1.44ml, 
1.44mmole) was added and stirred for 6h. ammonium chloride (NH4Cl) solution was added 
to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
used to purify the crude material (10% ethyl acetate in hexane) to provide MMA128 
(0.162g, 82.35%). 
1H NMR (400 MHz, Chloroform-d) δ 7.11 – 7.02 (m, 2H), 6.63 – 6.47 (m, 2H), 
5.82 (m, 2H), 5.72 (m, 1H), 4.01 (s, 1H), 3.64 (s, 3H), 2.73 (m, 1H), 2.20 – 1.86 (m, 2H), 
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1.78 (m, 2H), 1.64 (m, 1H),  1.57 (s, 3H), 1.36 (m, 6H), 1.28- 1.15 (m, 3H), 1.08 (m, 2H), 
0.98 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 201.53, 157.37, 155.38, 154.83, 137.87, 
132.74, 129.43, 125.92, 118.74, 113.80, 111.37, 78.59, 71.16, 57.39, 55.17, 47.72, 44.05, 
37.04, 34.27, 31.07, 29.68, 29.45, 29.40, 27.57, 26.21, 25.15, 17.24. HR-FT-MS calcd for 
C27H34O4Na1 447.25181 found 447.24621. 
 
3.4.18 Para-methoxyphenyl enone MMA265 and MMA333: 
O
H
H
H
O
HO
O
H
H
H
O
HO
O
LDA/ -78oC
THF
P-PhOMeCO
49%
8 and 8 MMA265 AND MMA333  
To a sirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry 
tetrahydrofuran (THF)  (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was 
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 h, then 
the solution of  Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to 
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room 
temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
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acetate in hexane) to provide Para-methoxy benzene enone MMA265 and MMA333 
(0.26g, 65%).  
Compound 265 1H NMR (400 MHz, Chloroform-d) δ 7.75 – 7.59 (m, 1H), 7.49 – 
7.37 (m, 2H), 7.15 – 7.01 (m, 1H), 6.86 – 6.74 (m, 3H), 6.57 (dd, J = 8.6, 2.8 Hz, 1H), 6.56 
– 6.47 (m, 1H), 5.86 (m, 1H), 4.30 (s, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 2.84 – 2.66 (m, 2H), 
2.23 – 2.08 (m, 4H), 2.00 – 1.72 (m, 3H), 1.64 – 1.55 (m, 3H), 1.48 (s, 3H), 1.35 – 1.25 
(m, 1H), 1.24 – 1.08 (m, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 200.61, 161.99, 157.43, 155.97, 144.24, 
137.83, 132.89, 130.47, 128.74, 127.08, 126.07, 117.20, 114.47, 113.85, 111.35, 79.03, 
60.42, 55.43, 55.17, 48.13, 43.90, 37.24, 36.26, 31.97, 29.76, 29.71, 29.69, 27.67, 26.56, 
25.26, 21.06. HR-FT-MS calcd for C31H36O4Na1 495.2506 found 495.24909. 
 
Compound MMA333 1H NMR (400 MHz, Chloroform-d) δ 7.74 – 7.57 (m, 1H), 
7.47 – 7.35 (m, 2H), 7.13 – 6.99 (m, 1H), 6.84 – 6.72 (m, 3H), 6.55 (dd, J = 8.6, 2.8 Hz, 
1H), 6.54 – 6.45 (m, 1H), 5.84 (m, 1H), 4.28 (s, 1H), 3.70 (s, 3H), 3.62 (s, 3H), 2.82 – 2.64 
(m, 2H), 2.21 – 2.06 (m, 4H), 1.98 – 1.70 (m, 3H), 1.62 – 1.53 (m, 3H), 1.46 (s, 3H), 1.32 
– 1.23 (m, 1H), 1.22 – 1.06 (m, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 200.59, 161.97, 157.41, 155.95, 144.22, 
137.81, 132.87, 130.45, 128.72, 127.06, 126.05, 117.18, 114.45, 113.83, 111.33, 79.01, 
60.40, 55.41, 55.15, 48.11, 43.88, 37.22, 36.24, 31.95, 29.74, 29.69, 29.67, 27.65, 26.54, 
25.24, 21.04. HR-FT-MS calcd for C31H36O4Na1 495.2506 found 495.24883. 
 
   145 
 
  
3.4.19 Para-flurophenyl enone MMA270 and MMA334: 
O
H
H
H
O
HO
O
H
H
H
O
HO
F
LDA/ -78oC
THF
P-PhFCO
51%
8 and 8 MMA270 and MMA334  
To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry 
tetrahydrofuran (THF)  (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 
h, then the solution of  Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was 
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the 
room temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide Para-flurobenzene enone MMA270 and MMA334 (0.32g, 
61.5%).  
Compound MMA270 1H NMR (400 MHz, Chloroform-d) δ 7.70 (m, 1H), 7.54 – 
7.35 (m, 2H), 7.10 (m, 1H), 7.05 – 6.96 (m, 2H), 6.87 (m, 1H), 6.69 – 6.51 (m, 2H), 5.91 
(m, 1H), 4.22 (s, 1H), 3.68 (s, 3H), 2.79 (m, 2H), 2.29 (s, 1H), 2.25 – 2.01 (m, 3H), 1.93 – 
1.76 (m, 3H), 1.76 – 1.37 (m, 3H), 1.37 – 1.36 (m, 1H), 1.36 – 1.22 (m, 2H), 1 1.04 – 0.75 
(m, 1H), 0.67 (s, 3H).   
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13C NMR (101 MHz, Chloroform-d) δ 200.56, 157.43, 155.69, 143.10, 137.99, 
137.84, 132.84, 130.64, 130.60, 130.55, 129.05, 126.07, 119.29, 116.32, 116.10, 113.85, 
111.37, 79.20, 55.21, 53.48, 48.13, 43.88, 37.23, 36.23, 31.14, 29.67, 27.64, 26.54, 25.10, 
17.49. HR-FT-MS calcd for C30H33O3F1Na1 483.2306 found 483.22909. 
 
Compound MMA334 1H NMR (400 MHz, Chloroform-d) δ 7.68 (m, 1H), 7.52 – 
7.33 (m, 2H), 7.08 (m, 1H), 7.03 – 6.94 (m, 2H), 6.85 (m, 1H), 6.67 – 6.49 (m, 2H), 5.89 
(m, 1H), 4.20 (s, 1H), 3.66 (s, 3H), 2.77 (m, 2H), 2.27 (s, 1H), 2.23 – 1.99 (m, 3H), 1.91 – 
1.74 (m, 3H), 1.74 – 1.35 (m, 3H), 1.35 – 1.34 (m, 1H), 1.34 – 1.20 (m, 2H), 1.02 – 0.73 
(m, 1H), 0.65 (s, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 200.54, 157.41, 155.67, 143.08, 137.97, 
137.82, 132.82, 130.62, 130.58, 130.53, 129.03, 126.05, 119.25, 116.30, 116.08, 113.83, 
111.35, 79.18, 55.19, 53.46, 48.11, 43.86, 37.21, 36.21, 31.12, 29.65, 27.62, 26.52, 25.08, 
17.47. HR-FT-MS calcd for C30H33O3F1Na1 483.2306 found 483.22909. 
 
3.4.20 Para-chlorophenyl enone MMA287 and MMA316: 
O
H
H
H
O
HO
O
H
H
H
O
HO
Cl
LDA/ -78oC
THF
P-PhClCO
59. 5%
8 and 8 MMA287 and MMA316  
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To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry 
tetrahydrofuran (THF) (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was 
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 h, then 
the solution of  Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to 
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room 
temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to obtained P-chlorobenzene enone MMA287 and MMA316 (0.25g, 
62%).  
Compound 287  1H NMR (600 MHz, Chloroform-d) δ 7.80 (m, 1H), 7.56 – 7.51 
(m, 2H), 7.44 – 7.38 (m, 2H), 7.21 (m, 1H), 7.03 (m, 1H), 6.73 (m, 1H), 6.66 (m, 1H), 6.03 
(m, 1H), 4.29 (s, 1H), 3.80 (s, 3H), 2.97 – 2.84 (m, 2H), 2.36 – 2.25 (m, 2H), 2.10 – 2.00 
(m, 1H), 1.97 – 1.87 (m, 1H), 1.77 (m, 1H), 1.64 (s, 3H), 1.55 – 1.41 (m, 2H), 1.37 – 1.25 
(m, 2H), 0.94 (m, 2H), 0.79 (s, 3H).   
13C NMR (151 MHz, Chloroform-d) δ 200.54, 157.45, 155.66, 142.92, 137.84, 
136.86, 132.83, 129.77, 129.30, 129.12, 126.07, 120.00, 113.86, 111.38, 79.24, 56.83, 
55.21, 48.14, 43.88, 37.24, 36.23, 31.96, 31.15, 29.74, 29.67, 29.40, 27.64, 26.54, 25.07, 
17.51. HR-FT-MS calcd for C30H33O3Cl1Na1 499.2010 found 499.19958. 
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Compound 316 1H NMR (600 MHz, Chloroform-d) δ 7.78 (d, m, 1H), 7.54 – 7.49 
(m, 2H), 7.42 – 7.36 (m, 2H), 7.19 (m, 1H), 7.01 (m, 1H), 6.71 (m, 1H), 6.64 (m, 1H), 6.01 
(m, 1H), 4.27 (s, 1H), 3.78 (s, 3H), 2.95 – 2.82 (m, 2H), 2.34 – 2.23 (m, 2H), 2.08 – 1.98 
(m, 1H), 1.95 – 1.85 (m, 1H), 1.75 (m, 1H), 1.62 (s, 3H), 1.53 – 1.39 (m, 2H), 1.35 – 1.23 
(m, 2H), 0.92 (m, 2H), 0.77 (s, 3H).  
13C NMR (151 MHz, Chloroform-d) δ 200.52, 157.43, 155.64, 142.90, 137.82, 
136.84, 132.81, 129.75, 129.28, 129.10, 126.05, 119.98, 113.84, 111.36, 79.22, 56.81, 
55.19, 48.12, 43.86, 37.22, 36.21, 31.94, 31.13, 29.72, 29.65, 29.38, 27.62, 26.52, 25.05, 
17.49. HR-FT-MS calcd for C30H33O3Cl1Na1 499.2010 found 499.19943. 
 
3.4.21 Para-bromophenyle enone MMA288 and MMA319: 
O
H
H
H
O
HO
O
H
H
H
O
HO
Br
LDA/ -78oC
THF
P-PhBrCO
59%
8 and 8 MMA288 and MMA319  
To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry 
tetrahydrofuran (THF)  (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 
h, then the solution of  Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was 
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the 
room temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
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(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide para-bromobenzene enone MMA288 and MMA319 (0.35g, 
59%). 
 Compound MMA288 1H NMR (600 MHz, Chloroform-d) δ 7.70 – 7.61 (m, 1H), 
7.53 – 7.42 (m, 2H), 7.41 – 7.32 (m, 2H), 7.15 – 7.08 (m, 1H), 6.93 (m, 1H), 6.63 (m, 1H), 
6.55 (d, 1H), 5.91 (m, 1H), 4.16 (s, 1H), 3.74 (s, 3H), 2.86 – 2.74 (m, 2H), 2.27 – 2.15 (m, 
2H), 2.03 (s, 1H), 1.98 – 1.89 (m, 1H), 1.86 – 1.76 (m, 1H), 1.65 (s, 3H), 1.51 (d, 2H), 1.47 
– 1.31 (m, 2H), 0.93 – 0.75 (m, 2H), 0.67 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 200.6, 157.5, 155.6, 142.9, 133.3, 132.9, 
132.4, 129.8, 129.3, 129.1, 126.1, 125.3, 120.1, 113.9, 111.4, 79.3, 55.2, 53.4, 48.2, 43.9, 
37.3, 36.3, 31.2, 29.8, 29.6, 27.8, 26.6, 25.2, 25.01, 17.6. HR-FT-MS calcd for 
C30H33O3Br1Na1 543.1505 found 543.15269. 
Compound MMA319 1H NMR (600 MHz, Chloroform-d) δ 7.68 – 7.59 (m, 1H), 
7.51 – 7.40 (m, 2H), 7.39 – 7.30 (m, 2H), 7.13 – 7.06 (m, 1H), 6.91 (m, 1H), 6.61 (m, 1H), 
6.53 (d, 1H), 5.89 (m, 1H), 4.14 (s, 1H), 3.72 (s, 3H), 2.84 – 2.72 (m, 2H), 2.25 – 2.13 (m, 
2H), 2.01 (s, 1H), 1.96 – 1.87 (m, 1H), 1.84 – 1.74 (m, 1H), 1.63 (s, 3H), 1.49 (d, 2H), 1.45 
– 1.29 (m, 2H), 0.91 – 0.73 (m, 2H), 0.65 (s, 3H).  
13C NMR (151 MHz, Chloroform-d) δ 200.4, 157.3, 155.4, 142.7, 133.1, 132.7, 
132.2, 129.6, 129.1, 128.99, 127.99, 125.1, 119.99, 113.7, 111.2, 79.1, 54.99, 53.2, 48.02, 
43.7, 37.1, 36.1, 31.01, 29.6, 29.4, 27.6, 26.4, 25.03, 24.99, 17.4. HR-FT-MS calcd for 
C30H33O3Br1Na1 543.1505 found 543.14872. 
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3.4.22 2-bromofuran enone MMA290 and MMA318: 
O
H
H
H
O
HO
O
H
H
H
O
HO
LDA/ -78oC
THF
5-Br-2-furanaldehyde
53.7%
8 and 8
MMA290 and MMA318
O Br
 
To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry 
tetrahydrofuran (THF)  (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 
h, then the solution of  Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was 
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the 
room temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide para-bromobenzene enone MMA290 and MMA318 (0.31g, 
53.7%).  
Compound MMA290 1H NMR (600 MHz, Chloroform-d) δ 7.47 (m, 1H), 7.21 
(m, 1H), 6.88 (m, 1H), 6.73 (m, 1H), 6.67 (m, 2H), 6.48 (m, 1H), 6.04 – 6.00 (m, 1H), 4.33 
(s, 1H), 3.83 (s, 3H), 2.97 – 2.84 (m, 2H), 2.31 (m, 2H), 2.11 – 1.98 (m, 1H), 1.99 – 1.88 
(m, 1H), 1.76 (m, 1H), 1.64 – 1.55 (m, 3H), 1.53 – 1.41 (m, 2H), 1.36 – 1.26 (m, 2H), 0.98 
– 0.83 (m, 2H), 0.78 (m , 3H). 
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 13C NMR (151 MHz, Chloroform-d) δ 200.53, 157.43, 155.42, 153.03, 137.88, 
132.90, 129.22, 128.92, 126.35, 126.07, 119.01, 117.47, 114.76, 113.85, 111.37, 79.17, 
56.78, 55.21, 48.13, 43.89, 37.24, 36.29, 31.16, 29.69, 27.65, 26.56, 25.06, 17.48. HR-FT-
MS calcd for C28H31O4Br1Na1 533.1298 found 533.12803. 
  
Compound MMA318 1H NMR (600 MHz, Chloroform-d) δ 7.45 (m, 1H), 7.19 
(m, 1H), 6.86 (m, 1H), 6.71 (m, 1H), 6.65 (m, 2H), 6.46 (m, 1H), 6.02 – 5.98 (m, 1H), 4.31 
(s, 1H), 3.81 (s, 3H), 2.95 – 2.82 (m, 2H), 2.29 (m, 2H), 2.09 – 1.96 (m, 1H), 1.97 – 1.86 
(m, 1H), 1.74 (m, 1H), 1.62 – 1.53 (m, 3H), 1.51 – 1.39 (m, 2H), 1.34 – 1.24 (m, 2H), 0.96 
– 0.81 (m, 2H), 0.76 (m , 3H).  
13C NMR (151 MHz, Chloroform-d) δ 200.51, 157.41, 155.40, 153.01, 137.86, 
132.88, 129.20, 128.90, 126.33, 126.05, 118.99, 117.45, 114.74, 113.83, 111.35, 79.15, 
56.76, 55.19, 48.11, 43.87, 37.22, 36.27, 31.14, 29.67, 27.63, 26.54, 25.04, 17.46. HR-FT-
MS calcd for C28H31O4Br1Na1 533.1298 found 533.12807. 
 
3.4.23 Para-trifluromethyl phenyl enone MMA292 and MMA320:  
O
H
H
H
O
HO
O
H
H
H
O
HO
CF3
LDA/ -78oC
THF
P-PhCF3CO
61.7%
8 and 8 MMA292 and MMA320  
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To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry 
tetrahydrofuran (THF)  (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was 
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 h, then 
the solution of  Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to 
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room 
temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to obtained para-trifluromethyl benzene enone MMA292 and MMA320 
(0.21g, 61.7%).  
Compound MMA292 1H NMR (600 MHz, Chloroform-d) δ 7.77 (m, 1H), 7.62 – 
7.53 (m, 4H), 7.05 – 6.98 (m, 2H), 6.59 (m, 1H), 6.53 (m, 1H), 5.97 – 5.93 (m, 1H), 4.32 
(s, 1H), 3.67 (m, 3H), 2.88 – 2.71 (m, 2H), 2.21-2.12 (m, 2H), 2.02 (m, 1H), 1.81 (m, 1H), 
1.53 (m, 1H), 1.49 – 1.37 (m, 3H), 1.30 (m, 1H), 1.11 (m, 1H), 0.97 (s, 3H), 0.90 – 0.71 
(m, 4H).  
13C NMR (151 MHz, Chloroform-d) δ 200.66, 157.42, 155.15, 142.93, 137.83, 
137.67, 132.74, 129.72, 128.80, 126.00, 125.98, 125.95, 125.93, 121.08, 113.82, 111.36, 
78.80, 57.47, 55.17, 47.85, 43.93, 37.09, 34.48, 31.96, 31.23, 29.74, 29.69, 27.59, 26.27, 
25.26, 17.21. HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22689. 
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Compound MMA320 1H NMR (600 MHz, Chloroform-d) δ 7.75  (m, 1H), 7.60 
– 7.51 (m, 4H), 7.03 – 6.96 (m, 2H), 6.57 (m, 1H), 6.51 (m, 1H), 5.95 – 5.91 (m, 1H), 4.30 
(s, 1H), 3.65 (m, 3H), 2.86 – 2.76 (m, 2H), 2.19-2.10 (m, 2H), 2.01 (m, 1H), 1.79 (m, 1H), 
1.51 (m, 1H), 1.47 – 1.35 (m, 3H), 1.28 (m, 1H), 1.09 (m, 1H), 0.95 (s, 3H), 0.88 – 0.69 
(m, 4H). HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22544. 
 
13C NMR (151 MHz, Chloroform-d) δ 200.64, 157.40, 155.13, 142.91, 137.81, 
137.65, 132.72, 129.70, 128.78, 125.98, 125.96, 125.93, 125.91, 121.06, 113.80, 111.34, 
78.878, 57.45, 55.15, 47.83, 43.91, 37.07, 34.46, 31.94, 31.21, 29.72, 29.67, 27.57, 26.25, 
25.24, 17.19. HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22544. 
 
3.4.24 Para-nitrophenyl enone MMA305 and MMA321: 
O
H
H
H
O
HO
O
H
H
H
O
HO
NO2
LDA/ -78oC
THF
P-PhNO2CO
52.7%
8 and 8 MMA305 and MMA321  
To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry 
tetrahydrofuran (THF)  (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 
h, then the solution of  Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was 
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the 
room temperature for 24h. The quench of the reaction was completed by the addition of 
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ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide para-nitrobenzene enone MMA305 and MMA321 (0.29g, 
52.7%).  
 
Compound MMA305  1H NMR (400 MHz, Chloroform-d) δ 8.16 (m, 2H), 7.77 
(m, 1H), 7.63 (m, 2H), 7.14 (s, 1H), 7.10 – 6.98 (m, 2H), 6.61 – 6.54 (m, 1H), 6.51 (d, 1H), 
5.97 (d, 1H), 4.26 (s, 1H), 3.66 (s, 3H), 2.81- 2.75 (m, 2H), 2.22-2.12 (m, 2H), 2.01 (m, 
1H), 1.81 (d, 1H), 1.50 – 1.37 (m, 1H), 1.34 – 1.15 (m, 3H), 1.10 (m, 1H), 0.96 (s, 3H), 
0.87- 0.78 (m, 4H).  
13C NMR (101 MHz, Chloroform-d) δ 200.47, 157.42, 154.97, 148.75, 141.76, 
140.37, 137.81, 132.64, 129.99, 129.26, 125.98, 124.22, 122.60, 113.80, 111.37, 78.91, 
57.50, 55.16, 47.85, 43.93, 37.07, 34.69, 34.56, 31.62, 31.26, 29.67, 27.59, 26.27, 25.31, 
25.20, 22.69, 17.21, 14.18. HR-FT-MS calcd for C30H33O5N1Na1 510.2251 found 
510.22450. 
 
Compound MMA321 1H NMR (400 MHz, Chloroform-d) δ 8.14 (m, 2H), 7.75 
(m, 1H), 7.61 (m, 2H), 7.12 (s, 1H), 7.08 – 6.96 (m, 2H), 6.59 – 6.52 (m, 1H), 6.49 (d, 1H), 
5.95 (d, 1H), 4.24 (s, 1H), 3.64 (s, 3H), 2.79- 2.73 (m, 2H), 2.20-2.10 (m, 2H), 2.01 (m, 
1H), 1.79 (d, 1H), 1.48 – 1.35 (m, 1H), 1.32 – 1.13 (m, 3H), 1.08 (m, 1H), 0.94 (s, 3H), 
0.85- 0.76 (m, 4H).  
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13C NMR (101 MHz, Chloroform-d) δ 200.45, 157.40, 154.95, 148.73, 141.74, 
140.35, 137.79, 132.62, 129.97, 129.24, 125.96, 124.20, 122.58, 113.78, 111.35, 78.89, 
57.48, 55.14, 47.83, 43.91, 37.05, 34.67, 34.54, 31.60, 31.24, 29.65, 27.57, 26.25, 25.29, 
25.18, 22.67, 17.19, 14.16. HR-FT-MS calcd for C30H33O5N1Na1 510.2251 found 
510.22454. 
 
3.4.25 5-bromothiphene enone MMA311 and MMA330:  
O
H
H
H
O
HO
O
H
H
H
O
HO
LDA/ -78oC
THF
5-Br-2-thiophenaldehyde
78. 5%
8 and 8 MM311 and MMA330
S Br
 
To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry 
tetrahydrofuran (THF)  (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was 
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 h, then 
the solution of  Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to 
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room 
temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
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acetate in hexane) to obtained 5-bromothiphene enone MMA311 and MMA330 (0.35g, 
78.5%).  
Compound MMA311 1H NMR (600 MHz, Chloroform-d) δ 7.86 (m, 1H), 7.19 – 
7.10 (m, 2H), 7.08 (m, 1H), 6.77 – 6.69 (m, 2H), 6.66 (m, 1H), 6.03 (m, 1H), 4.47 (s, 1H), 
3.80 (s, 3H), 2.98 – 2.84 (m, 2H), 2.39 – 2.29 (m, 2H), 2.07 (m, 1H), 1.94 (m, 1H), 1.70 – 
1.51 (m, 3H), 1.44 (m, 1H), 1.38 – 1.19 (m, 4H), 1.08 (s, 3H), 0.98 – 0.88 (m, 3H), 0.89 (s, 
1H).  
13C NMR (151 MHz, Chloroform-d) δ 200.39, 157.42, 155.26, 141.39, 137.85, 
136.24, 132.97, 132.82, 131.45, 129.46, 126.02, 117.97, 117.15, 113.83, 111.36, 78.54, 
57.42, 55.17, 47.81, 43.93, 37.13, 36.70, 34.25, 31.22, 27.61, 26.80, 25.34, 17.22. HR-FT-
MS calcd for C28H31O3Br1Na1S1 549.1069 found 549.10931. 
Compound MMA330 1H NMR (600 MHz, Chloroform-d) δ 7.84 (m, 1H), 7.17 – 
7.08 (m, 2H), 7.06 (m, 1H), 6.75 – 6.67 (m, 2H), 6.64 (m, 1H), 6.01 (m, 1H), 4.45 (s, 1H), 
3.78 (s, 3H), 2.96 – 2.82 (m, 2H), 2.37 – 2.27 (m, 2H), 2.05 (m, 1H), 1.92 (m, 1H), 1.68 – 
1.49 (m, 3H), 1.42 (m, 1H), 1.36 – 1.17 (m, 4H), 1.06 (s, 3H), 0.96 – 0.86 (m, 3H), 0.87 (s, 
1H).  
13C NMR (151 MHz, Chloroform-d) δ 200.37, 157.40, 155.24, 141.37, 137.83, 
136.22, 132.95, 132.80, 131.43, 129.44, 126.01, 117.95, 117.13, 113.81, 111.34, 78.52, 
57.40, 55.15, 47.79, 43.91, 37.11, 36.68, 34.23, 31.19, 27.60, 26.79, 25.32, 17.21. . HR-
FT-MS calcd for C28H31O3Br1Na1S1 549.1069 found 549.1019. 
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 Chapter Four 
 
 Design, Synthesis and Biological Screening of CUCUS-inspired Estrone Analogues 
with Sulfamoyl Moiety at C-3 Targeting Epidermal Growth Factor toward 
Treatment of Hepatocellular Carcinoma 
 
4.1  Introduction: 
The study of molecular docking provided background information about the 
behavior of the CUCUS-inspired estrone analogues in the binding pocket of the EGFR and 
pointed out at the analogues that will be synthesized and then biologically screened. 
Number of research groups have done chemical modification on the main structure of 
cucurbitacins such as installing tosyl functional groups in the ring A, followed by addition 
of halogens [1, 2] and alkylation reaction [3, 4]. Various synthetic approaches were 
conducted to totally synthesized cucurbitacins but all of these trays were failed to provide 
fully synthesized cucurbitacin [5, 6]. However, there are some successful studies on 
modification of cucurbitacins including quantitative structure activity relationship (QSAR) 
study of semi synthetic cucurbitacin by Bartalis and Halaweish [4], partial  synthesis of 
cucurbitacin B and D by Jung [7], synthesis of hexanorcucurbitacin compounds by Ryu [8] 
and synthesis of dihydrocucurbitacin B by Lang [1]. However, some of these synthetic 
paths are impracticable for cucurbitacins pharmacophores to be modified for biological 
activities.  
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There have been few studies and researches trying to install the cucurbitacins enone 
side chain into the C-17 of the steroid main structure (Fig4.1). However, assembling the 
enone side chain is challenging mission because of interfering functional groups on the 
main skeleton which may affect each other during the chemical reactions. Ourisson et al. 
1973 using Grinard reagent, tetrhydro pyranyl ether, tried to install cucurbitacin I side chain 
into C-17 of tetracyclic steroid but he ended up with racemic mixture of S- and R-isomers 
at C-20 [9]. An attempting to modify lanastrol, which is tetracyclic triterpins, Paryzek et 
al. 1981 resulted in the synthesis of different analogue which is 4, 4, 14α-trimethyl-19(10-
8β) abeo-steroids with side chain at C-2 and C-5 [10]. In another study Levy et al. tried to 
modify 3β-acetoxy-lanost-9 chemically to cucurbitacin structure; however, his attempts 
did not provide the expected results and instead they got organo-tin structure [11].  
The main structure of cucurbitacin which known as [19(10        9β) abeo-10α-lanost-
5-en][12] is similar in the structure to that of steroids in the fact of the presence of four 
rings system. However, they are structurally different from each other in the ring system 
that C-19 methyl group of cucurbitacin is at C-9 and ring C and B fusion. So, estrone 
scaffold was selected to install the cucurbitacin enone side chain at C-17 (Fig.4.1). In 
chapter 3, we discussed the importance of substitution at C-3 of estrone structure for the 
biological activities, particularly the presence methoxy at C-3 [13]. However, these estrone 
derivatives with cucurbitacin enone side chain at C-17 and methoxy at C-3 are slightly non-
polar as proved in our group previously [14]. In addition, metabolism of the methoxy group 
at C-3 by the CYP450 O-dealkylation might retrieve the estrogenic activity of the estrone 
as feminizing horman. So, substituting the methoxy group at C-3 with more polar groups 
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such as sulfamoyl will increase the polarity of the synthesized compounds and in the same 
time it will prevent the expected metabolism of the C-3 methoxy group. All of these 
structural modifications lead to dramatically change in the pharmacokinetic and biological 
activities of the CUCUS-inspired estrone analogues. 
H
HO
H
H OH
O
OR4O
Cucurbitacin
R1
R2
R5
R3
H
H H
O
R1
R2
R3
Steroidal Scofold
A B
C D
1717
3
 
Cucurbitacin R1 R2 R3 R4 R5 ∆1,2 ∆23,24 
A OH =O MeOH H AC - + 
B OH =O CH3 H AC - + 
C H OH MeOH H AC - + 
D OH =O CH3 H OH - + 
E OH =O CH3 H AC + + 
F OH OH CH3 H OH - + 
H OH =O CH3 OH OH - - 
I OH =O CH3 H OH + + 
J OH =O CH3 OH OH + - 
 
Figure 4.1 general structure of cucurbitacin and estrone. 
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Installation of sulfamoyl moiety into the estrone skeleton has got the attention due 
to its ability to change the biological activities. Leese et al proved that estratrine sulfmate 
compounds improved the anti-cancer activities and increased the oral bioavailability [15]. 
In addition, other studies demonstrated the ability of estrone derivatives with sulfamoyl 
group at C-3 to have effect on different cancer cell lines such as breast cancer cell line [16], 
and effect on pharmacokinetic of the modified estrone structure [17]. All of these studies 
and results proved that installing sulfamoyl functional group into C-3 of the estrone 
scaffold along with the cucurbitacin enone side chain at C-17 will enhance the anti-cancer 
activities as well as the pharmacokinetic properties of the CUCUS-inspired estrone 
analogues.  
 
R1= C(CH3)2 OH, P-PhF, P-PhCl, P-PhBr
P-PhCF3, P-PhNO2, 5-Bromo-2-thiophene, 
5-Bromo-2-furan.
11
3
17
O
HO
R1
O
H
HH
S
24
O O
NH2
11
3
17
HO
HO
R1
O
H
HH
24
 
Figure 4.2 proposed positions for estrone structure modification. 
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In order to find the hit analogues to identify the lead compounds (LDs) targeting 
EGFR, bioisosterism process are used to design systematically the CUCS-inspired estrone 
analogues. Therefore, a virtual library of 900 compounds were created including esterone 
derivatives with cucurbitacins enone side chain at C-17 and sulfamoyl or hydroxyl groups 
at C-3, known EGFR inhibitors a nd different types of cucurbitacins, to be involved in the 
molecular docking studies [18]. Estrone main structure were studied and investigated in 
three different positions 1) assembling of cucurbitacin enone side chain at C-17, 2) 
installation of sulfamoyl or hydroxyl moieties at C-3 and 3) installation of various aliphatic 
and aromatic substituents at C-25 (Fig.4.2). OpenEye® scientific software were utilized for 
the molecular docking studies including fast executive docking (FRED), OMEGA and 
VIDA.  
 
4.2  Results and Discussion: 
4.2.1 Results of Molecular Docking with EGFR: 
The molecular docking calculations of CUCUS-inspired estrone analogues that 
consist of cucurbitacins enone side chain at C-17, sulfomyl or hydroxyl groups at C-3 and 
different aliphatic and aromatic functional groups at C-25, such as MMA-240, MMA-242, 
MMA-294, MMA-295, MMA-297, MMA-300, MMA-301, MMA-306, MMA-307, 
MMA-308, MMA-309, MMA-310, MMA-312, MMA-313 AND MMA-314 (Fig. 2.8 
and 2.9), showed an outstanding binding mode toward the EGFR binding site compare to 
the known EGFR inhibitor, such as Erlotinib, by making H-bonds and hydrophobic 
interactions with the amino acids residues of the EGFR binding pocket (Fig. AP-3). 
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Analogues that contain cucurbitacin enone side chain at C-17 along with sulfamoyl moiety 
at C-3 such as MMA-240 and MMA242 showed a distinguishable binding affinity toward 
the EGFR binding site by associating in H-bond with ALA:719:A inside the EGFR pocket 
along with hydrophobic interactions with other amino acids inside the same binding 
pocket; while analogue with the same enone side chain at C-17 but with hydroxyl group at 
C-3 instead of sulfamoyl as in MMA301 demonstrated less binding mode with only 
hydrophobic interactions (Fig.4.3). This outstanding result proved that the presence of 
sulfmoyl moiety at C-3 along with the cucurbitacin enone side chain is essential for the 
binding affinity toward the EGFR binding pocket.  
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On the other hand, compounds that contain cucurbitacin enone side chain at C-17 
along with different aromatic substituents at C-25 and sulfamoyl group at C-3 such as 
MMA294, MMA295, MMA297, MMA300, MMA307 and MMA312 showed better 
binding mode toward the EGFR binding pocket by making H-bonds and hydrophobic 
interactions compare to the analogues that contain the same aromatic enone side chain but 
A 
B 
Figure 4.3 Visual 
representation of A) MMA-
240 (Red) B) MMA-301 
(purple) in the EGFR ATP-
binding site. 
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with hydroxyl group at C-3 such as MMA269, MMA306, MMA309, MMA310, 
MMA313 and MMA314 which only showed hydrophobic interactions with the amino 
acids of the EGFR binding pocket (Fig.4.4).  
 
In conclusion, CUCUS-inspired estrone analogues that contain cucurbitacin enone 
side chain at C-17 along with aliphatic and aromatic substituents at C-25 and sulfamoyl 
moiety at C-3 demonstrated significant binding mode toward the 3D crystal structure of 
EGFR binding side by making H-bonds and hydrophobic interactions. In addition, the 
presence of hydroxyl group at C-3 of the estrone scaffold along with cucurbitacin enone 
side chain at C-17 showed lower binding affinity toward the same binding site of the EGFR. 
All of these signs and results demonstrated the important of assembling of the sulfamoyl 
group at C-3 for the binding affinity and may be for the biological activities. The results of 
the molecular docking was the core to move to the synthesis of the most promising 
analogues to be investigated biologically in next step.   
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4.2.2 Synthesis of MMA Analogues:  
In order to investigating the biologically activities of CUCUS-inspired estrone 
analogues (CIEA), chemical reactions were used to assemble the cucurbitacins enone side 
chain at C-17 along with sulfamoyl or hydroxyl groups at C-3 of the estrone skeleton 
A 
B 
Figure 4.4 Visual 
representation of A) MMA-
312 (purple) B) MMA-313 
(yellow) in the EGFR ATP-
binding site. 
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(Fig.4.1). The challenges on conducting these chemical reactions were started by making 
the decision what step should the sulfamoyl group at C-3 to be installed during the process 
of assembling the cucurbitacin enone side chain at C-17. Due to the diversity of the 
chemical reactions that will be used to install the cucurbitacin enone side chain into the 
estrone scaffold, the concept of trial and error were used to optimaize the complete 
synthetic schemes. In the beginning, installation of sulfamoyl functional group at C-3 of 
the estrone structure were done utilizing sulfamoyl chloride in the presence of N, N-
dimethylacetamide to provide 3-sulfamoyl estrone (Scheme 4.1) [19]. However, the 
resulted 3-sulfamoyl estrone was found to be polar and cannot be used for the next chemical 
reactions to install cucurbitacin enone side chain. Therefore, protection of hydroxyl group 
at C-3 of the estrone main structure with tert-butyldimethylsilyl chloride were carried out 
first in the presence of imidazole and dimethyl formamide to provide estrone tert-
butyldimethylsilyl ether 1 [20]. Wittig reaction was utilized on estrone tert-
butyldimethylsilyl ether 1 to prepare alkene 2 by reacting the phosphonium yield with C-
17 ketone [21].  
HO
H
H H
O
Estrone
S Cl
O
O
H2N
N, N-dimethylacetamide
O
H
H H
O
SO O
NH2
3-sulfamoyl estrone
92%
 
Scheme 4.1 Synthesis of 3-sulfamoyl estrone. 
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Alcohol 3 was produced by hydroboration reaction on alkene 2 using 9-
Borabicyclo[3.3.1]nonane (9-BBN) in presence of tetrahydrofuran (THF) as solvent for 
overnight followed by the drop wise addition of sodium hydroxide (NaOH) and hydrogen 
peroxide (H2O2) [14]. This was followed by oxidation of alcohol 3 utilizing pyridinum 
chlorochromate (PCC) to give ketone 4 in 91% yield [22, 23]. Treatment of ketone 4 with 
trimethylsilyl cyanide (TMSCN) in the presence of zinc iodide (ZnI2) as Lewis acid to 
activate the ketone to provide the desired disteriomer cyanohydrin 5 [24]. Ahmed et al. was 
the first to form cyanohydrin using OTMS in this scaffold [14]. Addition of methyl lithium 
to cyanohydrin 5 in the presence of ether as solvent to produce the desired disteriomer α-
hydroxyl ketone 6 (Scheme 4.2) [14]. The 3-D structure of the Compound MMA242 were 
confirmed using x-ray crystallography as shown in Figure 4.5, which demonstrated the R-
configuration.   
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Scheme 4.2 Synthesis of α-hydroxyl ketone 6. 
 
Figure 4.5 X-ray crystallography of α-hydroxyl ketone MMA242. 
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α-Hyd roxyl ketone 6 was utilized as a starting material to install various functional 
groups including cucurbitacin D enone side chain at C-17 with different aromatic moieties 
at C-25 and sulfamoyl at C-3. First, α-hydroxyl ketone 6 was used as starting material for 
Aldo condensation reaction with the prepared aldehyde 9 to prepare compound 10, which 
is protected estrone with protected enone side chain [14]; followed by deportation of 
protected hydroxyl groups at C-3 and C-25 using tetra-n-butylammonium fluoride (TBAF) 
to produce estrone derivative MMA301 with hydroxyl group at C-3 and cucurbitacin D 
enone side chain at C-17 [25]. Compound MMA240 was prepared to by adding sulfamoyl 
chloride to compound MMA301 in presence of N, N-dimethyl acetamide as solvent; 
sulfamoyl chloride selectively reacted with phenolic hydroxyl group as shown in scheme 
4.3 [19]. Aldehyde 9 was prepared in our group previously as shown in scheme 4.4 [14].  
O
TBS
H
H H
HO
O
1- LDA/  -78oC/ 1h
2- Aldehyde 9
56%
O
TBS
H
H H
HO
O
O
HO
H
H H
HO
O
OH
TBAF/ THF
86%
MMA301
TBS
SMCl/
DMACM
91%
O
H
H H
HO
O
O
H
MMA240
6 10
SO O
NH2  
Scheme 4.3 Synthesis of compounds MMA301 and MMA240. 
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TPAP/NMO
DCM/ 5oMS
7 8
9
methyl 2-hydroxy-
isobutyrate  
Scheme 4.4 Synthesis of Aldehyde 9. 
In addition, α-hydroxyl ketone 6 was used to prepare analogue MMA280 by 
deportation of TBS-protecting group utilizing tetra-n-butylammonium fluoride (TBAF) 
[25]; followed by preparing compound MMA242 by adding sulfamoyl chloride in presence 
of N, N-dimethylacetamide as solvent  (Scheme 4.5) [19].   
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
86%
MMA280
SMCl/ DMACM
94%
O
H
H H
HO
O
MMA242SO O
NH2
6
 
Scheme 4.5 synthesis of compounds MMA280 and MMA242. 
 
Various number of aromatic enone side chains, such as para-methoxybenzene 
enone side chain along with hydroxyl group at C-3 as in MMA268 or sulfamoyl group at 
C-3 as in MMA267, para-flurobenzene enone side chain along with hydroxyl group at C-
3 as in MMA269 or sulfamoyl group at C-3 as in MMA271, para-chlorobenzene enone 
side chains along with hydroxyl group at C-3 as in MMA309 or sulfamoyl group at C-3 as  
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O
TBS
H
H H
HO
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1- LDA/  -78oC/ 1h
2- Aldehydes
O
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H
H H
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O
R
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H
H H
HO
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TBAF/ THF
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DMACM
O
H
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O
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6
SO O
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R
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Aldehyde Compound 12 Compound 13 
R= p-methoxybenzaldehyde MMA268 MMA267 
R= p-flurobenzaldehyde MMA269 MMA271 
R= p-chlorobenzaldehyde MMA309 MMA294 
R= p-bromobenzaldhyde MMA310 MMA295 
R= p-trifluromethyl -
benzaldhyde 
MMA308 MMA300 
R= p-nitrobenzaldehyde MMA306 MMA307 
R= 5-bromo-2-furan aldehyde MMA297 MMA314 
R= 5-brom-2-thiophene 
aldehyde 
MMA313 MMA312 
Figure 4.6 Synthesis of estrone derivatives with various aromatic enone side chain along 
with hydroxyl or sulfamoyl groups at C-3. 
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in MMA294, para-bromobenzene enone side chain along with hydroxyl group at 
C-3 as in MM310 or sulfamoyl group at C-3 as in MMA295, 5-bromofuran enone side 
chain along with hydroxyl group at C-3 as in MMA297 or sulfamoyl group at C-3 as in 
MMA314, para-trifluromethyl benzene along with hydroxyl group at C-3 as in MMA308 
or sulfamoyl group at C-3 as in MMA300, para-nitrobenzene enone side chain along with 
hydroxyl group at C-3 as in MMA306 or sulfamoyl group at C-3 as in MMA307 and 5-
bromothiphene enone side chain along with hydroxyl group at C-3 as in MM313 or 
sulfamoyl or sulfamoyl group at C-3 as in MMA312, were assembled in the C-17 of  α-
hydroxyl ketone 6 using Aldol condensation reaction to form the related compound of 11 
followed by the deportaction reaction of TBS group with TBAF [25] followed by addition 
of sulfamoyl chloride (Scheme 4.6) [19]. 
 
4.2.3 Biological Evaluation of the Synthesized Compounds: 
The biological studies for the synthesized compounds started by in vitro study to 
identify their capability to inhibit the EGFR. MTT cell viability assay were utilized to find 
the cytotoxicity of the synthesized compounds against the hepatocellular carcinoma cell 
line (HepG2) and that expressed as IC50 (inhibition concentration). Compound MMA242, 
which contain α-hydroxyl ketone on C-17 along with sulfamoyl group at C-3, showed 
potent inhibitory activity toward the HepG2 cell line with IC50 value of 3µM compare to 
the known EGFR inhibitor, Erlotinib with 25 µM (Table 4.1). Compounds with aliphatic 
enone side chain at C-17 along with sulfamoyl at C-3 such as MMA240 demonstrated 
modest inhibitory activity with IC50 value of 8µM; while the same compound but with 
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hydroxyl group at C-3 instead of sulfamoyl such as MMA301 lost their cytotoxicity 
completely. These results verify the importance of possessing sulfamoyl group at C-3, 
which we confirmed at the molecular docking study (Fig. 4.3). Analogues that contain 
cucurbitacin enone side chain at C-17 with various aromatic and heterocyclic functional 
groups at C-25 along with sulfamoyl moiety at C-3 such as MMA267, MMA271, 
MMA294, MMA295, MMA297, MMA300, MMA307 and MMA312 demonstrated 
various cytotoxicity levels with IC50 values 12 µM, 8 µM, 11.5 µM, NA, 1 µM, 3 µM, 10 
µM, 8 µM; respectively (Table 4.1). On the other hand, compounds with same enone side 
chains at C-17 but with hydroxyl group at C-3 Such as MMA268, MMA269, MMA306, 
MMA308, MMA309, MMA310, MMA313 and MMA314 showed various cytotoxicity 
with IC50 values 7 µM, 2 µM, 8 µM, 8 µM, NA, 6 µM, 9 µM and 1.5 µM; respectively 
(Table 4.1). All of the previous results proved the biological importance of possessing the 
sulfamoyl moiety at the C-3 of the estrone main structure along with various aliphatic, 
aromatic and heterocyclic functionalities at the enone side chain compare to the first set 
synthesized compounds that contain methoxy group at C-3 (Table 3.1).  
 
 
 
 
 
 
 
   179 
 
  
Table 4.1 IC50 values of the synthesized compounds. 
 
Compound IC50 (𝜇𝑀) Compound IC50 (𝜇𝑀) 
Erlotinib 25 𝜇𝑀 MMA310 6 𝜇𝑀 
MMA240 8 𝜇𝑀 MMA295 NA 
MMA301 NA MMA297 1 𝜇𝑀 
MMA242 3 𝜇𝑀 MMA314 1.5 𝜇𝑀 
MMA267 12 𝜇𝑀 MMA300 3 𝜇𝑀 
MMA268 7 𝜇𝑀 MMA308 8 𝜇𝑀 
MMA269 2 𝜇𝑀 MMA306 8 𝜇𝑀 
MMA271 8 𝜇𝑀 MMA307 10 𝜇𝑀 
MMA309 NA MMA313 9 𝜇𝑀 
MMA294 11.5 𝜇𝑀 MMA312 8 𝜇𝑀 
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Figure 4.7 Chart represent the ability of CIEA to inhibit the growth of HepG2 cell line. 
 
4.3 Conclusion: 
CUCUS-inspired estrone analogues were structurally designed utilizing molecular 
docking technique by assembling the  biologically important pharmacophores such as 
cucurbitacin’s enone side chain at C-17, various aromatic and heterocyclic substituents at 
C-25 and sulfamoyl or hydroxyl groups at C-3 to be explored biologically as anti-cancer 
candidates toward the treatment of Hepatocellular carcinoma (HCC) through the inhibition 
of EGFR. Various aliphatic, aromatic and heterocyclic enone side chains were installed 
chemically on the estrone main skeleton such as isopropanol, para-methoxybenzene, para-
flurobenzene, para-chlorobenzene, para-bromobenzene, 5-bromofuran, para-
0
5
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trifluromethyl, para-nitrobenzene, 5-bromothiphene along with sulfamoyl or hydroxyl 
groups at C-3 (Fig. 4.6). The biological evaluation demonstrated that analogues that 
contain cucurbitacin enone side chain at C-17 of the estrone along with sulfamoyl group at 
C-3 such as MMA240 showed a modest inhibitory activity; while the same compound but 
with hydroxyl group at C-3 such as MMA301 lost their biological activity.  On the other 
hand, compounds with various aromatic and heterocyclic enone side chains at C-17 showed 
wide range of cytotoxicity compare to the known EGFR inhibitor, erlotinib. However, 
installing sulfamoyl group at C-3 of the CUCS-inspired estrone analogues (CIEA) proved 
to increase the cytotoxicity in comparison to the same analogues but with methoxy group 
at C-3. Compound MMA292 showed the most potent cytotoxicity in HepG2 with IC50 
value 1𝜇𝑀.  
 
4.5 Experimental section: 
 
4.5.1 General: 
All chemicals and solvents (ACS grades) were provided from Fisher Scientific or 
Sigma Aldrich and used without any additional purification. All glassware were cleaned, 
washed and dried in oven for overnight before conducting chemical reactions requires 
anhydrous environment and nitrogen gas applied at the reaction time. Pre-coated silica gel 
PE plates were used to analyze the reaction condition and UV-light were also used at 254 
or 365 to visualize the chemical reactions spots. All synthetic intermediate and final 
compounds were purified using column chromatography with 230ˣ400 mesh silica gel.  1H 
and 13C NMR spectra were using Bruker AVANCE-400 MHZ and 600 MHZ NMR 
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spectrometer, in CDCl3 and D-acetone. NMR chemical shifts were presented in 𝛿(PPM) 
using residual solvent peaks as standards (CDCl3, 7.26 (H), 77.16 (C)). High resolution 
mass (HRMS) was gained using thermofinnigan MAT 95XL mass spectrometer at Buffalo 
mass spectroscopy facility. X-ray crystallography were conducted in University of South 
Dakota on compound 8  using Brouker APEXᴵᴵ diffractometer.  
 
4.5.2 3-Sulfamoyl Estrone: 
HO
H
H H
O
Estrone
S Cl
O
O
H2N
N, N-dimethylacetamide
O
H
H H
O
SO O
NH2
3-sulfamoyl estrone
92%
 
Estrone (0.2g, 0.74mmole) were dissolved in N, N-dimethyacetamide (1.8 ml) then 
cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.26g, 2.22mmole). the 
reaction mixture was allowed to be stirred and warm to the room temperature for 18h. 
amixture of ethyl acetate (30ml) and water (30ml) was added to the reaction mixture and 
the organic layer was separated, washed by water (3×25ml) followed by the addition of 
brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, filtered and 
concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) to provide 
white solid of 3-Sulfamoyl Estrone (0.24g, 92%).  
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1H NMR (400 MHz, Acetone-d6) δ 7.35 (dd, J = 8.6, 1.1 Hz, 1H), 7.07 (dd, J = 8.5, 
2.6 Hz, 1H), 7.06 – 7.02 (m, 2H), 3.03 – 2.84 (m, 2H), 2.57 – 2.37 (m, 2H), 2.30 (m, 2H), 
2.14 – 1.98 (m, 4H), 1.86 (m, 1H), 1.76 – 1.34 (m, 5H), 0.90 (s, 3H).  
 
13C NMR (101 MHz, Acetone-d6) δ 219.62, 149.44, 139.22 (d, J = 6.2 Hz), 127.46, 
123.03, 120.25, 51.07, 48.40, 45.01, 38.90, 36.11, 32.56, 30.06, 27.02, 26.56, 22.16, 14.15. 
 
4.5.3 Estrone tert-butyldimethylsilyl ether 1: 
HO
H
H H
O
O
TBS
H
H H
O
TBSCl /Imidazol
DMF
95%Estrone 1  
 
To a stirred solution of estrone (5 g, 18.5 mmole) in DMF (75 ml); followed by the 
addition of imidazole (3.5 g, 50.85 mmole), tert-butyldimethylsilyl chloride (TBSCl) (4.2 
g, 27.75 mmole). The reaction stirred at room temperature for 24h. The reaction solvent 
were evaporated to provide brown oil. Column chromatography (40% ethyl acetate in 
hexane) were used to purify the crude material which give white solid of Estrone tert-
butyldimethylsilyl ether 1 (6.75 g, 95%). 
 
 1H NMR (400 MHz, Chloroform-d) δ 6.91 (dd, J = 8.6, 1.0 Hz, 1H), 6.47 – 6.33 
(m, 2H), 2.72 – 2.59 (m, 3H), 2.28 (dd, J = 18.7, 8.7 Hz, 1H), 2.16 (dt, J = 14.0, 3.7 Hz, 
   184 
 
  
1H), 2.08 – 1.65 (m, 5H), 1.48 – 1.14 (m, 7H), 0.79 (s, 9H), 0.75 – 0.65 (m, 4H), 0.00 (s, 
6H). 
13C NMR (101 MHz, Chloroform-d) δ 219.97, 153.47, 137.57, 132.47, 126.17, 
120.02, 117.35, 50.44, 47.98, 44.04, 38.34, 35.87, 31.65, 29.54, 26.62, 25.85 21.63, 18.20, 
13.90, -4.30. 
 
4.5.4 Alkene 2: 
O
TBS
H
H H
O
EtPPh3 / T-BUOK
THF O
TBS
H
H H
86%1 2
 
First, the ylide was prepared by adding potassium tert-butoxide in different portions 
(5.85 g, 52.13 mmole) to the solution of ethyl triphenylphosphonium bromide (20.73 g, 
55.85 mmole) in THF (93 ml) at room temperature for 1h. Then solution of Estrone tert-
butyldimethylsilyl ether 1 (6.5g, 18.617 mmole) in THF (37 ml) was added to the first 
mixture and allowed to be stirred for 6h at 70 0C. The reaction mixture was allowed to cool 
down to the room temperature, solution of saturated ammonium chloride (NH4Cl) was 
added to the reaction mixture followed by extraction of the aqueous layer using ethyl 
acetate (3×100 ml), brain, dried over sodium sulfate anhydrous (Na2SO4), filtrated and 
concentrated in vacuo. The purification of the crude material was purified by silica gel 
column chromatography (20% ethyl acetate in hexane) to obtained alkene 2 (5.8 g, 85%). 
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1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.04 (m, 1H), 6.62 – 6.49 (m, 2H), 
5.12 (m, 1H), 2.87 – 2.69 (m, 3H), 2.45 – 2.12 (m, 3H), 1.95 – 1.82 (m, 1H), 1.77 – 1.60 
(m, 5H), 1.58 – 1.42 (m, 1H), 1.42 – 1.21 (m, 3H), 1.09 – 0.99 (m, 1H), 0.96 (s, 9H), 0.86 
(m, 4H), 0.16 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 153.38, 150.26, 137.87, 133.35, 126.17, 
120.04, 117.25, 113.53, 55.40, 44.69, 44.00, 38.48, 37.41, 31.58, 29.86, 27.76, 27.05, 
25.89, 24.33, 18.30, 17.12, 13.33, -4.22. 
 
4.5.5 Alcohol 3: 
O
TBS
H
H H
2
O
TBS
H
H H
OH
1- 9-BBN/THF, 0oC
2-10%NaOH/30%H2O2
91% 3
 
To a solid alkene 2 (5.5 g, 13.865 mmole), 9-BBN (0.5 M in THF, 110.9 ml, 55.46 
mmole) was added at room temperature. The reaction mixture was allowed to be stirred for 
20h, then cooled down to 0 0C; followed by the addition of 105ml of 10%NaOH and 180ml 
of 30% H2O2 sequentially in drop-wise matter. The reaction mixture then stirred for 1h at 
0 0C, then stirred for 1h at room temperature. Ethyl acetate (3×100 ml) was utilized to 
extract the organic layer, then the collected organic layers washed with 100 ml of saturated 
sodium thiosulfate, dries over sodium sulfate anhydrous (Na2SO4) and concentrated in 
vacuo. Column chromatography was used to purify the crude material (20% ethyl acetate 
in hexane) to provide alcohol 3 (5.25 g, 91%).  
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1H NMR (400 MHz, Chloroform-d) δ 6.94 (m, 1H), 6.47 – 6.32 (m, 2H), 3.56 (m, 
1H), 2.75 – 2.52 (m, 2H), 2.25 – 21.98 (m, 1H), 1.79 – 1.44 (m, 4H), 1.40 – 1.12 (m, 4H), 
1.14 – 1.01 (m, 6H), 0.98 (d, 3H), 0.82 (s, 9H), 0.61 (s, 3H), 0.02 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 153.25, 137.80, 133.41, 126.15, 119.97, 
117.17, 70.45, 58.63, 55.07, 43.93, 42.84, 41.96, 40.05, 38.67, 29.78, 27.92, 27.24, 26.67, 
24.31, 23.79, 18.23, 12.56, -4.27. 
 
4.5.6 Ketone 4: 
O
TBS
H
H H
OH
3
O
TBS
H
H H
O
4
PCC / NaOAC
DCM
87%
 
The produced alcohol 3 (5 g, 12.01 mmole) was dissolved in DCM (60.3 ml); 
followed by the addition of 4 0A powdered molecular sieves (4.73g), sodium acetate 
(NaOAc) (4.73 g, 57.6 mmole) and Pyridinium chlorochromate (PCC) (5.2 g, 24.02 
mmole). The reaction mixture was allowed to be stirred at room temperature for 2h. Ether 
was added to the reaction mixture, then filtered over silica gel pad using ether to elute the 
material. The collected material then concentrated in vacuo. The resulted crude material 
was purified by column chromatography (20% ethyl acetate in hexane) to give ketone 4 
(4.3 g, 87%).  
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1H NMR (400 MHz, Chloroform-d) δ 6.91 (m, 1H), 6.46 – 6.32 (m, 2H), 2.70 – 
2.53 (m, 2H), 2.39 (m, 1H), 2.17 – 1.98 (m, 2H), 1.94 (s, 4H), 1.76 – 1.02 (m, 10H), 0.79 
(s, 9H), 0.45 (s, 3H), 0.00 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 209.20, 153.37, 137.74, 132.81, 126.06, 
120.01, 117.23, 63.83, 55.72, 44.39, 43.74, 39.04, 38.73, 31.52, 29.67, 27.77, 26.65, 25.79, 
24.20, 22.91, 18.21, 13.48, -4.31. 
 
4.5.7 Cyanohydrin 5: 
O
TBS
H
H H
O
4
O
TBS
H
H H
O N
TMS
TMSCN/ZnI2
DCM
79%
5
 
To attired solution of ketone 4 (4 g, 9.7 mmole) in DCM (19.4 ml), zinc iodide 
(ZnI2) (0.25 g, 0.78 mmole) was added, followed by the addition of trimethylsilyl cyanide 
(TMSCN) (2.4 g, 24.25 mmole) in one portion. The reaction mixture then allowed to be 
stirred at the room temperature for 3h. Then the solvent was evaporated to produce a slurry 
mixture which was mixed with ethyl acetate/water (2:1, 100 ml). The aqueous layer was 
extracted using ethyl acetate (3×100 ml), then the extracted organic layer dried over 
sodium sulfate anhydrous (Na2SO4) and concentrated in vacou. Column chromatography 
was used to purify the crude material (20% ethyl acetate in hexane) to give cyanohydrin 5 
(3.95 g, 79%).  
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1H NMR (400 MHz, Chloroform-d) δ 6.95 (m, 1H), 6.50 – 6.37 (m, 2H), 2.76 – 
2.58 (m, 2H), 2.17 – 1.94 (m, 3H), 1.87 (m, 1H), 1.78 – 1.50 (m, 4H), 1.46 (m, 3H), 1.42 
– 0.96 (m, 5H), 0.85 (s, 9H), 0.78 – 0.73 (m, 1H), 0.14 (s, 9H), 0.10 (m, 3H), 0.05 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 151.67, 136.05, 131.49, 124.44, 120.43, 
118.32, 115.56, 70.77, 58.90, 53.28, 42.24, 42.15, 38.40, 36.53, 33.11, 30.06, 29.21, 28.03, 
26.13, 26.01, 24.88, 24.16, 23.72, 23.26, 22.27, 21.12, 19.49, 16.57, 12.61, 11.23, -5.94. 
 
4.5.8 α-hydroxyl ketone 6:  
O
TBS
H
H H
O N
TMS
5
O
TBS
H
H H
HO
O
6
MeLi / Et2O/0
oC
GAA
77%
 
To a stirred solution of cyanohydrin 5 (3.5 g, 6.88 mmole) in a dry ether (20ml), 
methyl lithium (MeLi) (1.6 M in ether, 17.2ml, 27.52 mmole) was added in dropwise at 
00C. The reaction mixture was allowed to stir for 2h at 00C, then the reaction quenched by 
adding glacial acetic acid (2.9 ml) in one portion at 00C and allowed to stir for 30 min at 
00C. Sodium bicarbonate solution was added to neutralize the acidic mixture. 
Dichloromethane (DCM) was used to extract the aqueous layer (3ˣ50ml), dried under 
sodium sulfate anhydrous (Na2SO4), then concentrated under vacuo. The resulted 
diasteriomers were purified by silica gel column chromatography (100% hexane, 5% ethyl 
acetate in hexane and 10% ethyl acetate in hexane) to give the α-hydroxyl ketone 6 (2.4 g, 
77%).  
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1H NMR (400 MHz, Chloroform-d) δ 6.99 – 6.87 (m, 1H), 6.47 – 6.34 (m, 2H), 
3.79 (s, 1H), 2.73 – 2.52 (m, 3H), 2.16 – 2.04 (m, 2H), 2.02 (s, 3H), 1.74 – 1.57 (m, 2H), 
1.55 – 1.31 (m, 3H), 1.27 (s, 3H), 1.26 – 0.93 (m, 5H), 0.79 (s, 9H), 0.74 (s, 3H), 0.00 (s, 
6H). 
13C NMR (101 MHz, Chloroform-d) δ 211.71, 153.32, 137.78, 133.10, 126.05, 
119.99, 117.18, 80.12, 55.77, 55.14, 44.26, 43.88, 40.72, 38.08, 29.68, 27.72, 26.61, 25.81, 
24.67, 23.77, 23.32, 22.15, 18.22, 13.59, -4.29. 
 
4.5.9  Ester 7:  
O
O
OH
O
O
O
TBS
7
TBSCl/
Imidazol
DMF
methyl2-hydroxy
 isobutyrate  
To a stirred solution of commercially available methyl2-hydroxy isobutyrate (5g, 
42.3mmole) in dimethyl formmide (DMF) (12.5ml), tert-butylsilyl chloride (TBSCl) 
(7.65g, 50.75mmole) were added followed by the addition of imidazole (7.45g, 
110mmole). The reaction was stirred for 24h, then solution of sodium bicarbonate (25ml) 
was added. The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over 
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. The crude 
product was purified using silica gel column chromatography (10% ethyl acetate in hexane) 
to give ester 7 (7.2g, 73.2%) as a yellow oil.  
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1H NMR (400 MHz, CDCl3): d=3.60(s, 3H), 1.34 (s, 6H), 0.80 (s, 9 H), 0.08 ppm 
(s, 6H);  
13C NMR (100 MHz, CDCl3): d=175.8, 74.5, 51.4, 28.4, 25.5, 17.9, _3.2 ppm. 
 
4.5.10 Alcohol 8:  
O
O
O
TBS
HO
O
7
TBS
8
DiBAL-H
Hexane/ -78oC
 
To a stirred solution of ester 7 (7.2g, 30.98mmole) in hexane (98ml), 
Diisobutylaluminium hydride (DiBAL-H) (56.8ml, 68.16mmole) was added at -78oC in a dropwise 
matter. The reaction stirred for 30 min. at 00C, then for 20 min. at the room temperature. The 
reaction then cooled back to -78oC, followed by the addition of solution of potassium tartrate 
(45ml). The reaction was allowed to stir for overnight. The aqueous phase was extracted 
using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and 
concentrated under vacuo. Silica gel column chromatography was used to purify the crude 
material (20% ethyl acetate in hexane) to give alcohol 8 (5.75g, 90.8%) as colorless liquid.  
1H NMR (400 MHz, CDCl3): d=3.19 (s, 2H), 2.31 (s, 1 H), 1.11 (s, 6 H), 0.76 (s, 
9 H), 0.08 ppm (s, 6H). 
 13C NMR (100 MHz, CDCl3): d=76.3, 74.4, 28.5, 28.0, 20.3, 0.3 ppm.   
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4.5.11 Aldehyde 9: 
HO
O
TBS
H
O
TBS
O
8 9
TPAP/NMO
DCM/ 5oMS
 
To a stirred solution of alcohol 8 (2g, 9.7858mmole) in a dry dichloromethane 
(DCM) (98ml), active molecular sieves (4oA, 2.3g) was added, then the reaction mixture 
was allowed to stir for 5 min. followed by the addition on N-Methylmorpholine N-oxide 
(NMO) (2.3g, 19.57mmole), then Tetrapropylammonium perruthenate (TPAP) (0.34g, 
0.98mmole) was added at  00C. The reaction stirred at 00C for 2h, then at room temperature 
for 24h. Pad of silica gel were used to filtrate the reaction mixture using diethyl ether as 
eluting solvent. The filtrated material concentrated under vacuo to provide aldehyde 9 
(1.45g, 73.3%) as colorless oil.   
1H NMR (400 MHz, CDCl3): d=9.44 (s, 1H), 1.17 (s, 6 H), 0.79 (s, 9H), 0.08 ppm 
(s, 6H).  
13C NMR (100 MHz, CDCl3): d=206.4, 80.3, 28.0, 27.2, 20.4, 0.3 ppm. 
 
4.5.12 Protected estrone with protected enone side chain 10: 
O
TBS
H
H H
HO
O
1- LDA/  -78oC/ 1h
2- Aldehyde 9
56%
O
TBS
H
H H
HO
O
O TBS
6 10
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To a stirred solution of α-hydroxyl ketone 6 (0.4g, 0.879 mmole) in a dry 
tetrahydrofuran (THF)  (5.85 ml), lithiumdiisopropyl amine (LDA) (1.6 ml, 3.154 mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC  for 1 
h, then the solution of aldehyde 9 (0.354 g, 1.75 mmole) in THF (11.5 ml) was added to 
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room 
temperature for 24h. The quench of the reaction was completed by the addition of 
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate 
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under 
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl 
acetate in hexane) to provide protected estrone with protected enone side chain 10 (0.31 g, 
56%).  
1H NMR (600 MHz, Chloroform-d) δ 6.96 – 6.92 (m, 1H), 6.89 (m, 1H), 6.55 (m, 
1H), 6.43 (m, , 1H), 3.96 (s, 1H), 2.62 (m, 2H), 2.18 – 1.97 (m, 2H), 1.71 – 1.60 (m, 2H), 
1.52 – 1.31 (m, 3H), 1.29 (s, 2H), 1.20 – 1.16 (m, 6H), 1.13 – 0.97 (m, 6H), 0.79 (s, 9H), 
0.76 (m, 9H), 0.00 (s, 6H), -0.04 – -0.11 (m, 12H). 
13C NMR (151 MHz, Chloroform-d) δ 204.55, 159.22, 156.58, 155.34, 139.88, 
135.17, 128.07, 126.60, 122.03, 120.34, 119.20, 81.15, 75.63, 57.97, 56.92, 55.48, 46.30, 
46.00, 42.79, 40.14, 32.01, 31.96, 31.72, 30.69, 29.71, 29.10, 28.02 – 27.77 (m), 26.24, 
25.75, 23.97, 20.36, 20.25, 15.63, 0.00, -2.31. 
 
 
   193 
 
  
4.5.13 Compound MMA301:  
O
TBS
H
H H
HO
O
O
HO
H
H H
HO
O
OH
TBAF/ THF
86%
MMA301
TBS
10
 
To a stirred solution of protected enone 10 (0.3 g, 0.47 mmole) in tetrahydrofuran 
(THF) (2.5ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 2.914 ml, 2.914 
mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to 
quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), 
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to 
purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA301 
(0.165 g, 86%).  
1H NMR (400 MHz, Chloroform-d) δ 7.13 – 6.96 (m, 2H), 6.64 – 6.44 (m, 2H), 
5.82 (m, 1H), 5.21 (s, 1H), 4.01 (s, 1H), 2.75 (m, 2H), 2.32 (s, 1H), 2.25 – 2.06 (m, 3H), 
1.96 – 1.69 (m, 3H), 1.61 (m, 2H), 1.44 (s, 3H), 1.41 (m, 6H), 1.23 – 1.06 (m, 4H), 0.85 – 
0.72 (m, 2H), 0.64 (s, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 201.36, 155.37, 151.23, 146.75, 137.73, , 
129.04, 125.07, 113.73, 111.28, 80.17, 75.25, 56.89, 55.07, 48.02, 43.86, 37.22, 36.18, 
31.01, 29.58, 29.39, 29.34, 27.57, 26.59, 24.88, 17.28. HR-FT-MS calcd for 
C26H36O4Na1 412.56163 found 412.56159. 
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4.5.14 Compound MMA240: 
HO
H
H H
HO
O
OH
MMA301
O
H
H H
HO
O
OH
MMA240SO O
NH2
SMCl
DMACM
91%
 
Compound MMA301 (0.1g, 0.24 mmole) was dissolved in N, N-dimethyacetamide 
(0.6 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.08 g, 
0.72 mmole). The reaction mixture was allowed to be stirred and warm to the room 
temperature for 18h. Admixture of ethyl acetate (30ml) and water (30ml) was added to the 
reaction mixture and the organic layer was separated, washed by water (3×25ml) followed 
by the addition of brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic 
layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in 
hexane) to provide compound MMA240 (0.102 g, 91%). 
1H NMR (400 MHz, Chloroform-d) δ 7.19 – 6.98 (m, 2H), 6.66 – 6.46 (m, 2H), 
5.85 (m, 1H), 4.06 (s, 1H), 2.77 (m, 2H), 2.35 (s, 1H), 2.27 – 2.08 (m, 3H), 1.99 – 1.72 (m, 
3H), 1.63 (m, 2H), 1.45 (s, 3H), 1.43 (m, 6H), 1.25 – 1.08 (m, 4H), 0.87 – 0.74 (m, 2H), 
0.66 (s, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 215.15, 151.37, 148.18, 146.21, 137.32, , 
130.07, 125.88, 113.97, 111.49, 80.17, 75.25, 56.89, 55.07, 48.02, 43.86, 37.22, 36.18, 
31.01, 29.58, 29.39, 29.34, 27.57, 26.59, 24.88, 17.28. HR-FT-MS calcd for 
C26H37N1O6S1Na1491.64006 found 491.64001. 
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4.5.15 Compound MMA280: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
86%
MMA2806
 
To a stirred solution of α-hydroxyl ketone 6  (0.3 g, 0.657 mmole) in 
tetrahydrofuran (THF) (2.2ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 
2.0367 ml, 2.0367 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) 
solution was added to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium 
sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. Silica gel column 
chromatography was used to purify the crude material (10% ethyl acetate in hexane) to 
provide compound MMA280 (0.195 g, 86%).  
1H NMR (400 MHz, Acetone-d6) δ 7.98 (s, 1H), 7.09 – 7.02 (m, 1H), 6.60 – 6.47 
(m, 2H), 4.06 (s, 1H), 3.22 (m, 2H), 2.82 – 2.62 (m, 3H), 2.23 (m, 1H), 2.20 (s, 3H), 2.11 
(m, 1H), 2.06 (s, 1H), 2.02 (m, 1H), 1.90 (m, 1H), 1.86 – 1.74 (m, 1H), 1.73 – 1.44 (m, 
2H), 1.40 (s, 3H), 1.37 – 1.09 (m, 3H), 0.88 (s, 3H). 
 
13C NMR (101 MHz, Acetone-d6) δ 213.19, 155.95, 138.35, 132.03, 126.99, 
116.00, 113.63, 81.00, 56.27, 56.03, 44.74, 44.68, 41.24, 39.24, 28.52, 27.51, 25.19, 
24.43, 24.11, 22.78, 14.09. 
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4.5.16 Compound MMA242: 
HO
H
H H
HO
O
MMA280
SMCl/ DMACM
94%
O
H
H H
HO
O
MMA242SO O
NH2  
Compound MMA280 (0.1g, 0.3 mmole) was dissolved in N, N-dimethyacetamide 
(0.7 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.1 g, 0.88 
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature 
for 18h. Admixture of ethyl acetate (30ml) and water (30ml) was added to the reaction 
mixture and the organic layer was separated, washed by water (3×25ml) followed by the 
addition of brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, 
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) 
to provide compound MMA242 (0.116 g, 94%).  
1H NMR (400 MHz, Acetone-d6) δ 7.32 (m, 1H), 7.07 (m,  1H), 7.01 (m, 3H), 4.09 
(s, 1H), 2.85 (m, 2H), 2.37 – 2.26 (m, 4H), 2.23 (s, 3H), 2.00 – 1.81 (m, 3H), 1.80 – 1.48 
(m, 3H), 1.43 (s, 3H), 1.40 – 1.12 (m, 4H), 0.91 (s, 3H). 
13C NMR (101 MHz, Acetone-d6) δ 213.26, 149.32, 139.73, 139.18, 127.36, 
123.02, 120.22, 56.22, 55.95, 44.81, 44.66, 41.09, 38.73, 30.63, 29.48, 28.17, 27.28, 25.21, 
24.44, 24.17, 22.78, 14.08. 
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4.5.17 general procedure for preparing protected estrone with various aromatic 
enone side chain at C-17 (compound 11): 
O
TBS
H
H H
HO
O
1- LDA/  -78oC/ 1h
2- Aldehydes
O
TBS
H
H H
HO
O
R
6 11
 
To a stirred solution of α-hydroxyl ketone 6 (0.4g, 0.876 mmole) in a dry 
tetrahydrofuran (THF)  (1.75 ml), lithiumdiisopropyl amine (LDA) (1.6 ml, 3.2 mmole) 
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78 oC  for 1 
h, then the solution of aldehydes  (1.75 mmole) in THF (0.15 M) was added to the reaction 
mixture at -78 oC. The reaction was allowed to stir and warm to the room temperature for 
24h. The quench of the reaction was completed by the addition of ammonium chloride 
(NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over 
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. Silica gel 
column chromatography was used to purify the crude material (10% ethyl acetate in 
hexane) to provide protected estrone with various aromatic enone side chain at C-17 
(compound 11).  
TBS-protected Para-methoxyphenyl  1H NMR (400 MHz, Chloroform-d) δ 7.63 
(m, 1H), 7.38 (m, 2H), 6.94 (m, 1H), 6.80 – 6.70 (m, 3H), 6.47 – 6.34 (m, 2H), 4.09 (s, 
1H), 3.65 (s, 3H), 2.72 – 2.53 (m, 2H), 2.23 – 1.96 (m, 3H), 1.76 – 1.59 (m, 2H), 1.57 – 
1.39 (m, 3H), 1.36 (s, 3H), 1.34 – 0.96 (m, 6H), 0.79 (m, 12H), 0.00 (m, 6H). 13C NMR 
(101 MHz, Chloroform-d) δ 201.84, 162.03, 153.31, 145.52, 137.86, 133.18, 130.53, 
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127.03, 126.04, 119.99, 117.15, 115.98, 114.48, 79.02, 55.79, 55.46, 55.21, 44.32, 43.91, 
40.76, 38.11, 29.66, 27.68, 26.64, 25.78, 24.48, 23.70, 22.06, 18.22, 13.69, -4.32. 
TBS-protected Para-Flurophenyl  1H NMR (400 MHz, Chloroform-d) δ 7.62 (m, 
1H), 7.46 – 7.37 (m, 2H), 6.97 – 6.87 (m, 3H), 6.80 (m, 1H), 6.46 – 6.34 (m, 2H), 3.98 (s, 
1H), 2.61 (m, 2H), 2.20 – 1.96 (m, 2H), 1.75 – 1.59 (m, 3H), 1.57 – 1.38 (m, 3H), 1.33 – 
0.92 (m, 3H), 0.79 (m, 12H), 0.75 – 0.61 (m, 6H), 0.00 (s, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 201.75, 153.33, 144.34, 137.82, 133.11, 130.65 (d, J = 8.4 Hz), 126.02, 
120.00, 118.19, 117.16, 116.32, 116.10, 79.19, 55.80, 55.12, 44.37, 43.92, 40.77, 38.10, 
29.86 – 29.55 (m), 29.42, 27.68, 26.62, 25.76, 24.36, 23.69, 22.08, 18.21, 14.18, 13.69, -
4.35. 
TBS-protected Para-chlorophenyl 1H NMR (400 MHz, Chloroform-d) δ 7.59 
(m, 1H), 7.35 (m, 2H), 7.26 – 7.16 (m, 2H), 6.93 (m, 1H), 6.84 (m, 1H), 6.49 – 6.33 (m, 
2H), 3.96 (s, 1H), 2.73 – 2.52 (m, 2H), 2.19 – 1.95 (m, 3H), 1.66 (m, 2H), 1.44 (m, 3H), 
1.37 (s, 3H), 1.30 – 0.98 (m, 6H), 0.79 (m, 12H), 0.00 (s, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 201.76, 153.33, 144.18, 137.83, 136.90, 133.11, 132.81, 129.84, 129.31, 
126.04, 120.01, 118.93, 117.17, 79.26, 55.78, 55.08, 44.38, 43.90, 40.75, 38.10, 29.66, 
27.68, 26.62, 25.79, 24.35, 23.70, 22.10, 18.23, 13.72, -4.31. 
TBS-protected Para-bromophenyl 1H NMR (400 MHz, Chloroform-d) δ 7.57 
(m, 1H), 7.39 – 7.31 (m, 2H), 7.31 – 7.24 (m, 2H), 6.93 (m, 1H), 6.85 (d, J = 15.6 Hz, 1H), 
6.48 – 6.35 (m, 2H), 3.95 (s, 1H), 2.71 – 2.52 (m, 2H), 2.21 – 1.95 (m, 3H), 1.73 – 1.60 
(m, 2H), 1.54 – 1.39 (m, 3H), 1.37 (s, 3H), 1.33 – 1.01 (m, 6H), 0.79 (m, 12H), 0.00 (s, 
6H). 13C NMR (101 MHz, Chloroform-d) δ 201.77, 153.33, 144.25, 137.83, 133.22, 
   199 
 
  
133.16, 132.27, 130.02, 126.04, 125.32, 120.00, 119.02, 117.17, 79.27, 55.77, 55.06, 
44.38, 43.90, 40.75, 38.09, 29.65, 27.67, 26.62, 25.79, 24.34, 23.70, 22.09, 18.36 18.23, 
13.72, -4.31. 
TBS-protected Para-trifluromethylphenyl 1H NMR (400 MHz, Chloroform-d) 
δ 7.65 (m, 1H), 7.50 (m, 4H), 6.94 (m, 2H), 6.48 – 6.35 (m, 2H), 3.89 (s, 1H), 2.61 (m, 
2H), 2.21 – 1.94 (m, 3H), 1.75 – 1.60 (m, 2H), 1.45 (m, 3H), 1.39 (s, 3H), 1.32 – 0.99 (m, 
6H), 0.79 (s, 12H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 201.72, 153.34, 
143.60, 137.75 (d, J = 14.0 Hz), 133.06, 132.44, 128.75, 125.99 (d, J = 6.2 Hz), 120.84, 
120.00, 117.17, 79.40, 55.77, 55.04, 44.41, 43.89, 40.74, 38.09, 29.63, 27.66, 26.60, 25.75, 
24.27, 23.67, 22.10, 18.20, 13.70, -4.36. 
TBS-protected Para-nitrophenyl 1H NMR (400 MHz, Chloroform-d) δ 8.08 (m, 
2H), 7.65 (d, 1H), 7.61 – 7.54 (m, 2H), 7.10 – 6.91 (m, 2H), 6.49 – 6.33 (m, 2H), 3.81 (s, 
1H), 2.71 – 2.54 (m, 2H), 2.21 – 1.96 (m, 3H), 1.67 (m, 2H), 1.61 – 1.41 (m, 3H), 1.39 (s, 
3H), 1.01 – 0.83 (m, 6H), 0.79 (s, 12H), 0.00 (s, 6H). 13C NMR (151 MHz, Chloroform-
d) δ 201.50, 153.35, 148.78, 142.31, 140.38, 137.74, 132.97, 129.15, 125.97, 124.17, 
122.40, 119.97, 117.15, 79.51, 55.78, 55.05, 44.43, 43.89, 40.73, 38.09, 34.60, 31.96, 
29.75, 29.32, 29.07, 27.65, 26.58, 25.27, 24.22, 23.65, 22.11, 20.66, 18.72, 18.15, 14.08, 
13.66, 11.39, -4.44. 
TBS-protected 2-Bromofuran 1H NMR (400 MHz, Chloroform-d) δ 7.27 (d, 1H), 
6.94 (d, 1H), 6.70 (d, , 1H), 6.50 – 6.35 (m, 3H), 6.26 (d, 1H), 3.98 (s, 1H), 2.72 – 2.49 (m, 
2H), 2.22 – 1.95 (m, 3H), 1.77 – 1.59 (m, 2H), 1.56 – 1.39 (m, 3H), 1.35 (s, 3H), 1.32 – 
0.96 (m, 6H), 0.78 (d, 12H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 201.61, 
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153.29, 153.03, 137.83, 133.18, 130.01, 126.37, 126.05, 119.98, 119.08, 117.15, 116.41, 
114.78, 79.17, 55.70, 54.90, 44.35, 43.87, 40.65, 38.11, 29.66, 27.67, 26.62, 25.77, 24.31, 
23.70, 22.06, 18.21, 13.69, -4.32. 
TBS-protected 2-Bromothiophene 1H NMR (400 MHz, Chloroform-d) δ 7.62 (d, 
1H), 6.93 (d, 1H), 6.89 (m, 1H), 6.85 (m, , 1H), 6.52 (m, 1H), 6.46 – 6.34 (m, 2H), 3.92 (s, 
1H), 2.70 – 2.51 (m, 2H), 1.70 – 1.58 (m, 3H), 1.56 – 1.37 (m, 2H), 1.33 (s, 3H), 1.08 (q, , 
3H), 0.78 (m, 12H), 0.73 – 0.62 (m, 6H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroform-
d) δ 201.40, 153.32, 141.35, 137.82, 136.97, 133.13, 132.94, 131.41, 126.04, 119.99, 
117.58, 117.16, 117.06, 79.13, 55.74, 55.13, 44.35, 43.87, 40.71, 38.10, 29.66, 27.67, 
26.62, 25.77, 24.35, 23.69, 22.09, 18.22, 13.68, -4.33. 
 
4.5.18 Compound MMA268: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
O O
MMA268
87%
 
To a stirred solution of desired compound 11 (0.3 g, 0.5218 mmole) in 
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.62 
ml, 1.62 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was 
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA268 (0.21 g, 87.5%).  
1H NMR (400 MHz, Chloroform-d) δ 7.72 (m, 1H), 7.45 (m, 2H), 7.01 (m, 1H), 
6.88 – 6.78 (m, 3H), 6.60 – 6.45 (m, 2H), 4.34 (s, 1H), 3.72 (s, 3H), 2.67 (m, 2H), 2.34 – 
1.99 (m, 3H), 1.95 (m, 2H), 1.47 (m, 3H), 1.53 – 1.42 (m, 1H), 1.24 – 1.10 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 202.01, 162.10, 153.91, 145.96, 138.06, 
132.21, 130.65, 126.98, 126.36, 115.84, 115.45, 114.50, 112.88, 79.32, 55.70, 55.45, 
55.26, 44.31, 43.84, 40.69, 38.19, 32.00, 29.74, 29.68, 27.65, 26.71, 24.34, 23.67, 22.77. 
HR-FT-MS calcd for C30H37O4 461.2686 found 461.26819. 
 
4.5.19 Compound MMA267: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
O
O
89.7%
MMA268 MMA267
 
Compound MMA268 (0.2g, 0.434 mmole) was dissolved in N, N-
dimethyacetamide (1.05 ml) then cooled down to 0 0C; followed by addition of sulfamoyl 
chloride (0.15 g, 1.302 mmole). The reaction mixture was allowed to be stirred and warm 
to the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was 
added to the reaction mixture and the organic layer was separated, washed by water (3×25 
ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry 
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the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl 
acetate in hexane) to provide compound MMA267 (0.21 g, 89.7%).  
1H NMR (400 MHz, Chloroform-d) δ 7.75 (m, 1H), 7.58 – 7.44 (m, 2H), 7.26 (s, 
1H), 7.05 – 6.92 (m, 2H), 6.91 – 6.83 (m, 3H), 4.93 (s, 2H), 4.21 (s, 1H), 3.91 – 3.75 (m, 
3H), 2.34 – 2.13 (m, 2H), 2.11 (s, 3H), 1.97 (m, 2H), 1.68 – 1.50 (m, 3H), 1.48 (s, 1H), 
1.21 – 1.17 (m, 5H), 0.89 (s, 3H), 0.86 – 0.74 (m, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 202.03, 162.113, 148.88, 145.94, 138.03, 
132.19, 130.62, 126.95, 126.35, 115.85, 115.43, 114.52, 112.86, 79.37, 55.69, 55.43, 
55.24, 44.29, 43.82, 40.67, 38.17, 32.06, 29.73, 29.66, 27.62, 26.70, 24.32, 23.65, 22.75. 
HR-FT-MS calcd for C30H37O6N1Na1S1 562.2234 found 562.22222. 
 
4.5.20 Compound MMA269: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
F F
MMA269
92%
 
To a stirred solution of desired compound 11 (0.3 g, 0.533 mmole) in 
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.65 
ml, 1.65 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was 
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA269 (0.22 g, 92%). 
 1H NMR (400 MHz, Chloroform-d) δ 7.86 (m, 1H), 7.71 – 7.61 (m, 2H), 7.22 – 
7.10 (m, 3H), 7.05 (m, 1H), 6.70 (m, 1H), 6.62 (m, 1H), 6.33 – 6.14 (m, 1H), 4.39 (s, 1H), 
2.92 – 2.75 (m, 2H), 2.42 – 2.16 (m, 4H), 1.98 – 1.82 (m, 2H), 1.63 (s, 3H), 1.52 – 1.20 
(m, 5H), 1.01 (s, 3H), 0.92 (m, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 201.97, 153.65, 144.79, 138.15, 132.41, 
130.81, 130.72, 130.53, 130.50, 126.41, 118.04, 116.35, 116.13, 115.42, 112.83, 79.51, 
55.69, 55.14, 44.35, 43.83, 40.66, 38.14, 29.72, 29.65, 27.61, 26.68, 24.23, 23.65, 22.09. 
HR-FT-MS calcd for C29H33O3F1Na1 471.2306 found 471.23231. 
 
4.5.21 Compound MMA271: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
91.5%MMA269 MMA271
F F
 
Compound MMA269 (0.2g, 0.446 mmole) was dissolved in N, N-
dimethyacetamide (1.1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl 
chloride (0.2 g, 1.338 mmole). The reaction mixture was allowed to be stirred and warm to 
the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was 
added to the reaction mixture and the organic layer was separated, washed by water (3×25 
ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry 
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the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl 
acetate in hexane) to provide compound MMA271 (0.215 g, 91.5%).  
1H NMR (600 MHz, Chloroform-d) δ 7.73 (m, 1H), 7.58 – 7.46 (m, 2H), 7.25 – 
7.18 (m, 1H), 7.02 (m, , 3H), 6.95 (m, 1H), 6.89 (m, 1H), 5.14 (s, 2H), 4.11 (s, 1H), 2.83 – 
2.73 (m, 2H), 2.33 – 2.12 (m, 3H), 1.97 (s, 1H), 1.92 – 1.74 (m, 3H), 1.72 – 1.50 (m, 2H), 
1.47 (s, 3H), 1.44 – 1.24 (m, 3H), 1.23 – 1.16 (m, 5H).  
13C NMR (151 MHz, Chloroform-d) δ 201.75, 147.90, 144.57, 139.64, 138.90, 
130.71, 130.65, 126.69, 121.93, 118.95, 116.30, 116.16, 79.19, 55.69, 55.06, 44.22, 43.99, 
40.54, 37.66, 29.72, 29.51, 27.27, 26.45, 24.30, 23.64, 22.71, 22.02. HR-FT-MS calcd for 
C29H34O5F1Na1S1 550.2034 found 550.20497. 
 
4.5.22 Compound MMA309: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
Cl Cl
MMA309
83%
 
To a stirred solution of desired compound 11 (0.3 g, 0.518 mmole) in 
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.6 
ml, 1.6 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was 
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA309 (0.2 g, 83%).  
1H NMR (400 MHz, Chloroform-d) δ 7.71 (m, 1H), 7.57 – 7.42 (m, 2H), 7.38 – 
7.28 (m, 2H), 7.08 (m, 1H), 6.94 (m, 1H), 6.63 – 6.44 (m, 2H), 4.95 (s, 1H), 4.11 (s, 1H), 
2.83 – 2.63 (m, 3H), 2.33 – 2.17 (m, 3H), 2.11 (s, 3H), 1.86 – 1.71 (m, 2H), 1.67 – 1.50 
(m, 3H), 1.49 (s, 3H), 1.42 – 1.09 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.80, 153.41, 144.30, 138.24, 136.95, 
132.74, 132.63, 129.83, 129.30, 126.42, 118.83, 115.27, 112.66, 79.31, 55.69, 55.07, 
44.35, 43.82, 40.67, 38.10, 30.98, 29.61, 27.56, 26.65, 24.27, 23.64, 22.04. HR-FT-MS 
calcd for C29H33O3Cl1Na1 487.2010 found 487.20045. 
 
4.5.23 Compound MMA294: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
89%MMA309 MMA294
Cl Cl
 
Compound MMA309 (0.2g, 0.43 mmole) was dissolved in N, N-
dimethyacetamide (1.1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl 
chloride (0.15 g, 1.3 mmole). The reaction mixture was allowed to be stirred and warm to 
the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was 
added to the reaction mixture and the organic layer was separated, washed by water (3×25 
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ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry 
the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl 
acetate in hexane) to provide compound MMA294 (0.209 g, 89%).  
1H NMR (400 MHz, Acetone-d6) δ 7.86 (m, 2H), 7.50 (m, 3H), 7.35 (m, 1H), 7.12 
– 7.00 (m, 3H), 5.13 (m, 2H), 4.29 (m, 1H), 2.35 (m, 3H), 2.29 – 2.22 (m, 3H), 2.12 (s, 
3H), 1.71 (m, 2H), 1.62 – 1.57 (m, 3H), 1.43 (m, 3H), 1.39 – 1.19 (m, 5H).  
13C NMR (101 MHz, Acetone-d6) δ 203.04, 149.36, 143.75, 139.68, 139.16, 
136.79, 134.54, 131.22, 129.95, 127.32, 122.99, 121.30, 120.18, 80.17, 56.30, 55.61, 
44.89, 44.80, 41.01, 38.77, 32.68, 28.14, 27.26, 24.83, 24.38, 23.39, 22.80. HR-FT-MS 
calcd for C29H34O5N1Cl1Na1S1 566.1738 found 566.17551. 
 
4.5.24 Compound MMA310: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
Br Br
MMA310
79%
 
To a stirred solution of desired compound 11 (0.3 g, 0.48 mmole) in tetrahydrofuran 
(THF) (2.4 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.5 ml, 1.5 mmole) 
was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to quench 
the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous (Na2SO4), 
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to 
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purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA310 
(0.194 g, 79%). 
1H NMR (400 MHz, Chloroform-d) δ 7.69 (m, , 1H), 7.51 – 7.36 (m, 4H), 7.07 (d, 
J = 8.5 Hz, 1H), 6.96 (m, 1H), 6.63 – 6.44 (m, 2H), 5.17 (s, 1H), 4.12 (s, 1H), 2.85 – 2.64 
(m, 3H), 2.34 – 2.17 (m, 3H), 2.11 (s, 3H), 1.86 – 1.70 (m, 2H), 1.67 – 1.50 (m, 3H), 1.49 
(s, 3H), 1.41 – 1.10 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.84, 153.46, 144.43, 138.22, 133.15, 
132.57, 132.27, 130.02, 126.42, 125.37, 118.92, 115.30, 112.69, 79.37, 55.69, 55.06, 
44.35, 43.82, 40.67, 38.11, 31.61, 30.99, 29.63, 27.56, 26.65, 24.25, 23.64, 22.06. HR-FT-
MS calcd for C29H33O3Br1Na1 531.1505 found 531.15002. 
 
4.5.25 Compound MMA295: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
90%MMA310 MMA295
Br Br
 
Compound MMA310 (0.1 g, 0.2 mmole) was dissolved in N, N-dimethyacetamide 
(0.5 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.07 g, 0.6 
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature 
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction 
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the 
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, 
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) 
to provide compound MMA295 (0.104 g, 90%). 
1H NMR (400 MHz, Acetone-d6) δ 7.69 (m, 2H), 7.54 (m, 3H), 7.47 (m, , 1H) 7.08 
– 6.92 (m, 3H), 5.16 (s, 2H), 4.09 (s, , 1H), 2.41 (s, 3H), 2.30 – 2.25 (m, 3H), 2.25 – 2.12 
(s, 3H), 1.84 – 1.70 (m, 2H), 1.58 (m, 3H), 1.47 (m, 3H), 1.27 – 1.16 (m, 5H). 
 13C NMR (101 MHz, Acetone-d6) δ 203.09, 149.36, 143.84, 139.70, 139.17, 134.93, 
132.95, 131.40, 127.32, 125.20, 122.98, 121.42, 120.18, 80.18, 56.37, 55.47, 44.89, 44.85, 
41.01, 38.78, 32.66, 28.11, 27.26, 24.80, 24.36, 23.37, 22.79. HR-FT-MS calcd for 
C29H34O5N1Br1Na1S1 610.1233 found 610.12377. 
 
4.5.26 Compound MMA308: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
CF3 CF3
MMA308
90%
 
To a stirred solution of desired compound 11 (0.3 g, 0.49 mmole) in tetrahydrofuran 
(THF) (2.5 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.519 ml, 1.519 
mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to 
quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA308 (0.23 g, 90%).  
1H NMR (400 MHz, Chloroform-d) δ 7.73 (m, 1H), 7.57 (m, 4H), 7.07 – 6.99 (m, 
2H), 6.58 – 6.42 (m, 2H), 5.54 (s, 1H), 4.07 (s, 1H), 2.86 – 2.62 (m, 3H),  2.55 (m, 3H), 
2.28 – 2.01 (m, 3H), 1.85 – 1.66 (m, 2H), 1.66 – 1.51 (m, 3H), 1.51 – 1.45 (m, 3H), 1.38 – 
1.02 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.83, 153.55, 143.86, 138.18, 137.61, 
132.48, 128.79, 126.40, 125.94, 120.73, 115.35, 112.75, 79.59, 55.68, 55.06, 44.39, 43.81, 
40.65, 38.12, 31.96, 29.62, 27.57, 26.65, 24.17, 23.64, 22.73, 22.10. HR-FT-MS calcd for 
C30H33O3F3Na1 521.2274 found 521.22942. 
 
4.5.27 Compound MMA300:  
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
92%
MMA308 MMA300
CF3 CF3
 
Compound MMA308 (0.2 g, 0.4 mmole) was dissolved in N, N-dimethyacetamide 
(1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.14 g, 1.2 
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature 
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction 
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the 
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, 
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) 
to provide compound MMA300 (0.214 g, 92%).  
1H NMR (600 MHz, Chloroform-d) δ 7.77 (m, 1H), 7.68 – 7.57 (m, 4H), 7.24 (m, 
1H), 7.03 (s, 2H), 6.95 (m, 1H), 4.97 (s, 2H), 4.01 (s, 1H), 2.79 (m, 3H), 2.56 (m, 3H), 2.33 
– 2.13 (m, 3H), 1.86 – 1.73 (m, 2H), 1.69 – 1.52 (m, 3H), 1.50 (s, 3H), 1.20 – 1.17 (m, 5H).  
13C NMR (151 MHz, Chloroform-d) δ 201.66, 147.90, 143.76, 139.66, 138.92, 
137.62, 132.45, 132.23, 128.75, 126.71, 121.90, 120.71, 118.92, 79.36, 55.69, 55.02, 
44.28, 43.99, 40.55, 37.66, 30.96, 29.25, 27.26, 26.45, 24.26, 23.64, 22.71. HR-FT-MS 
calcd for C30H34O5N1F3Na1S1 600.2002 found 600.20229. 
 
4.5.28 Compound MMA306: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11
NO2 NO2
MMA306
78%
 
To a stirred solution of desired compound 11 (0.3 g, 0.51 mmole) in tetrahydrofuran 
(THF) (2.5 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.6 ml, 1.6 mmole) 
was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to quench 
the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous (Na2SO4), 
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to 
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purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA306 
(0.187 g, 78%).  
1H NMR (400 MHz, Chloroform-d) δ 8.30 – 8.13 (m, 2H), 7.77 (d, J = 15.7 Hz, 
1H), 7.72 – 7.65 (m, 2H), 7.15 – 7.04 (m, 2H), 6.60 – 6.46 (m, 2H), 5.02 (s, 1H), 3.95 (s, 
1H), 2.85 – 2.63 (m, 3H), 2.58 (m, 3H),  2.33 – 2.04 (m, 3H), 1.86 – 1.72 (m, 2H), 1.72 – 
1.54 (m, 3H), 1.51 (d, J = 2.8 Hz, 3H), 1.42 – 1.04 (m, 5H). 
 13C NMR (101 MHz, Chloroform-d) δ 201.59, 153.46, 148.78, 142.48, 140.35, 
138.20, 132.51, 129.21, 126.40, 124.22, 122.34, 115.28, 112.68, 79.60, 55.68, 55.02, 
44.42, 43.80, 40.65, 38.10, 31.94, 29.60, 27.55, 26.63, 24.21, 23.64, 22.11. HR-FT-MS 
calcd for C29H33O5N1Na1 498.2251 found 498.22654. 
 
4.5.29 Compound MMA307: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
91%
MMA306 MMA307
NO2 NO2
 
Compound MMA306 (0.15 g, 0.135 mmole) was dissolved in N, N-
dimethyacetamide (0.8 ml) then cooled down to 0 0C; followed by addition of sulfamoyl 
chloride (0.12 g, 0.945 mmole). The reaction mixture was allowed to be stirred and warm 
to the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was 
added to the reaction mixture and the organic layer was separated, washed by water (3×25 
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ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry 
the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl 
acetate in hexane) to provide compound MMA307 (0.16 g, 91%). 
1H NMR (400 MHz, Chloroform-d) δ 8.36 – 8.19 (m, 2H), 7.82 (d, J = 15.7 Hz, 
1H), 7.79 – 7.71 (m, 2H), 7.20 – 7.09 (m, 2H), 6.68 – 6.56 (m, 2H), 5.12 (s, 2H), 4.13 (s, 
1H), 3.99 (s, 1H), 2.89 – 2.65 (m, 3H), 2.62 (m, 3H),  2.35 – 2.10 (m, 3H), 1.92 – 1.79 (m, 
2H), 1.75 – 1.58 (m, 3H), 1.62 (d, J = 2.8 Hz, 3H), 1.45 – 1.10 (m, 5H). 
 13C NMR (101 MHz, Chloroform-d) δ 201.12, 149.46, 146.78, 142.31, 140.12, 
138.22, 132.43, 129.09, 126.36, 124.17, 122.29, 115.19, 112.57, 79.52, 55.61, 54.96, 
44.38, 43.67, 40.60, 38.01, 31.88, 29.60, 27.48, 26.58, 24.17, 23.59, 22.03. HR-FT-MS 
calcd for C29H34O7N2Na1S1 577.1979 found 577.19790. 
 
4.5.30 Compound MMA297: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11 MMA314
84%
O O
Br Br
 
To a stirred solution of desired compound 11 (0.3 g, 0.184 mmole) in 
tetrahydrofuran (THF) (1 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 0.6 
ml, 0.6 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was 
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
   213 
 
  
used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA297 (0.204 g, 84%). 
1H NMR (400 MHz, Chloroform-d) δ 7.38 (m, 1H), 7.07 (m, , 1H), 6.80 (m, 1H), 
6.57 (m, 2H), 6.49 (d, J = 2.7 Hz, 1H), 6.38 (d, J = 3.4 Hz, 1H), 5.46 (s, 1H), 4.17 (s, 1H), 
2.88 – 2.64 (m, 3H), 2.22 (m, 3H), 2.12 (m, 3H), 1.87 – 1.69 (m, 2H), 1.54 (m, 3H), 1.48 
(s, 3H), 1.40 – 1.05 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.72, 153.52, 152.98, 138.20, 132.57, 
130.18, 126.47, 126.42, 119.24, 116.29, 115.30, 114.81, 112.71, 79.31, 55.63, 54.92, 
44.33, 43.80, 40.58, 38.13, 30.99, 29.64, 27.58, 26.66, 24.22, 23.65, 22.04. HR-FT-MS 
calcd for C27H31O4Br1Na1 521.1298 found 521.12905. 
 
4.5.31 Compound MMA314: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
90%
MMA297 MMA297
O O
Br Br
 
Compound MMA297 (0.2 g, 0.4 mmole) was dissolved in N, N-dimethyacetamide 
(1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.14 g, 1.2 
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature 
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction 
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the 
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, 
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) 
to provide compound MMA314 (0.208 g, 90%).  
1H NMR (400 MHz, Chloroform-d) δ 7.56 – 7.45 (m, 3H), 7.39 – 7.27 (m, 1H), 
7.11 (m, 2H), 6.90 (m, 1H), 5.28 (s, 2H), 4.24 (s, 1H), 2.98 (m, 3H), 2.61 (m, 3H), 2.41 – 
2.22 (m, 3H), 2.02 – 1.84 (m, 2H), 1.66 (m, 3H), 1.56 (m, 3H), 1.23 – 1.09 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.52, 153.01, 147.92, 139.86, 138.85, 
130,15, 126.68, 126.44, 122.10, 119.21, 118,98, 116.17, 114.77, 79.14, 55.70, 55.02, 
44.21, 43.99,  34.45, 34.23, 32.78, 31.98, 29.76,  28.01, 26.80, 26.49, 22.74. . HR-FT-MS 
calcd for C27H32O6N1Br1Na1S1 600.1026 found 600.10038. 
 
4.5.32 Compound MMA313: 
O
TBS
H
H H
HO
O
HO
H
H H
HO
O
TBAF/ THF
11 MMA313
93%
S S
Br Br
 
To a stirred solution of desired compound 11 (0.3 g, 0.476 mmole) in 
tetrahydrofuran (THF) (2.4 ml), tetrabutyl ammonium fluoride  (TBAF) (1 M in THF, 1.47 
ml, 1.47 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was 
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous 
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was 
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound 
MMA313 (0.229 g, 93%).  
1H NMR (400 MHz, Chloroform-d) δ 7.86 (d, J = 15.3 Hz, 1H), 7.21 – 7.03 (m, 
3H), 6.83 – 6.57 (m, 3H), 6.17 (s, 1H), 4.32 (s, 1H), 2.95 – 2.73 (m, 3H), 2.48 (m, 3H), 
2.24 (m, 3H), 1.88 (dd, J = 12.2, 6.4 Hz, 2H), 1.82 – 1.62 (m, 3H), 1.60 (d, J = 3.3 Hz, 3H), 
1.51 – 1.19 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.59, 153.63, 141.28, 138.12, 137.36, 
133.19, 132.41, 131.47, 126.40, 117.40, 117.32, 115.42, 112.83, 79.44, 55.65, 55.19, 
44.34, 43.80, 40.63, 38.15, 32.00, 29.66, 27.62, 26.68, 24.22, 23.67, 22.11. HR-FT-MS 
calcd for C27H31O3Br1Na1S1 537.1069 found 537.10627. 
 
4.5.33 Compound MMA312: 
HO
H
H H
HO
O
O
H
H H
HO
O
SO O
NH2
SMCl
DMACM
91%
MMA297 MMA312
S S
Br Br
 
Compound MMA313 (0.2 g, 0.388 mmole) was dissolved in N, N-dimethyacetamide (1 
ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.134 g, 1.164 mmole). 
The reaction mixture was allowed to be stirred and warm to the room temperature for 18h. 
Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction mixture and the 
organic layer was separated, washed by water (3×25 ml) followed by the addition of brain (30 ml). 
Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, filtered and concentrated in vacuo. 
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Column chromatography (30% ethyl acetate in hexane) to provide compound MMA312 (0.21 g, 
91%). 
 1H NMR (600 MHz, Chloroform-d) δ 7.97-7.80 (m, 1H), 7.38-7.27 (m, 2H), 7.09 
(m, 3H), 6.73 (m, 1H), 5.36 (s, 2H), 4.18 (s, 1H),  2.82 (m, 3H), 2.59 (m, 3H), 2.35 – 2.17 
(m, 3H), 1.90 – 1.79 (m, 2H), 1.54 (m, 3H), 1.47 (m, 3H), 1.13 – 0.89 (m, 5H).  
13C NMR (101 MHz, Chloroform-d) δ 201.43, 147.88, 141.25, 139.63, 138.88, 
137.28, 133.19, 131.47, 126.69, 121.97, 118.98, 117.34, 117.22, 79.17, 55.63, 55.08, 
44.19, 43.95, 40.49, 37.65, 31.96, 29.74, 27.27, 26.45, 24.25, 23.64, 22.74. . HR-FT-MS 
calcd for C27H32O5N1Br1Na1S2 616.0797 found 616.07782. 
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Chapter Five 
 
Design, Synthesis and Biological Evaluation of CUCS-Inspired Estrone Analogues 
Targeting Multidrug Resistance Protein 1 (MRP1) 
 
5.1 Introduction: 
Cancer is a serious disease that rank on the second position among diseases that 
lead to death, which found to be behind the death of one person in every five or six people 
in the western countries. It is also responsible for 8.2 million of deaths around the world. 
Every year more than 14.1 million cancer cases revealed mainly in the developing 
countries. In addition, people who live with cancer count more than 32.5 million [1, 2]. 
 
Cancer is known as serious genatic disorder when the cells become abnormally fast 
divided. So, if the abnormal divided cells untreated, it will affect the other tissues of the 
body and lead to death. The main available treatments of cancer are chemotherapeutic 
agents which can either stop or slow the abnormal fast division of the cells [3, 4]. The 
major problem associated with the available chemotherapeutic agents is the drug resistance 
which involved with 30%- 80% of cancer patients [5]. Therefore, there is an urgent need 
to find a new agent to overcome the chemotherapeutic resistance.  
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Drug resistance in cancer cells is not specific for one anticancer drug, but the whole 
available chemotherapeutic agents within the same family can be influenced by the same 
mechanism. Some cancer cells that developed drug resistance can be resistance to other 
type of drugs that different in their mechanism of action and structure. This process defined 
as multidrug resistance (MDR). This phenomenon might clarify the failure drug 
combination to overcome the cancer cell resistance [3]. There are two main clinical times 
of MDR; first one happen at the time of treatment and the second is already present at the 
time of the diagnosis [6].      
 
Various biological reactions represent the frist defense for the cells include:  
 Activation of cellular elimination process, cellular uptake process and metabolic reactions 
to inactivate the drug process inside the cell, all of these processes will cause the decrease 
of the chemotherapy concentration inside the cell (Fig.5.1) [7-9]. 
 Changes of the drug delivery to the targeted tissues because of different reasons 
including poor pharmacokinetics profile of the drug such as absorption, distribution, 
metabolism and excretion (ADME) [10, 11].  
 Enhance the process of DNA repair [9, 11]. 
 Structural modification of the targeted tissues [9, 11]. 
 
All the previous process were extracellular factors that increase the cell anticancer 
drug resistance. However, the cellular factors that affect the drug presence inside the cell 
play the main role for the cell resistance to anticancer drugs through biochemical changes 
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in the tumor cells and this process include transport-based MDR known as ATP-binding 
cassette (ABC).  
 
 
 
Figure 5.1 Different mechanisms of cell development of drug resistance (copied from 
[3]). 
Different transporter proteins are located in the lipophilic membrane of the cell, 
which play significant role in the pharmacodynamics and pharmacokinetics of various 
drugs. Therefore, enormous studies on the transporters have been conducted to identify 
their locations, functions, structures, selectivity and cellular distribution [3, 12]. Cellular 
MDR decrease the intracellular concentration of the drugs by enhance the ATP-dependent 
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efflux pumps, which is one of the family membrane of ATP-binding cassette (ABC) [13]. 
ATP-binding cassette is the largest transmembrane protein family that demonstrated wide 
range of specificity. There are 49 known human ABC genes, which are categorized into 7 
subfamilies starting with ABC and end with ABCG and the classification were relay on the 
arranging of the domain and similarity of the sequence [9, 14].    
 
Products resulted from the metabolic reactions, lipids and various types of 
chemotherapeutic agents are pumped out of the cells through ATB-transporter utilizing 
ATP-energy dependent movement processes [15-17]. The chemotherapeutic agents that 
commonly affected by MDR process are hydrophobic containing drugs, natural products 
such as docetaxel and paclitaxel, anthracyclines (daunorubicin, doxorubicin), anti-
microtubule alkaloids (vincristine), antimetabolic agents (6-mercaptpurin, methotrexate, 
gemcitabine, fluorouracil), natural compounds of epipodophyllotoxin (teniposide and 
etoposide) and RNA elongation inhibitors (actinomycin-D) [3, 18, 19].  
MRP1 (Multidrug Resistance Protein 1) is one of the ABC-transporter protein 
family specifically belong to the C subfamily that consist of 12 proteins [19, 20]. MRP1 
functionally categorized as an ATP-dependent protein [19]. They can be found in various 
types of human cells and tissues with distinguishable level in placenta, lung, macrophages, 
kidney, cardiac muscle, testis and skeletal muscle [21]. MRP1 is responsible for low 
intracellular concentration of many hydrophobic anticancer drugs by ATP-dependent 
efflux mechanism, which lead to improve the cell resistance toward these drugs [17, 22]. 
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For example, various number of hydrophobic and cationic chemotherapeutic agents such 
as anthracycline (epirubicin, daunorubicin, doxorubicin), methotrexate, mitoxantrone and 
flutamide have been resisted by MRP1 ATP-binding efflux [17]. In addition, some phase 
II metabolic products such as glutathione, sulfate and glucuronide conjugates are preferable 
substrates of MRP1 [23]. Therefore, discovery of new agents that has the ability to inhibit 
the MRP1 and lead to increase the intracellular concentration of the chemotherapeutic 
agents to perform their anticancer activity without being pumped out of the cell. 
Natural products possess many pharmacophores that provide fertile base for the 
chemists to discover new analogues targeting various molecular biology [10]. Natural 
products were extensively studied as precious source for drug design and discovery [24]. 
Cucurbitacins is one of the natural products that is known of their broad biological 
activities such as anticancer, hepatoprotective and antiviral activities such as chronic 
hepatitis [25] (Fig5.2). in addition, cucurbitacins proved to be potent on various molecular 
pathways [26]. Therefore, cucurbitacins have been chosen to be studied as anti-MRP1 
agents to overcome the drug resistance. However, the limitation of cucurbitacins as natural 
products was one of the obstacles that redirect our intention to conduct the chemical 
synthesis of and/or cucurbitacin-inspired estrone analogues. Due to the varieties of 
functional groups in the cucurbitacins, the total synthesis of cucrbitacins s almost 
practically challenging. 
 
A study conducted on 24 different types of cucurbitacins, Van Dang identified all 
the pharmacophores that responsible for different biological activities [27]. In the result of 
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their studies they demonstrated that α-β-unsaturated ketone of the enone side chain, C-3 
functionality and C-16 functional groups are significant for the biological activities [27, 
28]. Therefore, possessing these pharmacophores during the chemical synthesis are very 
important.  
H
HO
H
H OH
O
OR4O
Cucurbitacin
R1
R2
R5
R3
H
H H
O
R1
R2
R3
Steroidal Scofold
A B
C D
1717
3
 
Cucurbitacin R1 R2 R3 R4 R5 ∆1,2 ∆23,24 
A OH =O MeOH H AC - + 
B OH =O CH3 H AC - + 
C H OH MeOH H AC - + 
D OH =O CH3 H OH - + 
E OH =O CH3 H AC + + 
F OH OH CH3 H OH - + 
H OH =O CH3 OH OH - - 
I OH =O CH3 H OH + + 
J OH =O CH3 OH OH + - 
Figure 5.2 General structures of cucurbitacins and steroid. 
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The similarity between cucurbitacins general structure and steroids moieties is very 
close, mainly in the tetracyclic system (Fig5.2). However, the main differences between 
the two structures are in the presence of aromatic ring of the steroids which is aliphatic ring 
in the cucurbitacins, also the presence of gem-dimethyl group at C-4 [29] (Fig 5.2). Due to 
the similarity between the main skeletons of estrone and cucurbitacins, the main 
pharmacophores of cucurbitacins were chemically installed into the steroid skeleton to be 
synthesized and biologically evaluated [30, 31].  
Utilizing estrone as main skeleton to assemble the cucurbitacin’s enone side chain 
has been done by Ahmed et al. [32]. However, further structural modifications on estrone 
like cucurbitacin analogues were performed such as assembling various aliphatic and 
aromatic enone side chains at C-17, modification on C-16 and substituting the hydroxyl 
group at C-3 with methoxy and sulfamoyl groups to investigate their biological activities 
as anti-MRP1 agents (Fig.5.3). The ability of estrone derivatives to dramatically possess a 
new biological activity along with losing the estrogenic activity as a side effect was the 
motive to use the estrone as starting scaffold to install various cucurbitacins 
pharmacophores [33-35].  
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Figure 5.3 Proposed modified estrone structures. 
 
To prove the ability of CUCUS-inspired estrone analogues to bind to MRP1, 
molecular docking study were conducted. First, a virtual library of 900 compounds were 
prepared using the concept of bioisosterism to have a systematic way of designing the 
structures and these include esterone derivatives with cucurbitacins enone side chain at C-
17, various aliphatic and aromatic groups at C-25, double bond at C-16 and C-17 and 
hydroxyl, methoxy and sulfamoyl groups at C-3, known MRP1 inhibitors, cucurbitacins. 
Second, OpenEye® scientific software were utilized for the semi-flexible molecular 
docking studies including fast executive docking (FRED), OMEGA and VIDA.  
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5.2 Materials and Methods: 
5.2.1 General: 
Calcein-AM  was acquired from Corning life science. Doxorubicin, Adenosine 
triphosphate (ATP), Adenosine monophosphate (AMP), estradiol, thiazolyl blue 
tetrazolium bromide (MTT) and poly-D-lysin were purchased from sigma Aldrich. MK-
571 was purchased from Cayman chemical. H69AR cells were provided from ATCC.  
 
5.2.2 Inhibition screening of MRP1 with florescent accumulation of calcein-Am in 
H69AR cell line: 
The inhibition screening of MRP1 were completed in H69AR cells in the presence 
of known MRP1 inhibitor as positive control (MK-571) and fluorescent substrate (Calcein-
AM). The inhibition screening of the CIEA were conducted in 96-well Optical-Bottom 
plates. The seeding of the cells started by the injection of 6 ˣ 104 cells per well in 100 µL 
of cultural medium then to be incubated for 24 h. before the injection of the CIEA, cultural 
medium was substituted with 80 µL of serum-free medium, followed by the addition of 10 
µL of the tested compounds (10 µM). the negative control, 0.2% of DMSO in medium, and 
the positive control, 50 µM of MK-571, were injected in the 96-well plates. Calcein-Am 
were injected (10 µL, 0.25 µM) after 30 min and the cells were incubated for 1 h. then the 
cells were washed two times with 100 µL PBS that contain 10 mM HEPES and 4.5% 
glucose. The fluorescent measurements of the calcein-AM level were performed utilizing 
MetaXpress software [39].  
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5.2.3  Data analysis of the screened compounds: 
The metaXpress software automatically measure the fluorescent intensity in every single 
well to obtain the % inhibition of MRP1 [39]. The inhibition activity of the injected 
compounds on MRP1 (Calcein-AM efflux) was calculated using: 
 
 
X= average florescent intensity,                  T= tested compounds.  
 
5.3 Results and Discussion: 
5.3.1 Results of Molecular Docking with Homology Structure of MRP1: 
To conduct the molecular docking, the crystal structure of the targeted protein 
should be used. Since there is no crystal structure for the MRP1 available in the protein 
data bank (PDB) [36], the homology structure of MRP1 was prepared using Swiss-Model 
Workspace (Fig.5.4). Homology modeling is commonly utilized in various studies 
including molecular docking of virtual library. It consists of four essential steps; first, 
template recognition of the protein structure; second, alignment between the structure of 
the template and the sequence of targeted protein; third, building the model; fourth, general 
evaluation of the resulted homology structure. The repetition of all of these steps is 
recommended until a satisfaction reached [37, 38].  
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The molecular docking studies of the CUCUS-inspired estrone analogues that 
contain the cucurbitacins enone side chains at C-17 along with various aliphatic and 
aromatic moieties at C-25, functionalities at C-16 and C-17 and hydroxyl, methoxy and 
sulfamoyl groups at C-3 on the homology structure of MRP1 showed distinguishable 
results of binding affinities to the MRP1. Several analogues showed better binding modes 
compare to the known MRP1 inhibitors such as brobenecide, MK-571 and JS-2190 (Table 
AP-3). Compounds that contain aromatic (hydrophobic) enone side chains at C-17, double 
bond at C-16 and C-17 and methoxy group at C-3 such as MMA265, MMA270, 
MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and MMA311 
showed significant binding affinity toward the 3D structure of the MRP1 by making H-
bonds and hydrophobic interactions compare to the analogues that contain aliphatic enone 
side chains such as MMA102 and MMA132 (Fig.5.5). These results are lined up with the 
nature of the MRP1, which is hydrophobic membrane protein and bind to substrates which 
are mostly hydrophobic ligands [35]. 
 
In addition, stereochemistry played a significant role in the determination of 
binding affinity. For example, compounds that possess cucurbitacin D stereochemistry 
with aromatic enone side chain at C-17, double bond at C-16 and C-17 and methoxy group 
at C-3 such as MMA265, MMA270, MMA287, MMA288, MMA289, MMA290, 
MMA292, MMA305 and MMA311 showed better binding affinity along with H-bonds 
and hydrophobic interactions compare to the compounds that possess the opposite 
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stereochemistry with the same functional groups such as MMA316, MMA317, MMA318, 
MMA319, MMA320,MMA321,MMA330 and MMA334 (Fig.5.6).  
 
 
Figure 5.4 Homology structure of MRP1. 
 
 
On the other hand, the presence of sulfamoyl moiety at C-3 of the estrone skeleton 
along with aromatic enone side chains at C-17 such in MMA271, MMA294, MMA295, 
MMA297, MMA300 and MMA312 showed significant binding affinity with H-bonds and 
hydrophobic interactions inside the binding site of the MRP1 compare to the analogues 
that have the same functional groups but with hydroxyl group at C-3 instead of sulfamoyl 
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such as MMA269, MMA306, MMA308, MMA309, MMA310, MMA313 and MMA314 
(Fig.5.7).  
Finally, compound MMA242 which contain α-hydroxyl ketone at C-17 and 
sulfamoyl moiety at C-3 demonstrated an outstanding binding mode with H-bonds and 
hydrophobic interactions with the amino acids inside the binding pocket of the MRP1 
crystal structure compare to known inhibitors of MRP1 such as MK-571 (Fig.5.8).  
In conclusion, CUCUS-inspired estrone analogues that contain aromatic enone side 
chain at C-17 demonstrated an outstanding binding affinity toward the binding site of the 
3D structure of MRP1 compare to the same analogues but with aliphatic enone side chain 
at C-17. In addition, stereochemistry played a significant role for the binding affinity; for 
example, analogues that contain the stereochemistry of cucurbitacin D enone side chain 
demonstrated better binding mode compare to the same analogues but with opposite 
stereochemistry. Finally, the presence of sulfamoyl moiety at C-3 of the estrone derivatives 
along with the aromatic enone side chains proved to improve the binding mode toward the 
crystal structure of MRP1 compare to the same compounds but with hydroxyl group at C-
3. All of the molecular docking calculations and results were the bases to decide the 
analogues that should be chemically synthesized and tested in different biological assays 
as MRP1 inhibitors to overcome the resistance of the anticancer drugs.  
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A 
B 
Figure 5. 5 Visual representation of A) MMA292 (black) B) MMA132 (brown) 
in the MRP1 binding site. 
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5.3.2 Study of synthesized CUCUS-Inspired Estrone Analogues Targeting MRP1:    
To explore the inhibitory activity of CUCUS-inspired estrone analogues as MRP1 
inhibitor, three sets of CUCUS-inspired estrone compounds which were synthesized using 
A 
B 
Figure 5.6 Visual representation of A) MMA292 (purple) B) MMA320 (green) in 
the MRP1 binding site. 
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various chemical reactions reported in the third and fourth chapters. First set of CUCUS-
inspired estrone derivatives contain the cucurbitacins enone side along with aliphatic and 
aromatic functional groups at C-17, double bond at C-16 and C-17, and methoxy group at 
C-3 (Fig.5.9). Second set of analogues consist of cucurbitacin enone side chain along with 
aliphatic and aromatic moieties at C-17 and sulfamoyl group at C-3 (Fig.5.10). Third set 
of synthesized compounds contain the cucurbitacin enone side chain along with aliphatic 
and aromatic moieties at C-17 and hydroxyl group at C-3 (Fig.5.11).  
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A 
B 
Figure 5.7 Visual representation of A) MMA300 (purple) B) MMA308 (green) in 
the MRP1 binding site. 
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A 
B 
Figure 5.8 Visual representation of A) MMA242 (red) B) MK-571 (yellow) in the 
MRP1 binding site. 
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Figure 5.11 Third set of synthesized MMA analogues. 
 
5.1.1 Biological Evaluation of CIAE towards MRP1: 
High-content imaging based assay were utilized on the CIEA to detect their inhibitory 
activities on MRP1. The screening were conducted on H69AR cells in the presence of 
Calcein-Am as MRP1 substrate. MK-571, which is known inhibitor of MRP1, was used 
as standard to compare the % inhibition of CIEA. Compounds MMAmix, MMA242, 
MMA132, MMA335, MMA337 and MMA320 showed potential inhibitory activity on 
MRP1 (Table 5.2). All of these results were compared to the known MRP1 inhibitor, MK-
571 as shown in figure 5.12. Compound MMAmix and MMA132, which possess the 
enone side chain, proved to be a potential candidate as MRP1 inhibitor with 70%, 46.2% 
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inhibitory activity; respectively. Compound MMA242, which contain sulfamoyl group at 
C-3 along with hydroxyl methyl ketone at C-17, demonstrated a very significant inhibitory 
activity for MRP1 with 63% inhibition, which demonstrated the important of possessing 
the sulfamoyl moiety. On the other hand, compounds MMA320 and MMA337, which 
contain hydrophobic functional groups at C-17, showed moderate inhibitory activities for 
MRP1. 
Table 5.2. Inhibitory effect of CIEA to MRP1 activities (% calcein accumulation inhibition) 
in comparison of standard MRP1 inhibitor MK-571. 
Compound ID Provided Average % Control 
Inhibition 
MK-571 100 
MMAMIX 70.2 
MMA242 62.6 
MMA132 46.2 
MMA335 46 
MMA337 30.2 
MMA320 21.8 
MMA326 18 
MMA328 17.8 
MMA318 17.4 
MMA315 16.3 
MMA324 15.6 
MMA321 15.3 
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Figure 5.12. Chart represent the inhibitory activities of CIEA for MRP1.  
 
 
5.2 Conclusion: 
 
CUCUS-inspired estrone analogues were structurally designed utilizing molecular docking 
technique by assembling the  biologically important pharmacophores such as 
cucurbitacin’s enone side chain at C-17, various aromatic and heterocyclic substituents at 
C-25 and sulfamoyl or hydroxyl groups at C-3 to be explored biologically as anti-cancer 
candidates toward the treatment of Hepatocellular carcinoma (HCC) through the inhibition 
of EGFR. Various aliphatic, aromatic and heterocyclic enone side chains were installed 
chemically on the estrone main skeleton such as isopropanol, para-methoxybenzene, para-
flurobenzene, para-chlorobenzene, para-bromobenzene, 5-bromofuran, para-
trifluromethyl, para-nitrobenzene, 5-bromothiphene along with sulfamoyl, hydroxyl and 
methoxy groups at C-3. The biological evaluation using high-content based assay 
demonstrated that compounds MMAmix and MMA132, which possess the enone side 
-20
0
20
40
60
80
100
120
M
K
-5
7
1
M
M
A
2
4
2
M
M
A
3
3
5
M
M
A
3
2
0
M
M
A
3
2
8
M
M
A
3
1
5
M
M
A
3
2
1
M
M
A
3
3
0
M
M
A
3
1
6
M
M
A
3
2
7
M
M
A
3
2
3
M
M
A
2
6
8
M
M
A
2
9
0
M
M
A
2
7
0
M
M
A
2
8
1
M
M
A
3
3
4
M
M
A
3
2
9
M
M
A
3
3
2
M
M
A
2
9
2
M
M
A
2
2
9
M
M
A
3
3
3
M
M
A
2
8
0
M
M
A
3
0
9
M
M
A
2
2
5
M
M
A
2
7
5
M
M
A
3
0
0
M
M
A
3
1
3
A
v
er
a
g
e 
%
 C
o
n
tr
o
l 
In
h
ib
it
io
n
CIEA
   243 
 
  
chain, proved to be a potential candidate as MRP1 inhibitor with 70%, 46.2% inhibitory 
activity; respectively. 
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Chapter Six 
General Conclusion and Future Trends 
 
Our objectives and goals of this study were accomplished through design, synthesis 
and biological evaluation of novel hit candidates as anticancer agents. Various 
cucurbitacins structures were studied and reviewed as promising anticancer natural 
products utilizing significant number of literature reviews and articles in order to determine 
essential pharmacophores that responsible for their anticancer activities. Studies in our 
group by Ahmed et al have determined the significant pharmacophores including α-β-
unsaturated enone side chain, functionalities at C-3, functional groups at C-11 and C16. 
However, cucurbitacins have very weak selectivity and specificity due to the presence of 
multiple functional groups which targets different biological targets. Therefore, there is 
need to design novel compounds based on the cucurbitacin main structure to overcome the 
side effects of the available cucurbitacins.  
 
The first step to find the lead compounds was the design step utilizing the concepts 
of hybrid structural design between the main scaffold of the estrone to assemble the 
cucurbitacins pharmacophores and investigate their anticancer activities. The concept of 
bioisosterism was used to install different aliphatic and aromatic moieties at C-3, C-16 and 
C-25 of the designed analogues along with the cucurbitacins pharmacophores. Three 
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different objectives were outlined in this research to optimize the biological activities of 
CIEA as anticancer agents.  
 
First objective, CUCS-inspired estrone analouges were designed by assembling the 
α-β-unsaturated enone side chain of the cucurbitacins at C-17 of the estrone main structure 
along with various aliphatic and aromatic moieties at C-25, methoxy at C-3 and double 
bond at C-16 and C-17. The molecular docking results reveled the significant of possessing 
the α-β-unsaturated enone side chain of cucurbitacin D with the exact stereochemistry at 
C-18 as in MMA132, which demonstrated an outstanding binding affinity toward the 
crystal structure of EGFR compare to known inhibitor such as Erlotinib. Compound 
MMA132 found to have H-bond with MET:769:A which is the same H-bond with 
erlotinib that responsible for its anticancer activity.; while the same compound but with 
opposite stereochemistry at C-18 as in MMA102 did not show H-bond inside the binding 
pocket of the crystal structure of EGFR. Compounds with various aromatic groups at C-
25 of the enone side chain showed different binding modes with the 3D structure of EGFR 
compare to erlotinib. The top consensus scored analogues were chemically synthesized 
utilizing different chemical reactions and their potential biological activity towards HCC 
were investigated. Biological assays including MTT cell viability assay, western blot and 
flowcytometry were used to study the mechanism of the anticancer activities of the 
synthesized compounds. Compound MMA132 and MMA102 showed a significant 
cytotoxicity with IC50 values 2µM and 3µM, respectively. Compounds that contain 
aromatic and heterocyclic enone side chains such as MMA265, MMA270, MMA287, 
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MMA288, MMA290, MMA292, MMA305, MMA311, MMA316, MMA318, 
MMA319, MMA320, MMA321, MMA330, MMA333 and MMA334 showed various 
cytotoxicity toward HepG2 with IC50 values 16 µM, 7 µM, 25 µM, 32 µM, 6 µM, 2 µM, 
29 µM, 0.7 µM, NA, NA, NA, 3 µM, 20 µM, 11 µM, 2 µM and 8 µM; respectively. 
Western blot experiment was used to detect the antiproliferative mechanism of the potent 
compounds, the results of the Western blot showed the ability of MMA132 to inhibit the 
phosphorylated EGFR after 48 h of incubation at 3 µM. Finally, flowcytometry assay 
showed induction activity at G1/S phases for compound MMA132. 
 
To overcome the higher hydrophobic characters of  the first set of CIEA compounds 
and expected O-demethylation of C-3 methoxy group which may trigger the estrogenic 
activity of the CUCUS-inspired estrone analogues side effects, sulfamoyl pharmacophore 
was assembled at C-3 to improve the pharmacokinetic profile of CIEA. Molecular docking 
study for the estrone analogs that contain cucurbitacin D enone side chain at C-17 along 
with different aliphatic and aromatic moieties at C-25 and sulfamoyl and hydroxyl groups 
at C-3 were conducted to predict the binding to molecular target (EGFR). The results of 
the molecular docking showed that compound with the sulfamoyl group at C-3 of the 
estrone scaffold along with various aliphatic and aromatic enone side chain showed 
significant binding affinity with H-bonds and hydrophobic interactions in comparison to 
the same compounds but with hydroxyl group instead of sulfamoyl at C-3. The results 
revealed the importance of assembling the sulfamoyl group along with the different enone 
side chains at the estrone scaffold for the binding affinity with the EGFR which may 
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enhance the biological activity. Different chemical reactions were utilized to install   these 
functionalities at the estrone main structure. All synthesized analogues were biologically 
screened to verify their anticancer activity. Cytotoxicity of all synthesized compounds on 
hepatocellular carcinoma cell line such as HepG2 were conducted using MTT cell viability 
assay. The IC50 values of the synthesized analogues including MMA240, MMA301, 
MMA242, MMA267, MMA268, MMA269, MMA271, MMA309, MMA294, 
MMA310, MMA295, MMA297, MMA314, MMA300, MMA308, MMA306, 
MMA307, MMA313 and MMA312 were 8 µM, NA, 3 µM, 12 µM, 7 µM, 2 µM, 8 µM, 
NA, 11.5 µM, 6 µM, NA, 1 µM, 1.5 µM, 3 µM, 8 µM, 8 µM, 10 µM, 9 µM and 8 µM; 
respectively.  
 
 Finally, our objective to study the potential of synthesized CIEA to overcome the 
resistance of cancer to current chemotherapy, we examine the inhibitory activity of 
synthesized analogs on MRP1 which is one of the known protein that responsible for 
multidrug resistance. Molecular docking study between the homology structure of MRP1 
and CIEA revealed that the presence of hydrophobic moieties in the enone side chain at C-
17 such as MMA265, MMA270, MMA287, MMA288, MMA290, MMA292, MMA305 
and MMA311 showed enhanced binding affinity in comparison to the aliphatic enone side 
chain such as MMA102 and MMA132. In addition, the presence of sulfamoyl group at C-
3 along with hydrophobic (aromatic) enone side chain is essential for the binding affinity. 
Biological activity of the synthesized compounds as MRP1 inhibitors were verified using 
high-content imaging based assay. Compounds MMAmix, MMA242, MMA132, 
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MMA335, MMA337 and MMA320 showed potential inhibitory activity on MRP1 (Table 
5.2) with % inhibition 70%, 63%, 46.2%, 46%, 30% and 22%; respectively, in comparison 
to MK-571, which known MRP1 inhibitor.  
Our study demonstrated the design, synthesis of novel CIEA analogs of potent anti-
proliferation/anticancer activities toward hepatocellular carcinoma and potential 
application to overcome cancer resistance to current chemotherapeutic agents. 
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Appendix 
Protocol of the Molecular Modeling 
I- Steps of designing the virtual library:   
The first step of designing the virtual library was the drawing of the structure of the 
compounds utilizing Chem Draw software. Then all compounds in the virtual library were 
energy minimized using chem3-D software, specifically MMFF94 application to obtain the 
relative crystal structure of each compound. Every single compound was saved in pdb 
format. After that, all created pdb files were combined into single pdb file. All of these 
processes were conducted utilizing the command prompt as following start menu> 
command prompt, then the address where the pdb file of the ligands were copied to be used 
to combined into single pdb file as following: 
cd address where the pdb file are located (enter) 
Then using command, copy *.pdb name.pdb (enter), which tells the computer to 
combined all the pdb files to be in one pdb file. The created pdb file can be visualized 
utilizing notepad as shown in figure AP-1.  
 
II- Creating Different Conformers of each Ligands: 
OMEGA application, particularly MMFF94 force filed was used to create different 
conformers of each ligand so to be in the fast rigid exhaustive docking (FRED). The 
resulted file of this process will be in this format name.gz.pdb. this process were done 
following these steps: 
a- Copy the combined file of ligand pdb.  
b- Past it where the OMEGA application is. 
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c- The application license should be available at the same place. 
d- The following command was used to generate the conformers “omega2.2.1 –in name.pdb 
–out newname.gz.pdb –includeinput –warts (Enter). The created file is the one that 
should be used in the FRED calculation.  
 
 
Figure AP-1 created pdb file using command prompt.  
III- Preparation of the targeted receptor: 
FRED make receptor were utilized to prepare the targeted receptor. By starting the 
program, clicking on file to import the pdb file of the receptor that downloaded from the 
protein data bank to show the chains of the receptor, water molecules, binding ligands and 
co-factors. Choosing the ligand that co-crystalized with the targeted protein help to 
generate the grid box for the docking calculations, since it binds to the binding pocket. The 
size of the created box cannot exceed 50,000- 60,000 Ao and that can be controlled by the 
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mods controls. Next step is to generate the shape of the grid box by choosing the shape 
mode. The created shape assign the shape of the active site of the receptor which will be 
used during the molecular docking. The active site consist of two contours outer and inner 
contours. Finally, the prepared receptor should be saved as .oeb.gz format (Fig.AP-2). 
 
Figure AP-2 Sample of the prepared grid box. 
IV- Fast Rigid Executive Docking (FRED) Calculations: 
In order to conduct the FRED calculations, three files should be available at where 
the FRED application is located. First, the file of the fred license; second, the file that 
contain the different conformers of each ligands, which generated by OMEGA 
name.gz.pdb; third, the prepared rigid receptor “receptor.oeb.gz”. then certain command 
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used to start the FRED calculations “fred.exe –rec receptor.oeb.gz –dbase name.gz.pdb –
prefix newname shapegauss –chemgauss3 –oechemscore –screenscore –plp –hitlist_size 
5000 (enter)”. The result of FRED calculations will be in consensus score, which calculate 
the binding affinity between the ligands and the targeted receptors. The lower the 
consensus score the better the binding affinity (Fig.AP-3). 
Table AP-3 sample of consensus score of the FRED docking. 
VIDA Name VIDA 
ID 
PLP Chemgauss3 OEChemscore Screenscore Consensus 
Score 
MMA292_6 2 -48.8383 -62.3556 -41.8789 -126.747 11 
MMA305_71 3 -53.1802 -58.3102 -43.6724 -113.016 14 
MMA266_109 4 -55.3548 -52.8859 -45.5678 -122.833 18 
MMA311_103 5 -46.8621 -58.0439 -39.7369 -113.75 29 
MMA128_44 6 -42.578 -55.8818 -43.6541 -116.397 31 
MMA291_69 7 -44.6388 -54.3626 -39.1158 -118.789 36 
MMA262_67 8 -44.5989 -60.0755 -41.0308 -102.036 43 
MMA290_34 9 -44.039 -57.059 -39.6733 -108.785 43 
MMA282_93 10 -43.5212 -52.4658 -43.2122 -110.732 45 
MMA303_45 11 -43.5525 -51.6006 -45.7898 -105.967 48 
MMA270_125 12 -43.5141 -63.5376 -39.6715 -104.555 49 
MMA281_159 13 -45.0053 -48.3764 -43.1412 -116.666 50 
MMA271_33 14 -41.0513 -54.1366 -40.7371 -107.453 54 
MMA265_143 15 -42.9178 -53.0514 -41.1596 -101.578 64 
MMA289_39 16 -42.6201 -52.9413 -41.639 -95.7639 74 
MMA267_23 17 -39.3882 -53.0557 -37.9022 -107.407 77 
MMA296_154 18 -42.6266 -54.3291 -34.3674 -111.931 77 
MMA243_20 19 -37.7833 -53.6937 -39.8163 -104.531 78 
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MMA312_105 20 -45.2513 -48.6491 -37.2378 -105.689 80 
MMA285_15 21 -38.3901 -45.4425 -41.2682 -118.057 97 
MMA288_52 22 -39.5374 -54.1164 -35.5891 -97.6439 100 
MMA284_3 23 -40.9979 -53.7463 -34.8896 -96.2328 104 
MMA102_159 24 -35.2947 -45.2269 -39.7102 -109.6 132 
MMA100_33 25 -35.7384 -51.3318 -42.029 -83.6088 136 
MMA129_35 26 -40.7517 -45.4562 -39.0489 -92.2197 138 
MMA101_33 27 -35.7384 -51.3318 -42.029 -83.6088 140 
MMA287_27 28 -33.7545 -52.434 -36.1576 -96.1252 142 
MMA261_191 29 -43.7523 -41.8876 -34.9793 -93.2034 161 
MMA297_168 30 -37.1344 -50.7964 -33.1599 -94.6202 161 
MMA279_5 31 -36.2629 -52.6934 -33.4031 -87.0033 165 
 
V- VIDA visualization of the Docking Results: 
VIDA application can be utilized to visualize and show 3D structure of the docked 
ligands inside the targeted receptor (Fig.AP-4). In addition, by choosing the “Data 
analysis”, all the docking numbers can be shown as in figure AP-3. Snapshot of the best 
binding ligands with the receptor can be taken to visualize the behavior of the synthesized 
ligands with the targeted receptor.  
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Figure AP-4 Sample of VIDA Visual Representation.  
